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ABSTRACT
There is a need to improve our understanding of the mechanisms of pain, especially 
neuropathic pain in order to develop new analgesic drugs based on opioids. In recent 
years, the cloning of the novel opioid receptor like-1 (ORLi/NOP) receptor and 
studies on the effectiveness of opioids in pain models provides a basis for potential 
novel therapy. This thesis is based on nociceptin/orphanin FQ and its receptor ORLi, 
which represent a novel peptide/receptor system pharmacologically different from 
classical opioid systems. Nociceptin regulates several biological functions, both at the 
peripheral and central levels; therefore, the ORLi receptor may be viewed as a novel 
target for drug development. However, the pharmacology of this receptor is still 
under study, with few molecules selectively acting on this receptor. Little is known 
about the physiological roles of this new opioid system.
Using an in vivo electrophysiology study, spinal effects of nociceptin were 
investigated on deep dorsal horn neurones in normal, sham operated and neuropathic 
rats. Nociceptin induced a greater dose-dependent inhibition in normal animals when 
compared with the neuropathic and sham operated animals which were the least 
inhibited. Additionaly to clarify the role of nociceptin and its receptor in the spinal 
processing of pain a non peptide antagonist and agonist of nociceptin were studied. 
Another objective of this thesis was to study the interaction between nociceptin and 
cholecystokinin (CCK), an anti-opioid peptide. CCK enhanced the inhibitory effect of 
nociceptin in sham operated and neuropathic animals, whereas in normal animals 
CCK had the expected antiopioid action.
Furthermore, this thesis emphasizes the importance of opioid receptors located on 
lamina I expressing NK1 receptors in the modulation of spinal analgesia of nociceptin 
when compared to [D-Pen2, D-Pen5] enkephalin (DPDPE), a delta-opioid agonist. 
Finally, this thesis suggests a potential therapeutic value of oxytocin in the treatment 
of neuropathic pain.
2
ACKNOWLEDGEMENTS
I would like to thank Tony for giving me this opportunity, for all the support and 
encouragement when times were difficult. Thank you, for making the science so 
enjoyable and for being a friend more than a supervisor. Big thanks to all the present 
and past people from the lab Rie, Kate, Liz, Tansy, Wahida, Shaima, Lars, Lucinda, 
Sara, Louise, Miguel, Katie, Vicky, Gary, Ana-Paula, Lucy, Jean, Richard and Curtis. 
Guys I just want to say "thank you" for all the help and the constructive input.
These years have been the fastest and the greatest I have ever had, before you I did 
not know what is like getting drunk with coca cola! I wouldn’t know my potentials as 
a queen of salsa. Thanks for unforgettable English breakfast and the city tours.
Thank also to my project students for their company and hard work, Kate, Chandrika, 
Kemi, Fern, Lisa and Vidya.
My special thanks to Patrizia, for the support, if it wasn’t for the Leonardo I may 
never had the chance to be here!
I dedicate this thesis to my dad and mum for believing in me from the first day, my 
sisters which without them, I doubt I would have made it this far, my grandmother for 
all the prayers to find nice neurones and my husband for making my dreams come 
true.
3
CONTENTS
Chapter 1.
Introduction_____________________________________________________
1.1 Primary afferent fibres__________________________
1.1.1 Termination patterns of the afferent fibres______________
1.2 Lamina organization and neurones of the spinal cord_
1.2.1 Lamina I _________________________________________
1.2.2 Lam inall_________________________________________
1.2.3 Lamina III-VIII_____________ ______________________
1.3. Pharmacology of the spinal cord__________________
1.3.1 Excitatory and inhibitory transmissions________________
1.3.1.1 Receptors for glutamate including the 
N-methyl-D-aspartate (NMDA) receptor____________________
1.3.1.2 Substance P______________________________________
1.3.1.3 y-aminobutyric acid (GABA)_______________ _______
1.3.1.4 Monoamines______ ______________________________
1.4 Phathways involved in pain transmission___________
1.4.1 Spinothalamic tract (STT) __________________________
1.4.2 Spinoreticular (SRT) and spinomesencephalic tracts (SMT)
1.4.3 Spincervical (SCT) and postsynaptic dorsal column
tracts (PSDC)__________________________________________
1.5 Neuropathic pain_______________________________
1.5.1 Animal models of neuropathic p a in ___________________
15.2 Mechanisms of neuropathic pain_____________________
1.5.3 Anatomical changes within peripheral nerves____________
1.5.3.1 Ephatic transmission______________________________
1.5.3.2 Ectopic activity __________________________________
1.5.4 Alteration of ion channels in nerve injury_______________
1.5.5 Neurochemical changes in nerve in jury________________
1.5.5.1 Neurochemical up-regulation _____________________
12
14
15
15
16
17
18
21
22
22
24
26
27
30
30
31
32
33
35
38
39
41
42
43
45
45
4
1.5.5.2 Neurochemical down-regulation_________________
1.5.6 Sympathetic system_______________________________
1.5.7 Pharmacological treatments of neuropathic p a in _______
1.6 Inflammation________________________________
1.6.1 Choice of animal model for inflammation____________
1.7 Aims of Study________________________________
References______________________________________
Chapter 2.
Methods _____________________________________________________
2.1 Spinal nerve ligation (SNL)____________________
2.1.1 Behavioural studies ______________________________
2.2 Ablation of lamina I spinal neurones expressing NK1 
receptor______________________________________
2.3 Carrageenan ________________________________
2.4 Electrophysiology recordings___________________
2.4.1 Data acquisition in the electrophysiology recordings____
2.5 Analyses of isoleted neurones___________________
2.6 Drug application_____________________________
2.7 Statistical analysis of results____________________
2.6 Drugs employed_____________________________
References ____________________________________
Chapter 3.
The spinal effect o f  nociceptin and oxycodone________________________
3.1 Introduction_________________________________
3.1.1 Opioids  _____________________________________
3.1.2 Nociceptin (N/OFQ) ________________________
47
49
51
53
58
60
61
72
73
74
75
76
78
80
82
83
83
84
85
86
87
87
91
5
3.1.2.1 Distributions and biological actions of nociceptin ______ 93
3.1.2.2 Supraspinal nociceptin_____________________________ 94
3.1.2.3 Peripheral nociceptin______________________________ 95
3.1.2.4 Spinal nociceptin_________________________________ 96
3.1.3 Oxycodone________________________________________97
3.2 Results____________________________   99
3.2.1 Nociceptin effects on evoked neuronal responses in
normal animals __________________________________ _99
3.2.2 Effects of intrathecal nociceptin on evoked neuronal 
responses in sham operated and neuropathic animals__________102
3.2.3 Effects of oxycodone on evoked neuronal
respnses in normal animals_______________________________ 104
3.3 Discussion__________________________________  107
3.3.1 Effects of spinal nociceptin on evoked neuronal responses
in normal, sham operated and neuropathic animals____________107
3.3.2 Effects of spinal oxycodone on evoked neuronal responses
in normal animals_______________________________________ 110
References      113
Chapter 4.
Studies with a nociceptin receptor agonist____________________________ 120
4.1 Introduction___________________________________ 121
4.2 Results________________________________________ 122
4.3 Discussion_____________________________________ 129
References 131
Chapter 5
Studies with a nociceptin receptor antagonist__________________________132
5.1 Introduction    133
6
5.2 Results________________________________________ 135
5.2.1 Normal animals treated with nociceptin, J-l 13397
and morphine__________________________________________ 135
5.2.2 Normal and carrageenan animals treated
with only J-l 13397______________________________________136
5.2.2.1 Electrically-evoked responses______________________ 136
5.2.2.2 von-Frey evoked responses________________________ 141
5.2.3 Neuropathic and sham operated animals treated with
only J-l 13397________________  143
5.2.3.1 Electrically-evoked responses ._________________ 143
5.2.3.2 von-Frey evoked responses________________________ 146
5.3 Discussion_____________________________________ 150
5.3.1 Normal animals treated with nociceptin, J-l 13397
and morphine _______________________________________150
5.3.2 Animals treated with J-l 13397 alone__________________ 151
5.3.2.1 Endogenous nociceptin in inflammatoiy pain__________152
5.3.2.2 Endogenous nociceptin in neuropathic pain____________154
References 156
Chapter 6.
Interactions between nociceptin and cholecystokinin  __________________159
6.1 Introduction___________________________________ 160
6.2 Results_________________ 161
6.2.1 Nociceptin alone___________________________________161
6.2.2 CCK and nociceptin________________________________162
6.3 Discussion_____________________________________ 167
References 170
7
Chapter 7
The spinal effect o f  nociceptin and DPDPE in SAP and SP-SAP animals 173
7.1 Introduction_______________________________ 174
7.2 Results________________________________________ 176
7.3 Discussion_____________________________________ 183
References_________________________________ 187
Chapter 8.
The effects o f  oxytocin on spinal nociceptive processes _________________ 190
8.1 Introduction _____________________________ 191
8.2 Results________________________________________ 192
8.2.1 Effects of oxytocin on responses evoked by electrical 
stimulation in normal animals____________________________ 192
8.2.2 Effects of oxytocin on responses evoked by mechanical 
stimulation in normal animals____________________________ 193
8.2.3 Effects of oxytocin on responses evoked by electrical 
stimulation in neuropathic animals ________________________ 193
8.2.4 Effects of oxytocin on responses evoked by mechanical 
stimulation in neuropathic animals ________________________ 194
8.2.5 Comparisons between neuropathic and normal rats 
responses_____________________________________________ 194
8.3 Discussion_____________________________________ 203
References 206
Chapter 9.
Final discussion___________________________________________________208
References________________________________________ 216
Publications 220
8
ABBREVIATIONS
(3-FNA Beta-funaltrexamme
[Ca2+]i Intracellular concentration of Ca2+
5-HT 5-hydroxytryptamine
AMP A a-amino-3-hydroxy-5-methyl-4 isoxazolepropionate
ASICs Acid-sensing-ion-channels
ATP Adenosine triphosphate
B Bradykinin
BDNF Brain derived neurotrophic factor
CCI Chronic constrictive injury
CCK Cholecystokinin
CFA Complete Freund’s adjuvant
CGRP Calcitonin-gene related peptide
CNS Central nervous system
COX Cyclo-oxygenase
DAG Diacylglycerol
DAMGO [D-Ala2N-Me-Phe4,Gly-ol5]-enkephalin
DPDPE [D-Pen2,D-Pen5]-enkephaiin
DRG Dorsal root ganglion
GABA y-aminobutyric acid
GAL Galanin
GBP Gabapentin
GR38032F [ 1,2,3,9-tetrahydro-9-methyl-(2-methyl- 1-H-imidozol-l-
yl)methyl)-4-one], ondansetron 
i.p. Intraperitoneal
i.t. Intrathecal
ICS205-930 3-2 tropanyl-lH-indozole-3-carboxylic acid ester hydrochloride)
id. Internal diameter
IL Interleukins
IP3 1,4,5-inositol-triphospahte
9
J-l 13397 1-[(3R, 4 R)-l-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3- 
ethyl-1,3 -dihydro-2 benzimidazol-2-one
LCN Lateral cervical nucleus
L-NAME Aco-nitro-L-arginine methyl ester
LRN Lateral reticular nuclei
M3G Morphine-3-glucuronide
m-CPBG [l-(m-chloro-phenyl) biguanide]
mRNA Messenger Ribonucleic Acid (mRNA)
NA Noradrenalin
NGF Nerve growth factor
NK Neurokinin
NMDA N-methyl-D-aspartate
NO Nitric oxide
nor-BNI Norbinaitorphimine
NOs Nitric oxide synthase
NPV Paraventricular nucleus
NRM Nucleus raphe magnus
NS Nociceptive specific
NSAIDs Non-steroidal anti-inflammatory drugs
od. Outer diameter
ORLi Opioid-like receptor 1
OT Oxytocin
PAG Periaqueductal grey
PB Parabrachial
PBN Parabrachial nucleus
PK Protein kinase
PSDC Postsynaptic dorsal column
PSTH Post-stimuli time histogram
PSTL Partial sciatic tight ligation
s.c. Subcutaneous
S.E.M Standard error of mean
SAP Saporin
SCT Spinocervical tract
10
SG Substantia gelatinosa
SMT Spinomesencephalic tract
SNL Spinal nerve ligation
SP Substance P
SP-SAP Substance P-saporin
SRD Subnucleus reticular dorsalis
SRT Spinoreticular tract
STT Spinothalamic tract
TNF Tumor necrosis factor
Trk Tyrosine kinase
TTX-R Tetrodotoxin sensitive
TTX-S Tetrodotoxin resistant
VIP Vasoactive intestinal peptide
VR Vanilloid receptor
WDR Wide dynamic range
CHAPTER 1
INTRODUCTION
Pain is defined by the International Association for the Study of Pain as “an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage” (Merskey, 1994). Pain serves an important protective function: It 
warns of injury that should be avoided or treated. Also pain is considered as a 
complex phenomenon to which an individual’s response is determined by interactions 
between physical, psychological, cultural and social factors.
Pain can be divided into two categories, acute and chronic, which differ in their 
aetiology, mechanism and pathophysiology. Noxious stimulation and/or disease or 
abnormal functions of muscles or viscera provoke acute pain, which does not 
necessarily involve tissue damage. In many cases acute pain resolves within days or 
weeks if is treated properly. In contrast, chronic pain can persist for a long period of 
time, usually defined as more than 3 months, and involves tissue, nerve or visceral 
damage, or from dysfunction or lesions, either peripheral or central, of the nervous 
system. So it is not simply the duration that distinguishes acute from chronic pain but, 
more importantly, the inability of the body to restore its physiological function to 
normal homeostatic levels. Pain after tissue damage can be considered as 
inflammatory pain whereas nerve damage is termed neuropathic pain (Dickenson, 
2001).
Whatever the type of pain, pain is a result of over stimulation of a group of specific 
sensory receptors called nociceptors. Their activation stimulates individual 
specialized neurones known as primary afferent fibres with their cell bodies located 
in dorsal root ganglia (DRG).
The primary afferent fibres transmit the encoded stimulus information to the dorsal 
horn of the spinal cord by means of a number of synapses, the first of which is within 
the outer dorsal horn and the output that results from spinal processing is conveyed to 
higher centres of the brain.
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1.1 Primary alterent fibres
Both noxious and innocuous stimuli trom peripheral tissues such as skin or 
subcutaneous tissue including muscle, bone and viscera, activates primary afferent 
tiores terminals.
The primary afferent fibres convey sensory information to the spinal cord, and can be 
classified into A(3-, A6-, and C-fibres, according to their myelmation, size, 
conduction properties and thresholds as summarised in fable 1 as well as their 
different termination patterns in the spinal hom ot the spinal cord or kin and 
Carlton, 1 yy/).
Table 1. Physiological properties of primary afferent fibres.
Afferent
type
Diameter
(pm)
Myelination Conduction 
velocity (ms-1)
Modality
conveyed
ill) A0 6-12 Heavy 25-70 Innocuous
C U Ad 1-5 Light 10-30 Innocuous/noxious
«z> C 0.2-1.5 None <2.5 Noxious
1 he C-fibres. unmyelinated, slowly conducting fibres innervate nociceptors involved 
in the response to noxious stimuli, these nociceptors associated with C-fibres are 
called polymodal nociceptors since they are activated by highly-intensity mechanical, 
chemical or thermal stimuli (Dickenson, 2001). There are also silent or sleeping 
nociceptors which are unresponsive even to those intense stimuli. However, their
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response is influenced by inflammatory mediators or various chemical insults which 
reduce their firing threshold (Dray, 1995).
The AS-fibres, thinly-myelinated fibres, convey both noxious and innocuous 
information; they respond to thermo- and mechano-stimuli less intense than those 
needed to exceed the C-fibre threshold.
In contrast, Ap-fibres mediate innocuous information such as gentle touch; they have 
a large diameter and are heavily-myelinated. As a result of these properties Ap-fibres 
have the fastest conduction velocity of the other three fibres.
The cell bodies of spinal nociceptive afferent fibres lie in the dorsal root ganglia; 
fibres enter the spinal cord via the dorsal root, ending in the grey matter of the dorsal 
horn (Fig.l).
1.1.1 Termination patterns of the afferent fibres
The large diameter primary afferent fibres enter the spinal cord through the medial 
division of the dorsal root. After that they descend to either the medial region of 
lamina I or II, or curve around the medial edge of the dorsal horn down to the ventral 
horn and reaching deeper laminae, lamina IV and lamina V, whilst some then ascend 
back up into laminae III and IV.
The fine myelinated A5-fibres and the unmyelinated C-fibres afferents run laterally in 
Lissauer’s tract overlying the dorsal horn. Both A5- and C-fibres terminate on lamina 
I and II; in addition A5-fibres also terminate into lamina V (Sorkin and Carlton, 
1997), see Fig.l.
1.2 Lamina organization and neurones of the spinal cord
The spinal cord is classically divided into the white matter (axons) and grey matter 
(cell bodies and their processes). Further subdivision can then be made of the grey 
matter into ten layers (laminae). The lamina I-VI receive sensory input and compose
15
the dorsal horn, lamina VII-IX contain motor neurones and compose the ventral horn, 
and finally lamina X is surrounded by the central canal (Sorkin and Carlton, 1997), 
see Fig.l. Each lamina constitutes a functionally related group of cells.
1.2.1 Lamina I
The lamina I presents the marginal layer of the dorsal horn, a thin band that covers 
the grey matter. Lamina I contains large marginal neuronal population that have 
dendrites orientated along the rostrocaudal axis, some extending into deeper lamina 
and most of them are projection neurones. Studies done by (Lima and Coimbra, 
1986) on the basis of dendroarchitectiure and cell body shape, have identified four 
major neuronal types in lamina I of the spinal cord of the rat. Fusiform cells which 
represent 39% of lamina I neurone, multipolar (23%), flattened (13%) and pyramidal 
cells (25%) cells. The flattened and the pyramidal cells show the classical 
lateromedially elongated orientation of lamina I cells, and are also called Waldeyer 
cells most of which project in lateral spinocervical (SCT), spinoreticular (SRT) and 
spinothalamic tracts (STT) as well as to the periaqueductal grey (PAG), parabrachial 
nucleus (PBN) and nucleus submedius (Sorkin and Carlton, 1997). Recent studies by 
(Han et al., 1998) classified lamina I neurones into three types based on their 
morphology and receptive field properties; pyramidal and fusiform, as described by 
(Lima and Coimbra, 1986) and multipolar (which includes both the flattened and 
multipolar types of Lima and Coimbra).
Whatever the classification, lamina I neurones play a particular role in nociceptive 
transmission. They receive inputs from AS and C primary afferent fibres, including 
nociceptive specific (NS), wide dynamic range (WDR) and thermoreceptive cells. 
The NS cells respond only to intense pressure, pinch and noxious chemicals and 
temperatures > 45° C. The WDR which represent the most common spinal dorsal horn 
neurones, respond to gentle stimuli such as touch, brush, as well as to heat and 
chemicals. Finally there are also thermoreceptive cells responding to warm (35 - 43° 
C) and cooling (20 - 35° C) see (Wall, 1989).
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1.2.2 Lam ina U
Lamina II, known as the substantia gelatinosa (SG), further divided into outer layer 
(II0) and inner layer (Ih), contains a densely packed concentration of small neurones 
and has an absence of myelinated axons (Dickenson, 2001). The SG cells are mainly 
stalk and islet cells. The stalk cells are located in lamina II0, and most of their axons 
have ramifications in lamina I although some of them project also to deeper layers.
Dorsal root 
ganglion
Ap-fibre
—  A6-fibre
—  C-fibre
Figure 1. Morphology o f the spinal cord with the laminae termination zones o f the 
different afferent fibres.
The stalk cells predominantly relay excitatory transmission, while the islet cells are 
located in Hi, containing the inhibitory neurotransmitters, y -aminobutyric acid 
(GABA), glycine and enkephalins in their dendrites (Dickenson, 2001). Lamina Hi 
neurones receive input from low-threshold mechanoreceptive primary afferent (A5), 
while those in lamina II0 respond to high-threshold primary afferent (C-fibres).
Lamina II neurones serve as intemeurones, they project to lamina I and lamina V 
neurones where they regulate transmission at the first synapses in the nociceptive 
pathway, between the primary afferent fibres and the spinothalamic tract and other 
ascending transmission neurones (Sorkin and Carlton, 1997). This gatekeeper 
function was named ‘gate control theory’ by (Melzack and Wall, 1965). According to 
this theory the substantia gelatinosa cells respond to both activities from the afferent 
fibres and from the descending pathway, see Fig. 2.
1.2.3 Lamina III to VIII
Laminae III is located ventral to the substantia gelatinosa and the cells in this lamina 
are large and less densely packed than in the substantia gelatinosa. The main cell 
types of lamina III are neurones that receive monosynaptic input from Ap- and A5- 
fires. These neurones terminate onto non-nociceptive, low threshold neurones, and 
most of them project to SCT and postsynaptic dorsal column (PSDC). In addition 
lamina III contains some cells that project into laminae IV, V, and VI. Other branches 
of lamina axons terminate in laminae I and IV (Sorkin and Carlton, 1997).
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Thalamus
Descending
inhibitory
pathways
Lamina I Nociceptive 
Afferents (C/A5)
SGLamina
Mechanoreceptors (Ap)
Figure 2. The gate theory proposed that neurones in the SG o f the dorsal horn had 
their activity controlled by the balance o f descending inhibition and by primary 
afferent fibres.
The cells in lamina IV are heterogeneous and less densely packed than lamina III. 
There are at least four types of lamina IV cells according to their dendritic projection 
patterns termination and this includes SCT and PSDC cells. The 3rd cell type has 
dendridic patterns similar to SCT and PSDC cells, but with axons terminating locally 
into the spinal cord. The fourth cell type has unknown termination axons (Sorkin and 
Carlton, 1997).
Lamina V presents the narrow part or neck of the dorsal horn. The cells in this lamina 
are more diverse than those of lamina IV and their dendrites extend vertically toward 
the superficial layers (Sorkin and Carlton, 1997). Lamina V neurones are primarily 
WDR neurones, which receive both non-noxious and noxious primary afferent input, 
directly from A|3-fibre and indirectly via intemeurones from A8- and C-fibres (Sorkin
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and Carlton, 1997). The WDR cells then project to several areas of the brain such as 
in the STT, SCT and PSDC to areas important in the transmission of nociceptive 
information. Also lamina V neurones receive nociceptive inputs from viscera. In fact, 
because neurones in this lamina and adjacent areas have an important role in 
nociception most of the electrophysiological recording in these experiments were 
made in this lamina.
Lamina VI forms the base of the dorsal horn and is present only within the cervical 
and lumbar regions. Neurones in lamina VI receive input from large diameter 
afferents from muscles and joints, known as ‘movement detection cells’ and they 
respond to non-noxious stimuli of joints. Lamina VI cells are smaller than those of 
lamina V, their dendrites never reach into lamina I and II, and few axons appear to be 
contribute to the STT and SCT pathways (Sorkin and Carlton, 1997).
Laminae VII and VIII represent the ventral horn of the spinal cord. They are involved 
in pain transmission and have more complex response properties because of their 
polysynaptic inputs. Finally, lamina X has small cells restricted to the grey matter 
surrounding the central canal. Cells in this lamina have few projections in PAG, 
paramedial medulla and pontine reticular formation, for further discussion of other 
laminae see Sorkin and Carlton, (1997).
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1.3 Pharmacology of the spinal cord
The primary afferent fibres, which carry nociceptive sensory information from the 
periphery, terminate and make their first synapse with the central nervous system 
(CNS) within the dorsal horn of the spinal cord. Thus this is where the peripheral 
input undergoes anatomical convergence and modulation by a number of 
neurotransmitter systems, before projection to higher brain centres via ascending 
tracts.
The neurotransmission of pain in the dorsal horn of the spinal cord relies on many of 
the same transmitters and receptors sub-serving neurotransmission in other areas of 
the central and peripheral nervous system. This similarity might indicate that dorsal 
horn pharmacology would be much the same as pharmacology at other CNS cites, 
(Wilcox, 1997). The next few pages will discuss the pharmacology of the spinal cord 
with most attention given to events that occur in the dorsal horn of the spinal cord.
The pharmacology of the spinal cord is wide and contains a diverse range of 
neurotransmitters and receptors, which can be excitatory or inhibitory, depending on 
the consequence of their receptor activation and their location. The transmission of 
pain can be seen as a complex mechanism involving a balance between excitatory 
and inhibitory systems acting at different levels of the central nervous system. All 
these systems are subject to plasticity and alteration during pathological conditions, 
so it is clear that the response to pain is not always straightforward.
The arrival of a noxious stimulus from the periphery to the dorsal horn of the spinal 
cord, activates the nociceptive afferent fibres (A8- and C-fibre), followed by the co­
release of an excitatory amino acid such as glutamate, aspartate with neurokinins 
(predominantly substance P), calcitonin-gene related peptide (CGRP) and other 
peptide transmitters. At this stage, the excitatory transmission is initiated by AMPA 
receptor activation, which causes entry of Na+ ions and fast depolarization of 
postsynaptic neurones. Only neuronal depolarization with sufficient duration and 
intensity is able to lead to removal of the Mg2+ block of the NMDA receptor channel 
and results in Na+/Ca2+ entry. This amplified response of the nociceptive transmission
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is under control by a complex inhibitory system mediated by GABA, glycine, opioid 
and catecholaminergic system (Hudspith and Munglani, 2003).
1.3.1 Excitatory and inhibitory transmissions
1.3.1.1 Receptors for glutamate including the N-methyl-D-aspartate (NMDA) 
receptor
Glutamate is the main excitatory neurotransmitter in the central nervous system, is 
found in most primary afferents fibres synapsing in the dorsal horn of the spinal cord, 
including both small and large diameter fibres. Glutamate mediates its action via the 
depolarisation of two distinct classes of receptors, ionotropic and metabotropic 
receptors (Hollmann and Heinemann, 1994). The ionotropic receptors contain cation- 
specific ion channels, and are further subdivided into three groups, N-methyl-D- 
aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4 isoxazolepropionate (AMPA) 
and kainate receptors (Ozawa et al., 1998). On the other hand the metabotropic 
receptors are coupled to GTP-binding proteins (G-proteins), but their role in pain 
transmission is poorly understood.
AMPA and Kainate receptors are also known as non-NMDA receptors, prior to the 
development of selective ligands that allowed their differentiation. Recent studies 
have demonstrated that there are distinct receptors with different structure and 
functions. AMPA receptors subunits have four subunits (GluRl-GluR4) as have 
kainate receptors (GluR5-GluR7, KA1 and KA2) and the different assemblies of 
these subunits produce the different functions of native AMPA and kainate receptors 
(Ozawa et al., 1998). Although both kainate and AMPA receptors are widely 
distributed within the central nervous system, little is known about the function of 
kainate receptors compared to AMPA receptors.
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The majority of AMP A receptors are permeable to both Na+ and K+, and almost 
impermeable to Ca2+, so from this it seems that GluRl, GluR3 and GluR4 are 
important for Ca2+ permeability of the receptor complex (Ozawa et al., 1998). AMPA 
receptors mediate fast excitatory neurotransmission at most of the synapses in the 
CNS. In the dorsal horn of the spinal cord, a brief acute and more persistent stimulus 
from the periphery causes activation by glutamate of AMPA receptors located 
postsynapticaly, responsible for setting the initial baseline response to both noxious 
and innocuous stimuli. Subsequently, repeated and high frequency stimulation 
activate NMDA receptors, which is the receptor that has attracted most attention 
amongst the various glutamate receptors because of its complex properties and role in 
a number of persistent events within neuronal circuits.
Based on expression cloning techniques, it was found that the NMDA receptor has a 
heterometric structure composed of four subunits that include NR1 which is the 
fundamental subunit for the heterometric form of the receptor plus three of the four 
NR2 subunits (NR2A-NR2D) which determinate the functional diversity between the 
different NMDA receptors (Hollmann and Heinemann, 1994).
NMDA receptors in the spinal cord have gained attention particularly for their roles 
in nociception. As mentioned above, NMDA receptors are activated following 
persistent noxious stimulation, due to the unique property of this receptor compared 
to AMPA and kainate receptors. The NMDA receptor is blocked by physiological 
levels of Mg at the resting membrane potential so that only stimuli with sufficient 
duration and intensity that cause repeated depolarisation of the neurone, are able to 
activate the receptor after the removal of the Mg2+ block. Other than glutamate, 
NMDA receptors require the binding of glycine to its site for activation and are also 
indirectly controlled by different peptides such as substance P which are co-released 
with glutamate (Dray et al., 1994) and contribute to removal of the Mg2+ block by 
actions on their receptors. Once the NMDA receptor is activated, the result is a 
substantially amplified postsynaptic response (Dickenson, 1995). Activation of the 
NMDA receptor therefore leads to the generation of spinal hypersensitivity and 
amplification of peripheral inputs (Besson, 1999). Furthermore, activation of the
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NMDA receptor leads to entry of Ca2+ions into the neurone which can then increase 
the activity of enzymes such as nitric oxide synthase (NOs) that generates NO. NO 
may be involved, in a complex way, in nociceptive events in the periphery and also 
within the spinal cord (Haley et al., 1992). It has been proposed that NO production 
appears to mediate NMDA-induced hypersensitivity and may contribute to centrally 
induced hyperalgesia (Kitto et al., 1992).
Glutamate and tachykinin NK1 receptors are required to generate wind-up, first 
described 40 years ago (Mendell and Wall, 1965). In brief, the recording of dorsal 
horn neurones shows that repetitive stimulation of peripheral C-fibres with a constant 
stimulus intensity produces a progressively increasing action potential discharge, in 
terms of both number and duration. This system for the amplification in the spinal 
cord of the nociceptive message that arrives from periphery is known as wind-up. 
Wind-up of dorsal horn neurones is usually evoked by C-fibres stimulation (Mendell 
and Wall, 1965). Also studies done by Dickenson and Sullivan, (1987a) found that 
blockade of NMDA receptors inhibit the generation of wind-up, underlying the 
importance of NMDA receptors in the mechanism of the wind-up. Although a 
number of different neuronal populations in the spinal cord show wind-up, WDR 
neurones have the most pronounced wind-up (Dickenson and Sullivan, 1987a; 
Herrero et al., 2000).
13.1.2. Substance P
Substance P (SP), an 11-amino acid peptide, together with Neurokinin A (NKA) and 
Neurokinin B (NKB) constitute a family of structurally related peptides called 
tachykinins or neurokinins. Pharmacological studies have established that substance P 
acts preferentially at the NK-1 receptor while the other two neurokinins (NKA and 
NKB) act on NK2 and NK3 receptors respectively (Brown et al., 1995). Although 
substance P and NKA share the same protein precursor molecule, preprotachykinin; 
hence is not surprising that they are found in the same sensory neurones.
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All the tachykinin receptors are members of the superfamily of receptors coupled to 
G-proteins. The activation of these receptors leads to the stimulation of phospholipase 
C and thus to the generation of 1,4,5-inositol-triphospahte (IP3) and diacylglycerol 
(DAG) and finally to the release of Ca2+ from the internal stores (Krause et al., 1992). 
Substance P, the most abundant peptide and also the most studied of the tachykinins, 
is synthesised in the dorsal root ganglia, and from there migrates to the dorsal hom of 
the spinal cord and peripherally to the terminals of sensory neurones (Barber et al., 
1979). This peptide is released from primary afferent fibres following acute noxious 
stimulation and there is strong evidence to suggest that substance P and its receptor 
play an important role in nociceptive transmission. In fact both peptide and receptor 
are highly distributed in many areas of the central and peripheral nervous system. In 
particular substance P is present in small diameter primary afferents which terminate 
mainly in superficial laminae I, the outer layer of lamina II and some penetrate into 
deeper laminae of the dorsal hom of the spinal cord (Brown et al., 1995; Todd et al., 
2000). The NK1 receptor is present on certain neurones of the dorsal hom; those with 
cell bodies in lamina I and a population of large neurones with cell bodies in lamina 
III or IV and is also found on dendrites that enter the superficial laminae (Littlewood 
et al., 1995; Mantyh et al., 1995; Abbadie et al., 1997).
There seems to be a mismatch between the dense concentration of substance P and 
the amount of NK1 receptors in the different laminae, and this fact is more evident in 
lamina II (Littlewood et al., 1995). An explanation could be that the peptide released 
from the superficial laminae can diffuse over considerable distances and reach the 
deeper laminae at sites far from the initial synapse (Brown et al., 1995).
In the recent years substance P and its receptor gained particular attention especially 
after Mantyh and colleagues (1997) developed a technique for selective ablation of 
neurones expressing the NK1 receptor. They provided evidence that neurones in the 
superficial lamina expressing NK1 receptor play a critical role in the development of 
hyperalgesia, since this was dramatically reduced in rats with an ablation of lamina I 
neurones expressing the NK1 receptor. This approach attracted many laboratories
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involved in pain studies and in chapter 7 of this thesis I will talk more about studies 
based on this technique.
Substance P is also one of the factors that initiate increased vascular permeability and 
protein extravasation after tissue injury in the periphery (Schaffer et al., 1998). 
Mantyh’s group also found that after acute noxious stimulation, neurones expressing 
the NK1 receptor show internalization of the receptor only in their distal dendrites, 
while after inflammation or peripheral nerve injury the internalization sites are 
extended to other areas of the neurone (Abbadie et al., 1997). These observations 
suggest that this receptor and subsequently its peptide are important for the coding of 
the noxious intensity in both acute and chronic pain states.
1.3.1.3 y-aminobutyric acid (GABA)
GABA, an inhibitory amino acid neurotransmitter, is widely distributed throughout 
the CNS, where it exerts its inhibitory actions. The most studied GABA receptors in 
the spinal cord are GABAa and GABAb, both of which are found mainly pre- but 
also post-synaptically on nociceptive afferent fibres (Desarmenien et al., 1984). 
GABAa receptors are classically defined by their sensitivity to the antagonist 
bicuculline; these receptors are comprised of five subunits (a, (3, y, 8, s or 7t) that 
form the walls of ligand-gated anion channels permeable to Cf (Bormann, 2000). 
Therefore their activation results in an increase in permeability to Cf and 
hyperpolarization of neurones. In addition to the GABA agonists and antagonists, 
GABAa receptors have also binding sites for barbiturates, benzodiazepines and 
various general anaesthetics (Farrant, 2001).
Unlike the GABAa receptor, GABAb receptors are G-protein-coupled receptors 
linked to an inhibition of Ca2+ influx via K+ and Ca2+ channel mediated actions 
(Farrant, 2001). Activation of GABAb receptors causes either increases in K+ 
conductance, which mediate hyperpolarization of the neurone or a decrease in Ca2+ 
influx, which causes decreases in neurotransmitter release (Hammon and Graham,
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1997). Both GABAa and GABAb, activation result in an inhibition of neuronal 
transmission. GABA-ergic terminals can also contain other inhibitory transmitters 
such as, glycine, galanin and neuropeptide Y (Rowan et al., 1993; Simmons et al., 
1995; Todd etal., 1996).
Immunoreactive studies done by (Todd and McKenzie, 1989) showed that GABA is 
concentrated in intemeurones of the superficial dorsal hom where mainly A8- and C- 
fibres afferents terminate. They reported that 24-33% of neurones in lamina I-III of 
the spinal cord contain GABA which underlines the importance of GABA-ergic 
systems in the modulation of nociceptive input in normal conditions and also in 
presence of inflammation where GABA is up-regulated (Castro-Lopes et al., 1994; 
Green and Dickenson, 1997). Another inhibitory system is represented by opioid 
receptors and will be discussed in chapter 3.
1.3.1.4 Monoamines
Serotonergic and noradrenergic neurones descend through the dorsal lateral funiculus 
from the brainstem to the spinal cord and terminate in the dorsal hom where they 
participate in the mechanisms that control impulse transmission and that significantly 
contribute to the modulation of pain. Electrical stimulation of brain sites such as 
periaqueductal gray (PAG) or the nucleus raphe magnus (NRM) produces analgesia 
via the local spinal release of endogenous serotonin (5-hydroxytryptamine, 5-HT) and 
noradrenalin (NA) see review (Furst, 1999).
The role of descending serotonergic pathways in the modulation of pain transmission 
is rather complicated by the multiplicity of its target 5-HT receptors and their location 
on the afferent fibres and/or intremeurones, activation of which exerts both pro- and 
anti-nociceptive actions (Millan, 1997).
Currently, there are three major classes of 5-HT receptors: 5-HTj, 5-HT2, 5-HT3 and 
5 -HT4 which are further subdivided into subtypes. These multiple receptors are
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mainly present in laminae I, III and IV and therefore may play an important role in 
pain transmission. In this regard, particular attention has been given to the receptors 
5-HT] A and 5-HT3 highly concentrated in superficial lamina I/II. The 5-HTia receptor 
was suggested to produce an enhanced nociception effect in the dorsal horn that may 
be due to inhibition of GABAergic and other intemeurones (Millan, 1997).
5-HT2 receptors may mediate other inhibitory effects of serotonin by blocking the 
release of glutamate either by indirect actions or they may directly suppress 
neurotransmitter release in the dorsal hom (Obata et al., 2001). By contrast, 5-HT3 
receptors directly activate a cation-permeable ion channel which triggers the opening 
of voltage dependent calcium channels, and they can also induce phospholipase C and 
further increases in intracellular concentration of calcium ([Ca2+]i) (Millan, 1999). 
Thus, the [Ca2+]i increase will therefore cause release of neurotransmitters in the 
dorsal hom of the spinal cord.
Electrophysiological studies showed that under normal conditions intrathecal 
injection of 5-HT3 receptor agonist, m-CPBG [l-(m-chloro-phenyl) biguanide], 
mediates neuronal excitation while the application of 5-HT3 antagonists such as 
ondansetron (GR38032F) and ICS 205-930 causes a clear inhibition of nociceptive 
responses (Ali et al., 1996). Similar electrophysiological studies showed that during 
peripheral inflammation with formalin, 5-HT3 antagonist (ondansetron) decreases the 
response of both phases of formalin induced inflammation, suggesting that in contrast 
to the normal condition where there is little or no 5- HT3 receptor mediated control 
over nociceptive neurones in the dorsal hom, in presence of peripheral inflammation 
the descending serotonergic system is enhanced by acting via excitatory 5-HT3 
receptors in the dorsal hom. This can then maintain or enhance the response of 
nociceptive spinal neurones to formalin induced peripheral inflammation (Green et 
al., 2000).
Moreover, studies done on knockout mice (lacking a key 5-HT3 receptor subunit) 
show that these animals exhibit normal acute pain responses to mechanical and 
thermal stimuli, however persistent pain behavior in presence of formalin or nerve
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injury was significantly reduced in these animals (Zeitz et al., 2002). Although most 
of the studies that are mentioned above agreed the facilitatory role of 5-HT3 receptor, 
others have proposed paradoxical antinociceptive effects of this receptor probably by 
causing release of GABA, which may in turn inhibit nociceptive transmission in 
primary afferent fibres (Alhaider et al., 1991).
In recent years the role 5-HT3 in the descending facilitation has been further 
evaluated. Following depletion of lamina I expressing NK1 neurones receptor 
through the use of substance P conjugated with saporin which is cytotoxic (SP-SAP) 
(Mantyh et al., 1997), a markedly attenuated responses to pain behavior (mechanical 
and thermal) induced by intraplantar capsaicin injection was observed (Mantyh et al., 
1997). Also electrophysiological recordings in lamina I expressing NK1 ablated 
animals revealed clear reduction in the characteristic response of deeper (lamina V) 
dorsal hom neurones such as receptive field size, mechanical and thermal evoked 
responses, wind-up responses as well as responses to formalin induced inflammation 
(Suzuki et al., 2002). Surprisingly, most of these reduced effects were reproduced by 
blocking the 5-HT3 in the spinal cord using ondansetron in normal animals, except 
the wind-up response which was not effected by ondansetron, as this spinal 
phenomenon is intrinsically dependent on lamina I- lamina V circuit but not 
influenced by descending facilitation (Dickenson et al., 2004). This data provides 
evidence that the 5-HT3 receptor has a key role in the descending facilitation 
influence from the brainstem, and underlines the importance of NK1 expressing 
neurones in the ascending pathway lamina I-parbrachial (PB) in the pain response 
(Suzuki et al., 2002).
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1.4 Pathways involved in pain transmission
There are several afferent pathways from the spinal cord to the brain where the 
central processing of nociceptive information is initiated and the final sensation is 
established. These include components of the spinothalamic tract (STT) directly 
projecting to the thalamus, spinoreticular (SRT) and spinomesencephalic tracts 
(SMT) projecting to the brainstem as well as spinocervical (SCT) and postsynaptic 
dorsal column tracts (PSDC) (Craig and Dostrovsky, 1997).
1.4.1 Spinothalamic tract (STT)
The spinothalamic tract is the most important spinal cord pathway associated with the 
transmission of the information relating to pain and temperature sensation. The STT 
cells that terminate in the thalamus have their origins in lamina I, where 50% of STT 
cell are located, and the other 50% are found in lamina V and lamina VII (Craig and 
Dostrovsky, 1997). This was also confirmed by studies done by (Gauriau and 
Bernard, 2002) suggesting that the STT tract appears to be involved in nociceptive 
processing from deep dorsal hom neurones. As discussed previously in section 1.2 
and 1.3, each lamina is characterized by different primary afferent fibres and 
neurones suggesting that varied information is transmitted centrally.
Briefly, STT cells include nociceptive specific neurones that respond only to noxious 
stimuli, thermoreceptive-specific cells excited by innocuous cooling and inhibited by 
warming stimuli, the WDR cells that respond to both innocuous and noxious stimuli, 
and other complex cells responding to both innocuous and noxious stimuli with large 
and bilateral somatic regions (Craig and Dostrovsky, 1997).
The properties of the spinothalamic neurones enable them to respond to a variety of 
stimuli and their projections mainly end on the ventrobasal thalamus making the STT 
tract very suitable for a role in signalling noxious stimuli (Willis, 1989).
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The STT tract also projects to the lateral thalamus; including the ventral posterior 
nuclei (VPL, VPM); this area receives input from the superficial laminae and further 
projects to the somatosensory cortex, involved in the discriminative aspects of 
nociceptive processing (Gauriau and Bernard, 2002).
1.4.2 Spinoreticular (SRT) and spinomesencephalic tracts (SMT)
Spinoreticular and spinomesencephalic tracts are part of the spinobulbar projections, 
which make an important contribution to the neuronal activity underlying the 
motivational-affective aspect of pain, as well as somatic and autonomic motor 
reflexes (Willis, 1989). Overall the distribution of spinoreticular and 
spinomesencephalic cells is quite similar to the distribution of spinothalamic cells 
(Craig and Dostrovsky, 1997). The spinoreticular cells origins are primarily in the 
deep dorsal hom with some minor projection from laminae I and X (Sorkin and 
Carlton, 1997). These cells project to several reticular nuclei, such as the lateral 
reticular nuclei (LRN) a motor area close to the cerebellum, and the 
gigantocellular/paragigantocellular reticular nuclei (NGc). These projections together 
with the subnucleus reticular dorsalis (SRD) located in the caudal part of the medulla, 
make an important contribution to the motor reaction and escape behaviour induced 
by noxious stimuli, and also modulate the transmission of nociceptive messages in 
the deeper laminae (Gauriau and Bernard, 2002). In addition, descending projections 
from the spinoreticular area are proposed to provide inhibitory control of nociceptive 
input and participate in the endogenous analgesia system (Willis, 1989). However, 
descending controls from these areas can also be facilitatory.
The spinomesencephalic cells project mainly from laminae I and they selectively 
project to the lateral periaqueductal grey (PAG), while inputs from the deeper 
laminae terminate in both the lateral and the medial portion of die PAG (Sorkin and 
Carlton, 1997) and also a few cells project to the PB group (Craig and Dostrovsky, 
1997). The PB area comprises several nuclei that receive dense inputs from lamina I 
(Craig and Dostrovsky, 1997); they respond to visceral inputs (Gauriau and Bernard,
31
2002). High proportions of the PB neurones project to either the amygdala or 
hypothalamus and are specifically excited by noxious stimuli. These projections play 
an important role in the motivational behaviour produced by pain, for example, 
emotional reactions such as anxiety, the emotional memory of pain which induces 
fear, and the mechanism of defence and aggression (Gauriau and Bernard, 2002).
The PB areas communicate also with the brainstem via PAG, an area involved in the 
passive emotional response to pain such as immobility, and hyporeactivity as well as 
the active emotional response of pain for example aggression, fear and other forms of 
hypereactivity (Gauriau and Bernard, 2002). The PAG has a central role in the 
mechanisms of descending inhibition and is involved in the supraspinal analgesia of 
opioids (Stamford, 1995), for further discussion see chapter 3.
1.4.3 Spinocervical (SCT) and Postsynaptic dorsal column tracts (PSDC)
Spinocervical tract cells are located in lamina I, III and IV where they respond to both 
noxious and innoxious stimuli mainly from hair follicles (Sorkin and Carlton, 1997). 
The lamina I terminals of this tract project to the medial lateral cervical nucleus 
(LCN) and the deeper cells project to the lateral portion of the LCN. Less is known of 
the origin of the postsynaptic dorsal column cells in rats than other species but some 
neurones are nociceptive (Suzuki and Dickenson, 2002).
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1.5 Neuropathic pain
Neuropathic pain is initiated or caused by a primary lesion or dysfunction in the 
nervous system. Neuropathy can be divided into peripheral and central neuropathic 
pain, depending on where the lesion occurs or how the dysfunction affects the 
peripheral or central nervous system (Serra, 1999).
Peripheral neuropathy can Result from metabolic disorders, such as diabetes mellitus 
(diabetic neuropathy), infections, such as herpes zoster (post-herpetic neuralgia) and 
human immunodeficiency virus, nerve compression due to tumours, as well as 
neuroma formation arising from amputation or nerve transection (Garry, 1997). 
Central mediated neuropathic pain can result from disorders of the spinal cord such as 
multiple sclerosis and trauma or tumours in different region of the spinal cord and 
brain. This pain state differs from acute pain because the therapy provides only 
transient pain relief and does not resolve the underlying pathological process, and in 
fact, chronic pain will continue when the treatment stops (Loeser, 1999).
Peripheral nerve disorders are the major class of neuropathic pain encountered in 
patients. There are several symptoms of neuropathic pain, the most studied ones are 
associated with spontaneous pain, hyperalgesia and allodynia; which seriously 
compromise the quality of life of the patient.
Spontaneous pain, is a pain perception arising from the innervation area of the injured 
nerve and can occur in the absence of an external stimulus. This stimulus independent 
pain can be continuous (ongoing) or paroxysmal (episodic) pain and is often 
described by the patient as having ‘tingling, crawling, cramping, burning or stabbing’ 
components (Bennett, 1994). This type of pain appears to be common in patients with 
central and peripheral nerve damage.
In contrast, neuropathic pain is also characterised by the presence of stimulus-evoked 
pain and has two key features: allodynia and hyperalgesia. Allodynia is the sensation
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of pain evoked by a normally non-noxious stimulus such as gentle touch and 
brushing. It can be produced by the activation of low threshold myelinated Ap-fibres. 
A theory was proposed by Woolf et al., (1992), when they observed that after nerve 
injury there was a significant sprouting of the large Ap-fibres into the superficial 
lamina of the dorsal hom of the spinal cord, area that normally receive nociceptive 
input. This was taken as suggesting that the sprouting could lead formation of 
anomalous synapses with cells important for the transmission of nociceptive 
information (Ossipov et al., 1997). Recent work casts doubt on this theory since the 
tracer used may no longer be selective for large fibres after nerve injury and now is 
taken up by damaged fine fibres (Hughes et al., 2003).
Allodynia can be further defined in terms of the evoking stimulus, such that 
‘dynamic’ or tactile allodynia arises from a moving stimulus in contrast to the ‘static’, 
‘pressure’ and ‘punctate’, allodynias, produced by large or fine-tipped probes, 
respectively. Tactile allodynia sensation is one of the major debilitating pain 
symptoms among patients with neuropathic pain since even gentle contact with 
clothes can evoke intense pain sensations. In combination with the mechanical 
allodynia there may also be warm- and cooling-allodynia which are perceptions of 
pain produced by warm and cold stimuli respectively (Bennett, 1994).
Another stimulus-evoked pain is represented by hyperalgesia, which is described as 
an enhanced pain perception, such that there is an abnormal increased pain response 
to a normally noxious stimulus. As with the allodynia, the hyperalgesia can be further 
classified as mechanical, heat and cold hyperalgesia. Although allodynia and 
hyperalgesia are conceptually different, they are often confused or misinterpreted. 
The main difference between the allodynia and hyperalgesia is represented thus; 
while allodynia represents a qualitative change, hyperalgesia is more a quantitative 
change in the perception of pain.
Paradoxically, despite the sensory deficit that results from the sensory loss in 
neuropathic states, pain can on occasions, be evoked from that same area.
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Hyperpathia is the term given to that condition: a painful syndrome, characterized by 
increased reaction to a stimulus where the pain continues after the painful stimuli 
causing the pain stops. Hyperpathia can be evoked by both normal innocuous and 
normal noxious stimuli.
This classification of aetiology and symptoms presents part of the framework of 
neuropathic pain which is a complex state and still, the relation between the 
symptoms and underlying mechanisms is not fully understood. Several mechanisms 
may be at work in an individual patient, and the same mechanisms may not be present 
in all patients who share a specific neuropathic pain state. Furthermore one 
mechanism could be responsible for many different symptoms and this may change 
with time. This variability suggests that neuropathic pain can result through diverse 
mechanisms and consequently the treatment of neuropathic pain will be complex. In 
order to further clarify our understanding in the mechanisms of neuropathic pain it 
has been necessary to develop valid animal models of this clinical state.
1.5.1 Animal models of neuropathic pain
Basic scientific research into the causes and possible treatment of neuropathic pain 
has accelerated with the development of animal models that reflect some of the 
elements of clinical pain syndrome.
Earlier models of neuropathic pain involved a complete lesion or crush or nerve 
section to mimic the state seen after amputation, but more recently with the 
recognition that most neuropathic pain patients have a partial nerve injury, models 
which preserve some of the sensory information passing into the spinal cord become 
more common. The most popular of these are the mononeuropathy models which are 
the chronic constrictive injury (CCI) model (Bennett and Xie, 1988), partial sciatic 
tight ligation (PSTL) model (Seltzer et al., 1990) and the selective spinal nerve 
ligation (SNL) model (Kim and Chung, 1992), which are represented in Fig.3.
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Figure 3. Animal models o f neuropathy. PSTL (partial sciatic tight ligation) involves 
tight ligation o f 1/3 to 1/2 o f the sciatic nerve; CCI (chronic constrictive injury) 
consist o f loose ligature around the sciatic nerve. Finally the SLN (spinal nerve 
ligation) model used in this thesis involves tight ligation o f L5 and L6 spinal nerves. 
Figure modifiedfrom (Decosterd and Woolf 2000).
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The CCI model involves placement of four loose chromic catgut ligatures around the 
sciatic nerve, approximate to the trifurcation. In the PSTL model, neuropathy is 
caused by a partial ligation of the sciatic nerve in that a tight ligature is placed around 
one third to a half of the nerve. Following the surgery, behavioural studies reveal that 
both models show allodynia and hyperalgesia to mechanical and thermal (both hot 
and cold) stimuli (Bennett and Xie, 1988; Seltzer et al., 1990). These evoked 
responses are apparent within 1-2 days and maintained for a post-operative period of 
up to 3 months. Animals also display a characteristic ‘guarding’ posture on the side 
ipsilateral to the nerve injury and they avoid contact with the floor in the absence of 
external stimuli; this spontaneous nociceptive behaviour may indicate that the 
animals have on-going pain. Autotomy has been reported in the CCI model (Bennett 
and Xie, 1988), probably in an attempt to rid themselves of the pain or the unpleasant 
sensation of the painful hindpaw, which is not a common clinical observation 
relevant to the human condition. However, the self mutilation observed in the CCI 
model and the degree of variability associated with the main difficulty of creating the 
same amount of nerve damage in these former two models lead to the use of SNL 
model in this thesis.
The SNL presents an alternative approach to the CCI and PSTL models, and was 
developed by Chung and colleagues using partial ligation of the sciatic nerve by tight 
ligation of the L5 and L6 of the spinal segmental nerve, leaving the L4 component of 
the sciatic nerve intact in order to avoid motor deficits, see section 2.1. in the methods 
for the surgical description of this model. In this model rats develop long lasting 
hyperalgesia to noxious mechanical and thermal stimuli as well as mechanical and 
cold allodynia which persist for up to 2 months (Kim and Chung, 1992). However, 
Kim and Chung observed that the ipsilateral hind paw became extremely sensitive by 
2 weeks after the surgery, and can be seen in Fig.l of the methods section where the 
response to the lowest von Frey show further increases of foot withdrawals in day 14 
of the postoperative period, which indicates strong presence of mechanical allodynia 
around that period. In fact the electrophysiological studies of these animals are made 
after day 14.
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Using this model rather than the CCI and PSTL, since the same spinal nerves (L5/L6) 
in each animal are tightly ligated in the SNL model, so limiting the variability in the 
type and number of injured fibres between the experiments (Kim and Chung, 1992). 
An unique property of this model is presented by the fact that the location of the 
injured fibres are in completely separate segments from the uninjured fibres, since the 
dorsal root ganglia (DRG) which contains the injured nerves is separated from the 
adjacent DRG containing intact neurones (Kim and Chung, 1992). The situation is 
opposite in the CCI and PSTL, where the injured and the intact fibres are mixed.
The only variability in the SNL model is normal biological variability where 
differences between individual rats may exist in the proportion of the sciatic nerve 
contributed to by the 3 spinal nerve segments.
The behavioural consequences of these nerve injuries emphasizes that these animal 
models present predictable changes in the behaviour that are close parallels to the 
effects of injuries in humans. Investigating the altered functions-anatomical, 
electrophysiological and neurochemical in the neuropathic pain is important to 
provide more understanding of mechanisms and insights into the corresponding pain 
state in humans.
1.5.2 Mechanisms of neuropathic pain
In normal conditions as described above, the mechanisms by which a noxious or 
nociceptive stimulus is evoked, transmitted and finally perceived are complex. At 
each of these functional levels there is a balance between excitatory and inhibitory 
systems. In neuropathic pain this process becomes more complicated due to both the 
interruption of the normal connections of the system and the dynamic compensatory 
responses that occur throughout the nervous system. There are changes related to the 
tissue damage which cause excitability changes in the periphery and central nervous 
system that establish healing of the nerve injury and are reversible responses. Other 
changes are more permanent and persist despite resolution of the original neuropathic
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insult. This latter group is likely to correlate closely with neuronal plasticity that may 
be responsible for the chronic neuropathic pain syndrome. Some of these changes 
associated with nerve injury will be discussed below.
1.5.3 Anatomical changes within peripheral nerves
The sensory neuronal pathway starts within the primary afferent neurones that are 
characterized by a cell body located within the dorsal root ganglia (DRG) and a stem 
process that bifurcates into a central process that enters the dorsal hom of the spinal 
cord and peripheral processes that target tissue. The afferent fibres of this nerve, 
according to their degree of myelination and other properties discussed in section 1.1 
are classified into A- and C-fibres. In normal condition the myelinated fibres, myelin 
is important to facilitate the propagation and the conduction of impulses and their 
ongoing transmission along the axon. Also present are supporting Schwann cells with 
a primary function to myelinate and promote rapid nerve impulse transmission 
located along the axon of the peripheral nerves (Gillespie et al., 2000).
Following peripheral nerve injury, there are changes in the anatomy of the peripheral 
nerves that may explain the generation of neuropathic pain. Peripheral nerve damage 
usually results in the formation of a ‘neuroma’, a swollen end, due to continued 
axonal transport. In a state of nerve injury, in the same way as inflammation can 
induce infiltration of macrophages and immunocompetent cells (further discussion 
see section 1.6) these cells could damage nerves and DRG. This damage is thought to 
be mediated by the phagocytotic action of macrophages that invade the site of nerve 
injury following nerve injury. All these insults, together with a disruption to Schwann 
cell distribution and density that occurs along the damaged axon produces areas of 
demyelination, which causes disruption in the axonal transport essential for the 
maintenance and repair of the axonal process yet also leading to an alteration of 
conduction or excitability of the injured nerve (Garry, 1997). Following nerve injury 
there is a substantial decrease in the number of sensory axons distal to the site of 
damage accompanied by sensory neuronal cell death in the DRG. Is not surprising
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that the major loss involves the largely myelinated A(3- and A5-fibres, which reach up 
to 89% and 55% of fibres lost, respectively, with little reduction in C-fibre numbers 
(Garry, 1997).
Furthermore, following injury the denervated peripheral tissue does not passively 
wait for reinnervation, but rather, it actively responds to the lack of electrical and 
chemical communication by inducing direct regenerative efforts and sprouting of the 
axon to attempt to regain their appropriate connection to the central nervous system 
(Colburn and Munglani, 2003). The regeneration of injured peripheral nerves appears 
to be dependent on the presence of regeneration-promoting substances such as nerve 
growth factor (NGF) and apolipoprotein E in the outgrowth region (Garry, 1997). 
These substances are known to promote the development of the nervous system and 
their role in the myelination of the newly grown axon, respectively. Regeneration of 
the nerve and consequently the recovery of the target organ function are not always 
successful; it depends on fibre type of nerve fibre and the severity of nerve injury. It 
appears that large, myelinated A (3-fibres are least likely to regenerate, in comparison 
to C-fibres (Navarro et al., 1994).
In addition to these attempts to provide direction for the regenerating axon, however, 
uninjured sensory axons from the neighbouring nerves expand into the area 
previously innervated by the lesioned nerve. This phenomenon is termed collateral 
sprouting and leads to altered sensory properties that includes expanded receptor 
fields, sensitized stimuli transduction, and changes in central synaptic connectivity 
(Colburn and Munglani, 2003). All these altered sensory properties suggest that the 
collateral sprouting may be implicated in the development of hyperalgesia. An 
example can be presented by experiments done in the model of CCI, showing a 
marked hyperalgesia, where the hyperalgesia was prevented by saphenous nerve 
section to prevent collateral sprouting, one week after nerve injury (Ro and Jacobs, 
1993). A similar case may also occur in the partial denervation where the collateral 
sprouting can form connection with the damaged nerve. So it appears that following
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injury aberrant connections can cause both peripheral and central plasticity that 
contributes to the development of neuropathic pain.
Another important consequence following nerve injury is abnormal nociceptor 
sensitization, where the primary afferent fibres respond with increased sensitivity to 
various stimuli (mechanical, thermal and chemical) due to the local release of 
inflammatory mediatory such as bradykinin, histamine, prostaglandins and 
leukotrienes (Garry, 1997). This action of mediators may contribute to the 
maintenance and the development of hyperalgesia and allodynia following nerve 
injury.
1.5.3.1 Ephaptic transmission
In normal, uninjured physiological conditions each primary afferent neurone 
transmits impulses through independent sensory channels in the peripheral nervous 
system until convergence occurs in the dorsal hom. This is made possible by the 
myelination of A-fibres, and the presence of non-neuronal glia cells (Schwann cell) 
processes that separate them from unmyelinated C-fibres.
In contrast, following nerve injury the insulation of these processes can be disrupted 
as discussed previously and as consequence the impulse can be transmitted to the 
neighbouring fibres, leading to a phenomenon called ephaptic transmission or cross 
talk (Garry, 1997). This phenomenon maybe contributes to the expanding of the 
receptor field and so the central nervous system will not receive an accurate coding of 
information. All these may therefore contribute to the abnormal sensations related to 
neuropathic pain and explain how innocuous stimulation can result in perception as a 
noxious stimulation or vice verse as part of the abnormal response to the stimulus.
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1.5.3.2 Ectopic activity
Action potentials can travel in both directions in sensory axons. With nerve injury, 
ectopic discharge can result in antidromic action potentials leading to release of 
neuropeptides. These neuropeptides, such as substance P and CGRP, can lead to the 
sensitization of the peripheral sensory terminal of injured and uninjured fibres (Woolf 
and Mannion, 1999). As a result, sensitization of primary afferent nociceptors (A8- 
and C-fibre) is characterized by ongoing discharges, a lowered threshold for 
activation, and an increased response to a given stimulus.
Following nerve injury, it has been demonstrated that there is reorganization of the 
nature and levels of expression of the various channels, (see section 1.5.4). Sodium 
channels are one of the most important channels, indispensable for the conduction of 
neural impulses and changes in the expression of these channels are thought to 
contribute to the generation of the ectopic activity that can occur in the damaged 
primary afferent fibres, their DRG and also areas of demyelination along the axon of 
the injured nerves,see review (Teng, 2003).
Ectopic activity that occurs within the DRG is slow and irregular compared to the 
rhythm and high frequency of the ectopic activity in most injured afferent site. These 
ectopic discharges would then enter the spinal cord and sensitize spinal dorsal hom 
neurones (Yoon et al., 1996). The ectopic afferent activity is largely responsible for 
the development of hypersensitivity of spinal cord dorsal hom neurones and the 
hyperalgesia and allodynia associated with neuropathic pain in rats (Yoon et al., 
1996). Clinical studies also provide strong evidence that the ectopic discharges from 
afferent nerves are a source of ongoing spontaneous pain, and this abnormal afferent 
activity dynamically maintains a state of central hypersensitivity that underlies 
evoked-pain syndromes such as allodynia and hyperalgesia in patients with painful 
neuropathies (Gracely et al., 1992; Campero et al., 1998). Thus, drugs capable of 
suppressing the ectopic afferent activity may provide an effective therapy for the
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treatment of neuropathic pain. In this regard, the analgesic effect of anticonvulsants 
may be mediated partly by their action on ectopic afferent discharges (Pan et al.,
1999). Mechanisms underlying the generation of ectopic discharges from injured 
afferents are complex and likely to involve the interaction between endogenous 
chemicals and ion channels.
1.5.4 Alteration of ion channels in nerve injury
Ion channels such as Na+, Ca2+ and K+ regulate neuronal excitability and are involved 
in the initiation and propagation of action potentials along nerve axons.
Since impulse initiation at normal localization is dependent on Na+ channels, several 
studies have been done to understand changes that occur in the expression of these 
channels in DRG neurones following injury. In nerve injury there is both a triggered 
hyperexcitability and the ectopic initiation of impulses in primary afferent fibres.
In the sensory neurones two classes of functionally distinct Na+ channels are present, 
which are classified as tetrodotoxin sensitive (TTX-S) and TTX resistant (TTX-R) 
Na+ channels. The TTX-S Na+ channels are expressed in large and small diameter 
sensory neurones and are inactivated and sensitive to submicromolar concentration of 
TTX. While the TTX-R Na+ channels including the N avi.8 and Navi.9, are 
insensitive to submicromolar concentration of TTX and both channels are slow 
activated channels (Zhang et al., 2004). The small diameter nociceptive fibres express 
both TTX-S and TTX-R Na+ channels, this preferential expression of TTX-R in the 
nociceptive fibres suggesting the importance of these channels in the pharmacological 
treatment of pain (Waxman et al., 1999).
Previous studies have demonstrated that changes in Na+ channel expression at both 
DRG and the site of nerve injury occur after nerve injury. In particular a down- 
regulation of both TTX-R channels (Nav 1.8 and NaVl.9) and a TTX-S Na+ channel 
(Nav 1.7) as well as up-regulation of another TTX-S Na channel (Nav 1.3) were 
shown in DRG neurones, for further discussion see Zhang et al., (2004).
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On the other hand, immunolocalization studies showed that the level of Na+ channels 
increases at the site of nerve injury (Devor et al., 1993) and this was due to an 
accumulation of Nav 1.8 and Nav 1.9 at the site of nerve injury (Coward et al., 200(1).
As a result, changes in the expression of Na+ channels are thought to contribute to 
spontaneous activities, hypothesized to be one of the mechanisms underlying 
neuropathic pain (Dib-Hajj et al., 1999; Waxman et al., 1999; Zhang et al., 2004). 
Since low doses of TTX block the TTX-S Na+ channels, which in turn inhibits 
ectopic firing originating from neuromas, DRG and dorsal hom neurones (Omana- 
Zapata et al., 1997) and reduces neuropathic behaviors such as allodynia (Lyu et al.,
2000), it therefore appears that TTX-R and TTX-S Na+ channels may play differential 
roles in pain transmission with a significant contribution of TTX-R Na+ channels in 
uninjured neurones and TTX-S Na+ channels in injured neurones (Zhang et al., 2004).
Furthermore, Na+ channel blocker drugs including local anaesthetics and 
anticonvulsants that inhibit the opening of the Na+ channels, when applied directly to 
the nerve or administrated systemically reduce ectopic neuronal discharge, further 
discussion of the pharmacological treatment of neuropathic pain see section 1.5.7.
Sodium channels are not the only channels that are involved with neuropathic pain. 
Calcium channels have been shown to affect the development of hyperalgesia and 
allodynia. Several studies have demonstrated that hyperalgesia and allodynia can be 
reduced with the application of specific antagonists for neuronal N-type calcium 
channels, further discussion see section 1.5.7.
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1.5.5 Neurochemical changes in nerve injury
In nerve injury there are complex mechanisms since the sensory neurones and the 
non-neuronal cells associated with them are highly interdependent. They form an 
ecosystem, where a change in one of them affects many other systems. In the 
previous section I described changes related to anatomy, sensory property 
transmissions and some channels, important for the mechanisms of neuropathic pain. 
In addition to these changes it is believed that the sensory neurones in the DRG 
respond to the injury by altering the synthesis of various proteins in an effort to 
support and regenerate the injured neurones (Garry, 1997). More specifically, nerve 
injury triggers changes in gene expression in the DRG, where in some cases increases 
and in others, decreases in proteins are seen.
1.5.5.1 Neurochemical up-regulation
The presence of nerve injury cause an increase in the number of cells immunoreactive 
for vasoactive intestinal peptide (VIP) in the primary sensory neurones of the dorsal 
hom of the spinal cord and their DRG (Shehab and Atkinson, 1986). VIP is highly 
expressed in certain sacral afferents, but the fact that VIP gene expression is induced 
in the lumbar ganglia following injury suggest that VIP may be playing a role in 
control of neuronal degeneration and elicit a survival-enhancing effect as seen on 
neurones in vitro and in vivo (Hokfelt et al., 1994). Further, it is present in both A- 
and C-fibre where it acts as a facilitatory neurotransmitter in the dorsal hom, and this 
role may be accentuated subsequent to nerve injury. Thus, VIP assumes a major, 
excitatory role in nociceptive transmission in neurones in the dorsal hom following 
its induction by peripheral afferent fibres injury (Shehab and Atkinson, 1986); 
(Hokfelt etal., 1994).
Similar to VIP, galanin is also upregulated following nerve injury. In intact animals, 
the neuropeptide galanin is expressed in a small number of DRG neurones, 
preferentially in the small diameter cells and it is characterized by both facilitatory
45
and inhibitory effects (Wiesenfeld-Hallin et al., 1992). This biphasic effect of 
galanin, might be due to the fact that there are several galanin receptors involved. In 
fact there are three cloned galanin receptors, GalRl, 2 and 3 (Branchek et al., 2000). 
The galanin receptors in spinal cord and DRG are mainly represented by GalRl and 
GalR2. In normal animals low levels of galanin produce a pro-nociceptive response 
but the peptide inhibits at higher doses (Wiesenfeld-Hallin et al., 1992). Thus, after 
nerve injury where galanin receptor is upregulated, spinal administration of galanin 
causes predominantly inhibitory effects in the dorsal hom (Wiesenfeld-Hallin et al., 
1992; Hokfelt et al., 1994). Furthermore, experiments carried in rats with intact 
nerves, galanin antagonizes the facilitatory effect of substance P and CGRP. This 
condition is altered following injury; galanin in this case has no effect on exogenous 
substance P, but counteracts the facilitatory effect of VIP (Xu et al., 1990).
Another neuropeptide recently shown to be associated with sensory neurones is 
neuropeptide Y, which is up-regulated after nerve injury and mostly is present in the 
large myelinated A (3-fibres (Wakisaka et al., 1991). The intrathecal injection of 
neuropeptide Y induced a similar biphasic effect to galanin, with a facilitatory effect 
at lower doses and inhibitory effect at higher does (Xu et al., 1999). This biphasic 
effect may be related to several subtypes of neuropeptide Y receptor. In fact, anatomy 
and functional data suggest that neuropeptide Y receptors are heterogenous and can 
be classified into six subtype receptors Y1-Y6, where Y2 are mainly located in DRG 
neurones and Y1 in some dorsal hom intemeurones (Xu et al., 1999). Both peptide 
and receptors in the DRG and in the spinal cord undergo marked plasticity after nerve 
injury. Nerve injury induces an up-regulation of neuropeptide Y which increases both 
its excitatory and inhibitory effects (Xu et al., 1994).
Furthermore, nerve damage causes also alterations of neuromodulators in primary 
afferent fibres, such as nitric oxide (NO). Several studies suggested that spinal NO, a 
neuronal messenger, synthesised from L-arginine by nitric oxide synthase (NOs), 
which is found throughout the CNS, is involved in the mechanism of pain induction. 
In this regard, epidural injection of L-arginine produces a slowly developing thermal
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hyperalgesia in rats (Masue et al., 1999). This facilitatory effect of NO can be 
explained by the fact that spinal NO release is evoked by NMDA receptor activation 
suggesting that NO production and its extracellular movement may be linked in the 
pathways that follow NMDA receptor activation (Bogdanov and Wurtman, 1997) see 
also section 1.3.1.1. Also, nerve injury induced either by spinal nerve ligation (Luo et 
al., 1999) or sciatic nerve transection (Verge et al., 1992) causes marked increases in 
the expression of messenger RNA level of neuronal NOs in the DRG. Since, a 
nonspecific NOs inhibitor, Mo-nitro-L-arginine methyl ester (L-NAME), attenuates 
hyperalgesia and allodynia following nerve injury (Yoon et al., 1998), suggesting that 
spinal NO production may contribute to the control of pain behaviours following 
nerve injury. On the other hand administration of NOs inhibitors failed to decrease 
the background activity of dorsal hom neurones and to reverse the allodynia in 
normal and nerve injured rats respectively (Luo et al., 1999; Hoheisel et al., 2000). 
However, although the level of NO is upregulated after the nerve injury, the 
correlation between neuronal NOs expression and the development and/or 
maintenance of allodynia is not clear.
Finally, following nerve injury there is an increase level of cholecystokinin (CCK). 
This peptide is widely distributed in several areas of CNS important in the 
modulation of nociceptive transmission. Although CCK does not alter baseline pain 
thresholds (Xu and Wiesenfeld-Hallin, 1997), it is believed that CCK is partly 
responsible for the reduced opioid actions in neuropathic pain and this will be 
discussed in chapter 6.
1.5.5.2 Neurochemical down-regulation
In contrast to the increased expression of neuropeptide Y, VIP, galanin and CCK 
discussed above, some other peptides decrease in the DRG following nerve injury. 
Studies have reported that following nerve injury there is down-regulation of peptides 
such as CGRP and substance P (Cameron et al., 1991).
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CGRP and substance P, as mentioned in section 1.3, both facilitate transmission in 
the dorsal horn of the spinal cord. Since noxious peripheral stimulation evokes a 
release of these peptides in the dorsal horn of the spinal cord (Morton and Hutchison, 
1989) it has been established that both CGRP and substance P are colocalized in most 
primary sensory neurones, although CGRP is present in 50 % of neurones of all sizes 
while substance P is present in 20% of neurones of small size (Nothias et al., 1993; 
Hokfelt et al., 1994). These observations together with the finding that intrathecal 
administration of CGRP elicits hyperalgesia (Yu et al., 1994), have led to the 
suggestion that this peptide may have a role in nociceptive transmission and 
modulation. CGRP exerts its pronociceptive effect via two receptor types, CGRPi 
and CGRP2, both of which are positively coupled to adenyl cyclase, however it is not 
clear what the respective role of these receptors is in the mediating the action of 
CGRP (Millan, 1999).
In addition to the direct role of CGRP in the spinal cord, CGRP potentiates the effect 
of substance P by inhibiting substance P endopeptidase, an enzyme that catalyzes the 
substance P within the amino acid chain (Hokfelt et al., 1994). In nerve injury it 
seems that the role of pain transmitting mediators such as substance P and maybe also 
that of CGRP is taken over by VIP (Wiesenfeld-Hallin et al., 1990). This was 
suggested by studies done in normal animals which showed that a substance P 
antagonist attenuated the facilitatory effect of substance P, while in nerve injury the 
antagonist had no effect and surprisingly a VIP antagonist which had no effect under 
normal conditions antagonized the effect of substance P following injury 
(Wiesenfeld-Hallin et al., 1990).
As opioid receptors are down regulated in presence of injury this may explain the 
reduced effect of this class of drugs in nerve injury, and further discussion of the 
opioid system is in chapter 3.
These changes in the neuropeptide expression underline the complexity of the 
neuropathic mechanisms and subsequently the treatment of neuropathic pain. The 
overall effect is a state of spinal cord disinibition and increased receptivity to 
incoming stimuli.
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1.5.6 Sympathetic system
Under physiological conditions, the activity of the primary afferent fibres nociceptors 
is unaffected by sympathetic outflow, due to the lack of or low catecholamine 
sensitivity (Janig et al., 1996). However under pathological conditions such as nerve 
injury or inflammation, an interaction between afferent fibres and sympathetic system 
seems to be established. To elucidate the role of sympathetic influence in the 
pathological condition, several studies have been conducted in both animals and 
humans.
After nerve lesion, sympathetic postganglionic fibres that normally innervate blood 
vessels within the DRG sprout to form basket-like terminals around primary afferent 
soma that project into the lesioned nerve (McLachlan et al., 1993). These unusual 
connections provide a possible origin for abnormal discharge following peripheral 
nerve injury. Furthermore it has been observed that sympathetic stimulation can 
activate the lesioned nerve repetitively, suggesting that the sprouts of sympathetic 
axons from physical contact with the DRG of primary afferent fibres might trigger 
release of some substances in the vicinity of the peripheral afferent fibres and within 
the DRGs (McLachlan et al., 1993; Chung et al., 1997).
In addition, studies done on SNL animals with stable mechanical allodynia and 
thermal hyperalgesia showed that surgical sympathectomy performed prior to the 
SNL reverses the sensitivity of the innocuous mechanical and thermal stimuli 
developed in the injured paw, suggesting a contribution of sympathetic innervation in 
the development of mechanical allodynia and thermal hyperalgesia produced by 
peripheral nerve injury (Kim et al., 1993). Also after chemical sympathectomy 
sympathetic blocking agents such as phentolamine and guanethidine, rather than 
surgical sympathectomy caused a reduction in the mechanical allodynia and thermal 
hyperalgesia produced by peripheral nerve injury (Kim et al., 1993). Moreover, 
similar results after surgical and chemical sympathectomy have been reported in 
PSTL and CCI models (Neil et al., 1991; Shir and Seltzer, 1991).
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Overall the present studies show the importance of a sympathetic maintenance in 
these models of neuropathic pain, however reversal of neuropathic pain behaviours 
has not been successful in L5 spinal nerve ligated rats (Ringkamp et al., 1999). An 
important point in these experiments is the involvement of adrenoceptors in 
sympathetic- afferent coupling. Although the cellular mechanism underlying this 
interaction is not clear, an obvious explanation could be the increased sensitivity of 
adrenoceptors as a consequence of nerve lesion or infection (Baron, 2004). In normal 
conditions although the adrenoceptors are present on primary afferent fibres, they 
may not be functional. It is believed that the sympathetic-afferent coupling is largely 
mediated by alpha 2-adenoreceptors (Sato and Perl, 1991), and stimulation of this 
receptor may mediate increases in the spontaneous activity in nerve injury. 
Furthermore up-regulation of the mRNA for alpha 2-adenoreceptors in the DRG 
neurones has been confirmed after nerve lesion (Shi et al., 2000).
However, there is a discrepancy in the literature on the role of the sympathetic 
influence in nerve injury, that may well be explained by differences in the animal 
models used since types of peripheral nerve damage and animal strains may provide 
sources of variability in the generation and evolution of sympathetic sprouting. 
Alternatively, as seen in the classical review (Bonica, 1990) blockade of sympathetic 
innervations to the effected area is effective in alleviation of the pain symptoms only 
in certain patients. Thus sympathetic maintained pain is not seen in all patients with 
nerve injury. In addition clinical studies show that human peripheral painful 
neuropathy varies considerably in the development of adrenergic sensitivity, despite 
involving lesions of peripheral nerves e.g. polyneuropathies do not lead to adrenergic 
sensitivity (Baron, 2004). There is also evidence that patients with long-lasting 
painful neuropathy associated with inflammation lose the sympathetic maintained 
pain over time (Baron, 2004).
It seems that further research is needed to establish the mechanism of afferent 
adrenergic sensitivity in human neuropathies of different etiologies and in particular 
the time course during the disease process for the development of adrenergic 
sensitivity.
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1.5.7 Pharmacological treatments of neuropathic pain
The most extensively studied drugs for the pharmacological treatment of neuropathic 
pain are antidepressants and anticonvulsants.
The tricyclic antidepressants exert their analgesic effect by modulating voltage-gated 
sodium channels but at lower doses, inhibit the reuptake of the monoamines 
noradrenaline and serotonin. These tricyclics have been effective in relieving pain in 
neuropathic pain states independently of the mood state of the patients so that the 
treatment was effective in both depressed and non-depressed patients (McQuay et al.,
1996). Tricyclic compounds with mixed noradrenergic and serotonergic reuptake 
inhibition e.g. amitriptyline, imipramine and clormipramine have demonstrated 
greater therapeutic effects than the selective serotonin reuptake inhibitors such as 
paroxetine (Wolfe and Trivedi, 2004). The use of the tricyclics are limited because of 
their side effects which include urinary retention, cardiac arrhythmias, orthostatic 
hypotension and dizziness, effects mainly contraindicated in patients with 
cardiovascular problems and thus the elderly, who are more likely to suffer 
neuropathic pains (Wolfe and Trivedi, 2004).
Anticonvulsant medication such as carbamazepine and phenytoin have also been used 
for the management of neuropathic pain as a result of their membrane-stabilizing 
properties by blocking Na+ channels and therefore reducing neuronal excitability 
(Sindrup and Jensen, 1999; Dickenson et al., 2002). Based on NaT channel blocker 
mechanisms, the use of topical medication with local anaesthetics for treatment of 
neuropathic pain such as lidocaine has benefits in providing a barrier which helps 
protect the area of hypersensitive skin of the damaged peripheral nerve (Galer et al.,
1999).
Much interest has been focused on gabapentin (GBP), an anticonvulsant developed as 
a structural GABA analogue, yet despite its name, GBP has no direct GABAergic 
action nor any obvious effects on levels of the inhibitory transmitter. The mechanism 
of action of GBP is not clear, however several studies suggested an antagonistic
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effect of GPB on alpha 2-delta subunit of voltage-dependent Ca2+ channels and this 
may explain the analgesic effect of this drug (Gee et al., 1996; Matthews and 
Dickenson, 2002). This subunit as well as certain calcium channels such as the N- 
type are upregulated after nerve injury and P-type after tissue damage (Dickenson et 
al., 2002). This may be an explanation of why GBP is effective in the presence of 
nerve injury or inflammation and yet has no effect in normal animals (Stanfa et al.,
1997).
Another important class of drug for the treatment of neuropathic pain are opioids. 
Although studies done by Amer and Meyerson, (1988); Iadarola and Caudle, (1997) 
and Abdulla and Smith, (1998) indicated that morphine lacks full analgesic effects in 
neuropathic pain, it is now believed that opioids do have effectiveness but at higher 
doses (Dickenson and Suzuki, 2005), and there is further discussion of opioid 
treatments in neuropathic pain patients and animal models in chapter 3. This 
analgesic effect of morphine attracted attention of many research studies, and it 
appears that the efficacy of morphine in attenuating mechanisms of allodynia and or 
hyperalgesia, the classical symptoms of neuropathic pain, depends on the animal 
model and the route of administration of the drug, see Suzuki et al., (1999). This may 
explain some of the issues in patients where the syndrome and the symptom may well 
influence the effect of opioids.
Furthermore, the diverse mechanism and symptoms of neuropathic pain have drawn 
attention to the idea that combination therapy, based on multiple pharmacological 
targets and low drug doses, could improve both the pain and the side effect profile of 
treatments. In fact Matthews and Dickenson, (2002) demonstrated that combination 
of morphine and GBP had significantly improved effectiveness compared to 
morphine alone in a rat model of neuropathic pain.
There are other clinically licensed drugs that show potential for the treatment of 
neuropathic pain. These include NMDA antagonists, such as ketamine and 
memantine, although their use is limited by adverse side effects due to their global
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block of NMDA receptor types (Dickenson et al., 2002). In addition studies also 
confirm the capacity for analgesic potentiation when NMDA receptor antagonist is 
added to morphine (Portenoy, 2000). Another important class for the treatment of 
neuropathic pain are the alpha 2-adrenergic agonists such as clonidine, further 
discussion see section 1.5.6.
1.6 Inflammation
Inflammatory pain is characterized by increased afferent inflow to the CNS from the 
injured area as a result of increased activity and responsiveness of sensitized 
nociceptors. Also nociceptive neurones in the spinal cord undergo changes which 
alter their responsiveness to input from the periphery. These changes lead the subject 
to experience spontaneous pain, hyperalgesia and allodynia, all conditions described 
in the neuropathic pain section but here, having very different causal mechanisms.
Inflammatory states such as arthritis and postoperative pain are associated with tissue 
damage and result from the release of complex mediators such as cytokines and other 
neuroactive agents, from both inflammatory and noninflammatory cells at the site of 
tissue damage (see Fig.4). These mediators include release of adenosine triphosphate 
(ATP) and protons from the damaged cells, which might directly depolarize primary 
afferent through activation of membrane cation permeability of P2X3 receptors or 
acid-sensing-ion-channels (ASICs) (Millan, 1999). Mast cells release amines such as 
5-HT and histamine as well as arachidonic acid metablolites including 
prostaglandins. These prostaglandins are the prototype prostanoids and their synthesis 
is normally regulated by cyclo-oxygenase 1 (COX1) activity. However during 
inflammation large amount of prostanoids are synthesized due to the induction of 
COX2. In fact, due to the different properties of COX1 and COX2 enzymes, most 
non-steroidal anti-inflammatory drugs (NSAIDs) exercise their inhibitory effect on 
COX2 (Dray, 1997). Serotonin can cause direct excitation of sensory neurones by 
increasing Na+ permeability via activation of 5-HT3 receptors or by decreasing K+ 
permeability via G-protein coupled receptors such as 5-HT1 and 5-HT2 receptors, for
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review see Dray, (1995). The degranulation of mast cell releases also histamine that 
acts on sensory neurones expressing H1 receptors and produce increase of membrane
l
Ca permeability likely to evoke release of neuropeptides as well as other pro- 
inflammatory mediators.
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Figure4. Peripheral changes that occurs at peripheral terminasl o f the primary 
sensory neurones in response to inflammation.
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Furthermore, macrophages add to the inflammatory soup by releasing cytokines 
which includes interleukins (IL-1, IL-6), tumor necrosis factor (TNFa) and NGF. 
Bradykinin released from multiple cell types, exerts a number of proinflammatory 
effects mediated by two distinct receptors B1 and B2. The B2 receptors, the most 
studied receptors, are coupled with G-proteins to phospholipase C, thus generating 
the second messengers IP3 and DAG which will release Ca2+ from internal stores and 
activate protein kinase C, important in the excitation of afferent fibres, for review see 
Dray, (1995). As a consequence the release of those inflammatory and 
noninflammatory agents, generate the classical signs of inflammation (calor, dolor, 
tumor or rubor) and increase sensory inflow that might induce powerful hyperalgesia 
and perceived pain.
However, most mediators sensitize the nerve terminal causing peripheral sensitization 
rather than directly activating it. This peripheral sensitization is described as a drop in 
the peripheral threshold, to an extent that normal innocuous stimuli will activate the 
sensitized receptors (Cervero and Laird, 1996; Woolf and Costigan, 1999). It is the 
result of changes either in the transducing receptor molecules themselves, for 
example, vanilloid receptor 1 (VR1) is sensitized by protons, so that in moderate acid 
conditions the channel is activated at a lower temperature (± 22° C) rather then 
intense heat stimulus (> 45° C). Also it has been seen that Na+ channels are other 
contributors to peripheral sensitization. Here the phosphorylation of the TTXr Na+ 
channel by protein kinase A (PKA) and PKC increases Na+ channel currents in the 
terminals and subsequently by lowering the threshold of the neurone, a depolarizing 
stimulus will produce a greater excitation (Fitzgerald et al., 1999; Gold, 1999) see 
Fig.4.
These different chemical mediators not only initiate various signal transduction 
casqades that result in immediate changes as above described, but the response to 
inflammation is further amplified by later changes in gene transcription (Woolf and 
Costigan, 1999). This gene transcription will reinforce the inflammatory cascade by
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means of changes in expression and transport of proteins in the peripheral terminal 
(Fig.4) and in the DRGs of the neurones as well as dorsal horn neurones.
Example of the transcriptional changes are as follows; up-regulation of neuropeptides 
such as substance P that is transported back out to the peripheral terminal. This 
peptide as well as CGRP, induces vasodilatation which allows movements of protein 
and antibodies as a result of plasma extravasation and mast cell degranulation that 
will further promote the inflammatory process (Dray, 1995; Costigan and Woolf,
2000). Similarly to substance P, NGF, acting via a specific tyrosine kinase receptor 
(TrkA), presents a key step in the initiation of gene transcription. Its upregulation, 
thus further increases the synthesis of several neuropeptides including CGRP (Dray, 
1995), which causes vasodilatation together with its synergism effect on substance P 
as seen in section 1.5.5.1.
Furthermore, related to these changes is the upregulated expression of several 
channels such as VR1, TTXr, that may increase neuronal response following 
inflammation (Costigan and Woolf, 2000). Overall these inflammatory cascades 
cause sensitization of peripheral nociceptors and subsequently change their response 
properties such as generation of spontaneous activity which will provide a continuous 
spontaneous pain and a decrease in threshold. Moreover, these changes not only 
evoke excitation of the normal nociceptors but also recruit silent nociceptors (Dray, 
1995; Cervero and Laird, 1996).
In addition to the peripheral changes of inflammation, changes in the expression of 
neuropeptides and receptors transported to the central terminals of the neurones can 
amplify the central actions of the transmitters released from sensory neurones. 
Therefore, levels of neuropeptides and aminoacids such as glutamate, substance P 
and CGRP are upregulated and also expression of large molecules with modulatory 
roles such as brain derived neurotrophic factor (BDNF) are increased in the dorsal 
horn of the spinal cord (Woolf and Costigan, 1999). As results of these changes, 
multiple central receptors will be activated and increases in intracellular events such 
as Ca2+, both via Ca2+ influx and release from intracellular stores and a consequent
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activation of Ca2+ dependent enzymes including PKC, PKA, TrkA receptors will 
initiate multiple signal transduction cascades (Costigan and Woolf, 2000). These may 
target several receptors of which NMDA and AMPA are the prototypes, and cause 
changes in neuronal properties in response to noxious and innocuous stimuli, and 
therefore initiate central sensitization as well as altering the phenotype of sensory 
neurones (Neumann et al., 1996).
As a consequence, the neuronal excitability of the dorsal horn will increase and 
become more excitable in response to stimuli of lower intensity and also some lower- 
threshold A-fibres acquire the chemical phenotype typical of C-fibres. Furthermore, 
changes in neuronal response will be altered also in the uninjured area surrounding 
the injured site, a phenomenon known as secondary hyperalgesia which is thought to 
be mediated by plasticity of central synaptic processes and therefore related to central 
sensitization (Schmelz et al., 2000).
A variety of other substances are released following inflammation, these involve the 
reactive oxygen species (Dray, 1995) including hydrogen peroxide which enhances 
the effect of other mediators such as bradykinin and prostaglandin while NO prior to 
its contribution in mechanisms involving increase of neuronal excitability as 
discussed in section 1.5.5.1, may alter the responsiveness of sensory neurones to 
inflammatory mediates such as bradykinin (Dray, 1995).
The other family of spinal amino acids altered in this inflammatory process is the 
group of the inhibitory neurotransmitters such as GABA, since the levels of this 
neurotransmitter are increased in the dorsal horn (Castro-Lopes et al., 1994). The 
endogenous opioid systems also undergo changes that will be discussed in chapter 3.
As a result, all of these changes may contribute to alteration or modulation of 
nociceptive transmission in the periphery and central nervous system and further 
enhance and prolong the inflammatory pain state.
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1.6.1 Choice of animal model for inflammation
The model of inflammation used in the thesis was chosen as a model where the 
inflammation can be induced in a short time, in hours rather than days or weeks. This 
short time scale of the development of inflammation is important to allow study of 
the neuronal response from a control period pre-inflammation and through to the peak 
response of hyperalgesia. These criteria exclude models of chronic polyarthritis, 
where the intradermal injection of complete Freund’s adjuvant (CFA; emulsion 
containing inactive mycobacterium butyricum) at the tail, causes inflammation which 
reaches a peak level only after 3 weeks (Millan et al., 1986). Another inconvenience 
of this model is the generalized effect of this disease which involves changes in many 
organs and systems, not necessarily related to pain. In order to reduce the duration of 
the stable maximum inflammation effect and to restrict the area of inflammation, 
models of unilateral inflammation produced by intradermal injection of CFA into the 
plantar surface of the animal’s paw was considered. However the hyperalgesia 
produced in this model reaches the maximum peak 1-6 days after the injection 
(Iadarola et al., 1988), and therefore was not suitable for my study.
An interesting model of peripheral inflammation is the formalin test; in this model a 
dilute solution of formalin was injected into the hind paw and induces two phases of 
nociceptive behavioural which lasts for 1 h, for review see Tjolsen et al., (1992). The 
first phase, starting immediately after the injection of formalin and lasts for up to 5 
min, is thought to be mediated by direct chemical stimulation on C-fibres evoked 
activity (Dickenson and Sullivan, 1987b; Tjolsen et al., 1992). Subsequently, there is 
a second phase which starts approximately 10-15 min after the injection and lasts for 
20-40 min, and it is believed that this phase is mediated by inflammatory reaction 
since NSAIDs reduce nociceptive behavioural responses during this phase, while the 
first phase seems unaffected. Both phases cause functional changes in the dorsal horn 
of the spinal cord, moreover the pain behaviour displayed in these animals consists of 
licking and biting the injected paw and lasts one hour. Similarly electrophysiological
58
studies of this acute inflammatory model reveal this characteristic bi-phasic pattern of 
firing (Dickenson and Sullivan, 1987b) which correlates to the level of pain 
behaviour as well as the timing of the reactions in the behavioural studies. However, 
one limitation of this model is the short duration of the inflammation, and also the 
ongoing firing of the dorsal horn neurones evoked by this model complicates the 
investigation of the central mechanism of hyperalgesia which accompanies 
inflammatory pain state.
For these reasons, in these experiments was used a model of inflammation induced by 
subcutaneous injection of carrageenan into the hind paw of the rat. This model 
described in section 2.3 of methods, was first proposed by Winter et al., (1962), since 
then this model has been widely used as a model of acute cutaneous hyperalgesia, 
where animals develop hyperalgesia to mechanical and thermal stimuli without any 
indicative spontaneous pain behaviour. The signs of inflammation may already be 
seen at 1 h after the intraplantar injection of carrageenan and the inflammation is 
stabilized between 3 and 4 h, and largely resolved within 24-96 h (Kayser and 
Guilbaud, 1987).
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1.7 Aims of this thesis
The aim of this thesis was to investigate the role of the nociceptin receptor system in 
different pain states using responses of spinal dorsal horn neurones. Moreover, since 
the pharmacology of this receptor is still under study, with few molecules selectively 
acting on this receptor, it was interesting to study the potential of agonists and 
antagonists at this receptor. One major aim was to determine if the antagonist could 
reveal any endogenous activity of nociceptin at the ORLj receptor in the different 
pain models.
Since CCK is believed to be involved in processes that lead to a reduction in 
morphine analgesia, it is important to study any interaction between CCK and the 
ORLi receptor to determine if this receptor is modulated in the same way as the mu 
receptor.
In addition, taking into account the importance of lamina I neurones in the control of 
pain I wished to understand the influence if any of the ablation of lamina I NK1 
expressing neurones on the function of the nociceptin system on spinal processing 
and to compare with an opioid agonist acting on the delta receptor. The delta opioid 
receptors are present predominantly at pre-synaptic sites on peripheral terminals of 
afferent neurones and therefore it was important to study their effects in animals with 
ablated lamina I neurones expressing NK1 receptors which would remove post- 
synaptic opioid receptors found on these neurones. Moreover, delta receptors are 
appropriate to compare with ORL-1 receptors since both receptors are not the main 
opioid receptors in the spinal cord.
Finally, it was also my aim to study the spinal effect of oxytocin in normal and 
neuropathic animals.
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CHAPTER 2
METHODS
All experiments were carried out on male Sprague-Dawley rats obtained from 
University College London Biological Services. Animals were housed 4 or 5 per cage 
with a 12 h: 12 h light: dark cycle, water and food ad libitum. All procedures were 
conducted in accordance with the U.K. Home Office legislation for animal 
experimentation and the International Association for the Study of Pain 
(Zimmermann, 1983). Animals used in these experiments were divided into, normal, 
operated and carrageenan injected rats. The operated rats were subject to either: i) 
spinal nerve ligation (SNL), ii) sham operation for SNL surgery or iii) intrathecal SP- 
SAP injection, to produce an ablation of Lamina I spinal neurones expressing 
substance P receptor.
2.1 Spinal nerve ligation (SNL)
Male Sprague-Dawley rats initially weighing 130-150 g, were used for SNL surgery. 
Selective tight ligation of the spinal nerves L5 and L6, was performed as first 
described by Kim and Chung, (1992). Animals were divided into a control group 
(sham operation) and an experimental neuropathic group (SNL).
The animals were anaesthetised with a mixture of halothane (3.5% for induction, 
1.5% for maintenance) and 50% N2O: 50% O2. The rat was placed in a prone 
position. A midline incision of 2 cm length was made from L4-S2 and the left 
paraspinal muscles were separated from the spinal processes. The L6 transverse 
process and the sacrum were made visible by scraping off the attached ligaments. Part 
of the L6 transverse process was then removed to expose the L4 and L5 spinal nerve 
and L6 was identified as lying just under the sacrum. Using a 6-0 silk thread, the left 
spinal nerves L5 and L6 were tightly ligated distal to the dorsal root ganglion and 
proximal to their conjunction to form the sciatic nerve. Haemostasis was confirmed, 
the wound was closed using 3-0 surgical sutures and wound clips.
Sham operations were performed and the surgical procedure was identical to that of 
the experimental group, with the exception of the spinal nerve ligation. Only animals
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without impaired motility and showing mechanical and with satisfactory behavioural 
responses such as mechanical and cold allodynia were used in the experiments.
2.1.1 Behavioural studies
After the surgery, animals were housed under the same condition as before the 
preoperative period. The general behaviour of the animals was closely observed, and 
their weights monitored.
Successful reproduction of the neuropathic model was confirmed by behavioural 
testing performed postoperatively on days 2, 4, 8, 11 and 14. Animals were placed 
individually in transparent cages with a wire mesh bottom that allowed full access to 
the paws.
The mechanical sensitivity of the ipsilateral and contralateral hindpaw was assessed 
by measuring the frequency of withdrawal of the foot to a normally innocuous 
mechanical stimulus. The stimulus was applied, from below the mesh floor, to the 
plantar surface of the foot with three different von Frey filaments (1,5 and 9 g) until 
reaching the bending forces. Each trial consisted of the application of a single von 
Frey hair 10 times, each for a period of 2-3 sec. Using ascending and consecutive von 
Frey hairs each trial was separated by a period of at least 3 min. The number of 
withdrawals to each force was counted.
Cooling sensitivity was determined using a drop of acetone applied onto the dorsal 
region of the rat's foot using a 1 ml syringe connected to polyethylene tube 
(polyethylene; id. 1.57 mm; od. 2 mm). In order to avoid the mechanical response 
caused by the tube, particular attention was taken to not touch the foot of the rat while 
applying the acetone drop. Each test consisted of 5 applications and each trial was 
separated by a period of 5 min.
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Spinal nerve ligated animals demonstrated enhanced responses to both mechanical 
and cooling responses on the ipsilateral hind paw (Fig.l). These responses consisted 
of licking and shaking of the hindpaw. No withdrawal response was observed on the 
contralateral hind paw of SNL rats and on both sides in sham operated rats. These 
behaviours confirm the success of the surgery and the enhanced withdrawal response 
to innocuous stimuli was interpreted to be a sign of allodynia.
The response to both mechanical and cooling stimuli was quantified and expressed as 
different score:
Difference Score = number of foot withdraws on contralateral paw -  
number of foot withdrawals on ipsilateral Daw.
For example, if the difference score is a value close to zero (1, 0 or -1) then there is 
no difference between the contralateral and the ipsilateral paw and this was the case 
for sham operated animals; while in SNL animals the difference scores are more 
negative values (from -2 to -6) indicating a greater foot withdrawal response on the 
ipsilateral hindpaw and was interpreted to be a manifestation of mechanical or cold 
allodynia (Fig.l).
The behavioural tests show stable allodynia from 2 days after surgery and this 
gradually increased in magnitude and persisted over the 2 week testing period, see
(Fig.l).
Two week after the postoperative period, both SNL and sham operated animals were 
ready for the electrophysiology studies.
2.2 Ablation of lamina I spinal neurones expressing NK1 receptor
The procedure of ablating lamina I spinal neurones expressing the receptor for 
substance P was first described by Mantyh et al., (1997) and involves intrathecal 
administration of a cytotoxin conjugated to the ligand, SP (SP-SAP). In these 
experiments, rats weighing 130-150 g were anesthetized with a combination of
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intraperitoneal Diazepam (2.5 mg/kg, Phoenix Pharmaceuticals, UK) and 
intramuscular Hypnorm (0.3 ml/Kg, Janssen Animal Health, Belgium), and placed in 
a stereotaxic frame.
A small incision (1 mm long) was made in the atlanto-occipital membrane, followed 
by insertion of a cannula (8.5 cm, polyethylene, id x od, 0.28 X 0.61 mm) into the 
subarachnoid space. The cannula was used to deliver the conjugate at the lumbar (L4- 
L5) level. 10 pi of either saline or lO^M SAP or 10'6M SP-SAP (Advanced Targeting 
Systems, San Diego, USA) was injected, followed by a 5 pi saline flush using a 50 pi 
Hamilton syringe. Five min after the intrathecal injection, the cannula was carefully 
removed and the wound was closed using 3-0 surgical sutures and wound clips. 
Animals were housed in groups of 3-4 per cage and their behaviour was closely 
observed. Animals were used for the subsequent electrophysiology studies, 28 days 
after injection.
2.3 Carrageenan
First described by Winter et al., (1962), carrageenan, a substance used to induce 
inflammation is stable at > 3 h after subcutaneous injection into the plantar surface of 
the hindpaw.
In this study, after a neurone was found 100 pi of carrageenan 2% was injected into 
the plantar surface near the receptive field of the neurone. Controls were taken 
throughout the 3 h period following carrageenan injection after which pharmaco­
logical studies were commenced.
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Figure 1. The difference score offoot withdrawal frequencies to the application o f A) 
von Frey lg, B) von Frey 5g, C) von Frey 9 g and D) acetone in sham operated (n= 
24) and SNL/neuropathic (n= 24) rats. In all SNL rats there is a higher frequency o f 
foot withdrawal on the ipsilateral hindpaw and this indicates the present o f allodynia 
in these animals. The allodynia was observed from day 2 and gradually increased 
throughout the testing period (14 post-operative days).
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2.4 Electrophysiology recordings
This electrophysiological study follows the procedure previously described by 
Dickenson and Sullivan, (1986). For these studies, several animal groups were used 
including normal animals (weighing 200-250 g), those that had been operated for 
spinal nerve ligation, sham operation, or SP-SAP treated rats (weighing 350-400 g).
Rats were initially anaesthetised with 3.0-3.5% halothane in a gaseous mixture of 
66% N2O: 33% O2 and maintained throughout the experiment via a cannula 
(polyethylene tube; id. 1.57 mm; od. 2 mm) inserted into the trachea. The rats were 
placed in a stereotaxic frame and secured by ear bars to maintain stability during 
electrophysiological recordings. The vertebrae rostral and caudal to vertebra L1-L3 
were clamped and a laminectomy was performed to expose L4—L5 spinal cord 
segments, which receive afferent input from the toe regions of the rat. Subsequently, 
the level of halothane was reduced to 1.0-1.5%. The body temperature of the rat was 
maintained at 37 °C with the heating blanket connected to a rectal probe via an 
automatic feedback control unit. A parylene coated tungsten electrode was descended 
into the cord using a manipulator and extracellular recordings were made from single 
wide dynamic range neurones. The depth of the recording site was noted from the 
microdrive reading connected to the manipulator.
Extracellular recordings were made from single dorsal horn neurones that either 
receive input from the toe region ipsilateral to the spinal nerve ligation or sham 
procedure, or from either side of spinal cord in normal and saline/SAP/SAP-SP rats.
The selected neurone must respond to both noxious -and non-noxious stimuli. Two 
fine needles, attached to a stimulus isolator module, were applied to the receptive 
field, to allow transcutaneous electrical stimulation. The C-fibre threshold was 
determined by giving a single, electrical pulse (amplitude 0.1-3.3 mA) incrementally 
until a C-fibre latency response was evoked. Tests consisted of a train of 16 electrical 
stimuli (0.5 Hz, 2 ms pulse duration) given at 3-times the threshold required to evoke
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a C-fibre response. The action potentials evoked by each stimulus were superimposed 
and constructed into a post-stimulus time histogram (PSTH) by the Spike2 software 
(Fig.2). These were then separated on the basis of latency, into total Ap-fibre (0-20 
ms)-, A8-fibre (20-90 ms)- and C-fibre (90-300 ms)-evoked action potentials. The 
remaining neuronal responses recorded (300-800 ms post-stimulus) were classed as 
‘Post-discharge’ while input and wind-up responses were calculated as follows:
Input = (Action potentials recorded 90-800ms evoked by first stimulation) x 
(total number of stimuli (16)).
Wind-up = (Total action potentials recorded 90-800ms after the train of 16 
stimulation) -  Input.
ap
30
A6
25-
C-fibres
20
Post-discharge
c  15
80020 90 300
Time (ms)
Figure 3. A typical post-stimulus time histogram (PSTH) obtained from a single 
dorsal horn neurone showing the responses produced by the 16 electrical stimuli. 
Latency bands for Ap-, AS- and C-fibre-evoked responses and post-discharge are 
indicated.
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2.4.1 Data acquisition in the electrophysiology recordings
The headstage receives input from the recording tungsten electrode (A-signal), which 
contains the response from the neurone, background activity of the spinal cord and 
electrical interference of the surrounding environment. A second input (B signal) was 
received by the headstage, which monitored activity from the cardiovascular and 
respiratory system of the animal as well as an eventual electrical interference of the 
surrounding environment. Finally the headstage receives also input from a lead 
connected to the stereotaxic frame (earth), grounded prior to recordings.
The headstage, is attached to a manipulator which regulates the course and fine 
movements of the electrode and the output is sent to a Neurolog system.
The Neurolog system, amplifies and differentiates the received input (A signal -  B 
signal) to minimize the background activity and finally transduces the filtered 
neuronal activity to an audible and visible form on the oscilloscope. Neurones were 
differentiated according to their amplitude by the window discriminator and window 
height. The output of the isolated neurone was connected to a CED 1401 interface 
linked to a computer where the captured data is quantified, analysed and displayed 
using Spike 2 software (see Fig. 3).
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Figure 3. Schematic representation o f neuronal recording system. Adapted from 
(Stanfa and Dickenson, 2004).
81
2.5 Analyses of isolated neurones
After a single dorsal horn neurone was found by tapping the rat’s foot, the neuronal 
responses to electrical and natural stimuli were determined.
The electrical response was measured by giving a test of 16 electrical stimuli at 3 
times the threshold of the C-fibre firing as detailed in section 2.4. A post-stimulus 
time histogram (PSTH) was constructed from the evoked action potentials and 
subsequently quantified on the basis of their latency into A(3-, A5- and C-fibre 
evoked responses (Fig.2), as well as post-discharge and wind-up. The electrical 
response was measured every 2 0  min and was subsequently followed by 
determination of the natural response.
Measurement of the natural response involves the application of a variety of 
innocuous and noxious stimuli using a wide rage of von Frey filaments and hot water 
jets. Von Frey filaments were applied in an ascending order (2, 5, 9, 15, 30, and 75 g) 
onto the central receptive field of the neurone, each one applied for 10 s. Jets of water 
ranging in temperatures 32, 35, 40, 42, 45, 48 and 50° C were delivered from a 50 ml 
syringe. The spontaneous activities of the neurones were recorded prior to the 
application of natural stimuli over a period of 5 min or until response stabilization. 
The ongoing activity was then subtracted from the evoked response of the individual 
test. An interval of 2-3 min was allowed between each electrical, thermal and 
mechanical test. In some experiments, only responses to electrical stimulation were 
determined and tests were conducted every 10 min.
82
2.6 Drug application
Control values were taken for each test until a minimum of three consecutive stable 
values (< 10% variation) were obtained, this was then followed by the application of 
a drug. Most of the drugs studied in this thesis were applied intrathecally, directly 
onto the exposed spinal cord using a 50 pi Hamilton syringe, while others were 
injected subcutaneously into the scruff of the neck.
Drugs were administered in cumulative doses, where each dose was followed for 20- 
60 min in order to obtain a maximum effect, which normally occurred between 40-60 
min post drug application. The drug dose range was selected based on previous 
electrophysiological or relevant pharmacological studies.
2.7 Statistical analysis o f results
The three electrically evoked neuronal responses taken immediately prior to the drug 
administration were averaged and used as controls (pre-drug control value) to 
calculate the subsequent drug effects. The effects of drugs on the electrically evoked 
responses were then calculated as percentage of pre-drug control values (% control). I 
then determined the maximal change (largest increase or decrease from the control 
value) for each dose of drug in each experiment. The results for each dose were 
expressed either as mean % control or % inhibition (where the % inhibition = 1 0 0  - % 
change based on the control value, i.e. 80% control=2 0 % inhibition) ± standard error 
of mean (S.E.M.). Also the effects of the drugs on the natural evoked responses were 
expressed as mean number of action potentials evoked over 10 sec ± S.E.M.
Statistical analysis of drug effects at each dose compared to the pre-drug control 
values was assessed using repeated measures analysis of variance (ANOVA) as well 
as Tukey test on raw data. Comparison of drug effects between different experimental 
groups (normal, sham and neuropathic/SNL) was made using two way ANOVA and 
Tukey test on raw data. The level of significance was taken as P< 0.05. The only
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additional analysis was a Mann-Whitney test used for the particular experiments in 
Chapter 3, 6 and are described in that section. Statistical analysis of the data was 
performed using the programme InStat (GraphPad) installed on iMac computer.
2.8 Drugs employed
Nociceptin was obtained from Tocris. The peptide was dissolved in 0.9% saline 
solution.
J113397 was obtained from Banyou Pharmaceuticals, Japan. J113397 was dissolved 
in 0.9% saline and a drop of hydrochloric acid.
DPDPE was obtained from Tocris. The peptide was dissolved in 0.9% saline 
solution.
Oxycodone was obtained from Sigma and was dissolved in 0.9% saline solution.
Compound 20700857 was obtained from Solvay Pharmaceuticals. Due to solubility 
difficulties in saline, this was dissolved in a mixture of 1% methylcellulose and 5% 
mannitol.
CCK (Octapeptide Sulfate) was obtained from Tocris and was dissolved in 0.9% 
saline solution.
Oxytocin (Alpha-hypothamine) was obtained from Sigma and was dissolved in 0.9% 
saline solution.
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CHAPTER 3
THE SPINAL EFFECT OF NOCICEPTIN AND
OXYCODONE
3.1 INTRODUCTION
3.1.1 Opioids
The endogenous inhibitory opioid system has been manipulated to provide pain relief 
since the discovery of opium, of which morphine is the main active component. 
Opioid receptors, known for over 30 years were originally divided into mu (p), delta 
(8 ) and kappa ( k )  opioid receptors, for review see Pasternak, (1993). These receptors 
have been cloned and demonstrate a high degree of sequence homology (see Table 1 
for opioid receptors, their ligands, and physiological effects).
The opioid receptors are present both in the central and peripheral terminals of the 
thinly myelinated and unmyelinated sensory fibres, as well as within the peripheral 
and higher centres of the nervous system, for review see (Sawynok, 2003). In the 
spinal cord opioid receptors are mostly located in the superficial dorsal horn (lamina I 
and II). The contribution of p, 8  and k  receptors to the total opiate binding throughout 
the spinal cord was estimated at 70%, 24% and 6 %, respectively (Besse et al., 1990). 
However, this estimation was made prior to the discovery of the fourth opioid 
receptor.
Each receptor class exists in multiple subtypes; pi and p2, 8 i and 82 and ki, K2 and K3 
(Pasternak, 1993) according to some but as yet, there is no evidence from molecular 
studies of any subtypes.
Up to at 70% of these opioid receptors are found presynaptically on the central 
terminals of primary afferent fibres, and they are expressed by small diameter 
nociceptive primary afferents (A8 - and C-fibre). However, the remaining 30% are 
postsynaptic receptors that appear to hyperpolarize the dendrites of projection 
neurones and intemeurones, also they could disinhibit inhibitory intemeurones with 
the result of further inhibition of C-fibre transmission, for review see (Dickenson, 
2001).
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Opioids are used to relieve moderate to severe pain whatever the cause (accidents, 
pre- intra-post-operative pain, cancer, etc).
Table 1. Opioid receptors, their preferred ligands and physiological effects.
Mu (p) Delta (8) Kappa (k )
Endogenous
agonist
endorphins enkephalins dynorphins
Exogenous agonists morphine (morphine) (morphine)
DAMGO DPDPE nadoline
oxycodone
Antagonist naloxone naloxone naloxone
p-FNA naltrindole nor-BNI
Physiological analgesia, 4GI motility, analgesia analgesia
effects respiratory depression, 
sedation, nausea and 
euphoria
sedation dysphoria
DAMGO = [D-Ala2,N-Me-Phe4,Gly-ol5]enkephalin; DPDPE = [D-Pen2,D-Pen5]-enkephalin; 
(3-FNA = Beta-Funaltrexamine; nor-BNI = Norbinaltorphimine; >lGI motility = reduced 
gastrointestinal motility. Morphine produces most effects through mu receptors (Kieffer, 
2000) but has some affinity for delta and kappa and so is denoted as (morphine) for these 
receptors.
The mu-opioid receptors are thought to be responsible for most of the analgesic 
effects of opioids and for some major unwanted effects (e.g. respiratory depression, 
euphoria, sedation and dependence) (Kieffer, 2000).
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One strategy to produce opioid-mediated analgesia whilst avoiding the side effects 
attributed by opiate receptors in the brain and periphery is to target spinal action of 
opioids by using the intrathecal or epidural routes of administration.
Spinal application of morphine has been demonstrated to reduce the release of a 
number of transmitters in the spinal cord including substance P, CGRP, glutamate 
and aspartate, which are normally released after noxious stimulation (Yaksh et al., 
1980). This corresponds to one of the major mechanisms of action of opioids, through 
opioid receptor interaction with G-protein coupling (Gi or Go) to decrease adenosine 
3,5-monophosphate (cAMP), increase K+ efflux and decrease Ca2+ entry. These 
mechanisims attenuate the propagation of action potentials and release of 
neurotransmitters in the sensory nerve fibres (Sawynok, 2003).
Opioids also act at supraspinal levels, as injection of morphine into the PAG region 
causes marked analgesia, which can be prevented by surgical interruption of 
descending pathways to nucleus raphe magnus (NRM) or by blocking 5-HT synthesis 
(Fields et al., 2006). This last procedure interrupts the 5-HT pathways running from 
the NRM to the dorsal horn (Fields et al., 2006), however the mechanism of action of 
opioids at the supraspinal level are still poorly understood. It has been suggested that 
the descending controls filter sensory messages at the spinal level allowing a pain 
message to be extracted from the incoming message (Dickenson, 1994) and therefore 
supraspinal morphine is thought to reduce these controls and alter the perception of 
pain.
Opioid receptors are also present in the peripheral nervous system where they 
mediate analgesic effects similar to those observed at the spinal level (Stein et al., 
2001). Despite the widespread use of opioids in the management of “nociceptive” 
pain, their effects are particularly altered under inflammatory conditions or pain 
arising from neuronal damage.
During inflammatory processes, opioid receptors transported from DRG towards the 
peripheral sensory nerve endings are enhanced (Hassan et al., 1993; Stein et al.,
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2001). Thus, activation of these receptors can cause attenuation of the excitability of 
nociceptive input terminals, inhibit the release of neurotransmitters and ultimately 
result in increased analgesia. In addition to the increased receptor density, 
inflammation induces disruption of the perineurial barrier around the primary afferent 
that allows exogenous and also endogenous opioids released from immune cells to 
activate opioid receptors that are preexistent on sensory nerves, but inactive or 
inaccessible by the perineurial barrier under normal conditions (Antonijevic et al., 
1995). Moreover, it has been speculated that a decrease in the level of spinal CCK 
during inflammation could be the basis for the increased morphine potency in this 
pain state (Stanfa and Dickenson, 1993; Stanfa et al., 1994). All these changes may 
interact to enhance the inhibitory effect of opioids in presence of inflammation. In 
accordance with those hypotheses, several studies demonstrated that morphine and 
other opioid agonists are more efficacious as analgesic agents in animals with 
inflammatory condition than in normal animals (Stanfa and Dickenson, 1993; 
Ossipov et al., 1995).
Another pain state where the effect of opioid is a matter of considerable controversy 
is presented by neuropathic pain. Neuropathic pain as described previously in chapter 
1, was found in some studies to not be adequately treated by opioids (Amer and 
Meyerson, 1988; Iadarola and Caudle, 1997; Abdulla and Smith, 1998). The 
reduction of opioid sensitivity may be caused by a reduction in the number of spinal 
opioid receptors as studies have shown that mu-opioid receptors expression is mainly 
downregulated after nerve injury (Porreca et al., 1998; Zhang et al., 1998). Further, 
increased CCK (for discussion see chapter 6) and the excessive spinal 
hyperexcitability after repeated C-fibre stimulation which is hard to inhibit 
(Dickenson, 2001) may participate in the reduced opioid sensitivity in this pain state.
In addition to those factors, numerous studies suggested that antinociceptive abilities 
of morphine in behavioural studies on neuropathic animals depends on variables such 
as methods of behavioural assessment, nature of the stimuli utilized as well as the 
route of administration and the neuropathic model used, see (Suzuki et al., 1999) for
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further discussion. Thus, it appears that all these variables may explain the different 
sensitivity of opioids in neuropathic pain state and so it is now believed that opioids 
do have effectiveness but at higher doses (Dickenson and Suzuki, 2005). This may 
also be translated into higher side effects of opioids.
Therefore all attempts to separate the analgesic properties of opiates from their other 
CMS effects, the clinically problematic respiratory depression, nausea and sedation, 
or the perceived problems of dependence and euphoria, have been unsuccessful. All 
these effects, as well as the peripherally mediated constipatory effects of morphine 
are mediated via the mu- opioid receptor (Kieffer, 2000). In an effort to avoid these 
unwanted central effects, agents selective for the delta- and kappa-opioid receptors 
have been investigated as potential analgesics, but with limited success. It was the 
search for other more ‘pain’ specific opioid receptors (or subtypes) that led to the 
discovery of the orphan opioid receptor-like (ORL]/NOP) receptor (Mollereau et al., 
1994; Wang et al., 1994). The following section will be the basis for the study of 
ORLi agonists and also Oxycodone.
3.1.2 Nociceptin (N/OFQ)
The use of molecular biology approaches led to the discovery of a novel receptor 
identified as opioid-like receptor 1 (ORLi) receptor (Mollereau et al., 1994; Wang et 
al., 1994) whose ligand is the heptadecapeptide (FGGFTGARKSARKLANQ) known 
as Nociceptin or Orphanin FQ (N/OFQ) (Meunier et al., 1995; Reinscheid et al., 
1995). The term of orphanin FQ refers to its affinity for the “orphan” opioid receptor, 
while the F and Q refers to the first and last amino acids, phenylalanine and 
glutamine.
The ORLi like other opioid receptors is a G-protein-coupled receptor with seven 
predicted transmembrane domains (see Fig.l). This receptor shows overall 60% 
homology with the other opioid receptors and >90% sequence identities between
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species variants; human, rats and mouse (Calo et al., 2000; Mogil and Pasternak, 
2001).
As shown by several groups, activation of ORLi by nociceptin inhibits forskolin- 
stimulated cAMP accumulation, activates K+ channels and inhibits voltage-dependent 
Ca2+current in a similar way to the other three opioid receptors (Abdulla and Smith, 
1998; Hawes et al., 2000).
In spite of the morphological similarity between the ‘classic’ opioid receptors and 
ORLi, there is no pharmacological homology. In fact, none of the existing 
endogenous opioid-peptide agonists have significant affinity for the ORLi-site, 
except dynorphin A (Henderson and McKnight, 1997). Naloxone, a non selective 
opioid receptor antagonist showed very little affinity, if any, for ORLi (Mollereau et 
al., 1994).
Figure 1. Structure o f ORLI receptor, a G-protein coupled receptor with seven 
transmemhrane domains. The upper part (exrtacellular) contains N-terminal while 
the C-terminal side is in the intrsacellular. Picture adopted by (Mogil and Pasternak, 
2001).
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3.1.2.1 Distributions and biological actions o f nociceptin
The distribution of nociceptin and its receptor in the central and peripheral nervous 
system has been investigated with in situ hybridization and immunohistochemical 
techniques. Both the receptor and the peptide are widely expressed in brain areas, 
such as amygdala, hypothalamus, PAG, dorsal raphe nucleus and spinal cord dorsal 
horn suggesting its involvement in nociceptive processing and also in other general 
functions (Calo et al., 2000; Mogil and Pasternak, 2001).
Of the many proposed functions of nociceptin, an involvement in learning and 
memory has received particular attention. Knockout mice lacking the ORLi receptor 
have been reported as showing improved learning and memory, suggesting that 
nociceptin has inhibitory functions (Mamiya et al., 1998). Nociceptin and its receptor 
are also involved in emotional and stress regulation, as number of standard behavioral 
assays reveal the ability of supraspinal nociceptin to block fear and anxiety in both 
rats and mice (Jenck et al., 1997). Complementing findings were made with mice 
lacking ORLi receptor where they display an impairment of behavioural responses to 
stress (Reinscheid and Civelli, 2002). Moreover, nociceptin has an inhibitory effect 
on the cardiovascular system inducing hypotension and bradycardia in rats (Giuliani 
et al., 1997). Nociceptin also induces an increase in water excretion and decrease in 
urinary Na+ excretion when injected i.v. or i.c.v. so analogues of nociceptin may be 
useful water diuretics for patients with water retaining diseases (Kapusta et al., 1997). 
As with the other opioids, nociceptin inhibits in vitro neurogenic contraction of the 
stomach and the small intestine in a variety of species, and it has been also shown 
that nociceptin stimulates food intake in satiated rats, therefore ORLi antagonists may 
possibly constitute new anorexic agents (Pomonis et al., 1996).
Having summarized the widespread sites of action the nociceptin and its receptor, the 
following section will be focused on the role of the nociceptin in the mechanisms of 
pain modulation.
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3.1.2,2 Supraspinal nociceptin
In the first papers reporting the identification of nociceptin (Meunier et al., 1995; 
Reinscheid et al., 1995), it was shown that contrary to opioids, the i.c.v. injection of 
nociceptin has a pronociceptive dose-dependent effect, i.e. it reduces the tail flick and 
hot plate response latency in mice. Both groups interpreted these data as a 
hyperalgesic action; a decrease in nociceptive threshold produced by this peptide. 
Following these findings, several lines of studies obtained similar results (Calo et al., 
2000), while few others disagreed since they observed both hyperalgesia and 
analgesic effects of supraspinal nociceptin (Rossi et al., 1997). Moreover, Mogil et 
al., (1996) documented an anti-analgesic or ‘anti-opioid’ activity of nociceptin by 
showing the direct antagonistic effect of nociceptin on systemic morphine analgesia 
and also knowing that many forms of stress-induced antinociception are mediated by 
endogenous opioids, they suggested that i.c.v. injection of nociceptin does not 
produce hyperalgesia as predicted previously but rather reverses opioid-mediated 
stress-induced antinociception.
This was very much a surprise since ORLi receptor and classical opioid receptors 
share the same transductional mechanisms. Although little is known on the 
mechanisms behind the supraspinal effect of nociceptin, it is reasonable to speculate 
that the opposite effect of nociceptin compared to the classical opioid receptors could 
be due to a distinct localisation of nociceptin and opioid peptides and their respective 
receptors on the neuronal networks involved in pain transmission.
In fact ORLi receptors and opioid receptors are not co-localized in nociceptive 
centres such as raphe nuclei, periaqueductal grey, amygdala, hypothalamic region 
(Schulz et al., 1996). Furthermore in the rostral ventomedial medulla (RVM) of the 
rat, nociceptin exerts a marked inhibitory action on all neurones (on-cells, off-cells 
and neutral-cells) and doing so blocks the activation of those cells by opioids 
(Heinricher et al., 1997). A similar effect was found when studying the actions of 
nociceptin within the PAG where nociceptin inhibited nearly all neurones present in
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that area (Vaughan et al., 1997) and also attenuated the analgesic effect of locally 
injected morphine (Morgan et al., 1997). Overall, these studies suggest that the anti­
analgesic effect of OFQ/N may be result of a generalized inhibition of all the 
descending analgesic pathways.
Thus these findings suggest that ORLi antagonists could provide a new class of 
supraspinally acting analgesics which could enable a reduction in morphine dosage, 
thus minimising the risk of tolerance and dependence since nociceptin does not 
possess abuse ability (Devine et al., 1996), but a confirmation of the role of 
nociceptin as an anti-opioid peptide will require the development of a specific ORLi 
receptor antagonist.
5.1.2.3 Peripheral nociceptin
In addition to effects in the CNS, nociceptin modulates nociception at the peripheral 
nervous system, again with somewhat conflicting results.
Work carried out in our laboratory shows that nociceptin at low doses (5 pmol to 1 
nmol) administrated in the peripheral hind paw of anesthetised rats evokes excitatory 
responses from dorsal horn neurones (Carpenter et al., 2000). Similar responses were 
also observed by other groups showing the ability of peripheral nociceptin at very 
low doses (0.01 to 100 finol) to produce a flexor response which is dependent upon 
release of substance P in peripheral nerve endings of primary nociceptive afferent 
neurones. The phenomenon can be blocked by NK1 receptor antagonists, depletion of 
substance P by capsaicin and is abolished in NK1 gene knockout mice (Inoue et al.,
1998). However, the same group have also shown the ability of peripheral nociceptin 
at higher doses (> 100 finol) to produce an analgesic effect, producing a complete 
block of substance P actions (Inoue et al., 1999).
Peripheral nociceptin seems to have effects opposite to what was seen at supraspinal 
levels where nociceptin action has been described as a functional inhibition of
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analgesia (Heinricher et al., 1997; Morgan et al., 1997). This could suggest that the 
peripheral nociceptin may act through different mechanisms when compared to the 
supraspinal action or maybe there are several ORLi receptors and the peripheral 
receptor may be different from that in the CNS although nociceptin appears to be an 
agonist at both.
3.1.2.4 Spinal nociceptin
The presence of nociceptin and its receptor in the spinal cord, (Anton et al., 1996; 
Neal et al., 1999) suggest that this system may have a physiological role in the 
control of pain transmission at the spinal level. However, this role of nociceptin in 
modulating pain threshold in the spinal cord is also controversial. Since primary 
afferent neurones are bipolar cells, actions on the nociceptors of such neurones at the 
periphery could be expected to be similar to those at the spinal synapses (Inoue et al., 
1999).
The effects of spinal NC, similar to those seen in the periphery, reveals a dose- 
dependent direction of effect: nociceptin at low doses (pmol) causes hyperalgesia (as 
evidenced by behavioural tests), and hypersensitivity to thermal and mechanical 
stimuli, while at higher doses (nmol) a number of laboratories have observed 
antinociceptive effects and blockade of the hyperalgesic effects produced by 
substance P (Mogil and Pasternak, 2001).
Although the mechanisms for the hyperalgesic or the facilitatory effect is not clear, 
nociceptin may have a similar effect to that of morphine, where low doses have been 
shown to increase the release of excitatory neurotransmitters from the spinal cord, 
possibly via a direct excitatory effect on sensory neurones (Crain and Shen, 1990). 
Additionally, it is generally believed that inhibitory synapses are blocked at a lower 
concentration of inhibitory agents than excitatory synapses (Wagman et al., 1967) and 
therefore disinibition of inhibitory neurones may generate a facilitatory effect within
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a circuit from direct inhibitory agents such as morphine and nociceptin. On the other 
hand, studies have reported that i.t. injection of nociceptin even at higher doses 
produces hyperalsgesia/allodynia yet others have found no effect (Calo et al., 2000; 
Mogil and Pasternak, 2001). Despite many contradictions, most of the studies 
demonstrate that i.t. injection of nociceptin induces an antinociceptive effect similar 
to that evoked by classical opioid receptor agonists (Tian et al., 1997; Hao et al., 
1998; Xu et al., 1999). This effect is further substantiated by electrophysiological 
findings showing a major inhibitory action of nociceptin on neuronal activity in the 
spinal dorsal horn (Stanfa et al., 1996). These observations underline the complexity 
of nociceptin probably due to the large distribution of its receptor and its ability to 
modulate both transmitter release and neuronal activity.
Acute pain rarely presents a clinical problem, therefore in order to conduct clinically 
relevant studies, its necessary to employ models involving more persistent pain 
including inflammatory and neuropathic related pain states. Since the efficacy and the 
potency of the analgesic effect of opioids are not the same in different pain conditions 
(as described in the section 3.1.1), in this thesis I will be investigating the role of 
nociceptin on spinal dorsal horn neurones in normal, nerve injury and sham operated 
animals with methods described in the section methods.
3.1.3 Oxycodone
Oxycodone is among the most commonly used opioid analgesics for the relief of 
postoperative pain, cancer pain and generally in chronic pain, for review see (Kalso, 
2005). Indeed this effect of oxycodone is mainly due to its similarity to morphine and 
has been thought that oxycodone induces analgesia by acting on mu-opioid receptors 
(Beaver et al., 1978; Yobum et al., 1995). However recent studies believe that the 
antinociceptive effect of oxycodone is mediated preferentially at kappa-opioid 
receptors, whereas morphine interacts primarily with mu-opioid receptors (Ross and 
Smith, 1997). From the literature it is well known that activation of mu-opioid 
receptors has been associated with the analgesic and most of the side effects
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demonstrated by morphine (Kieffer, 2000). Therefore it was not surprising when 
several lines of evidence suggested that oxycodone evoked fewer side-effects than 
morphine (Kalso and Vainio, 1990; Maddocks et al., 1996; Mucci-LoRusso et al.,
1998).
The mechanism of action of oxycodone is similar to other opioid agonists; briefly the 
common mechanism of opioids consist of a presynaptic activation of opioid receptor 
neurones whereby the release of neurotransmitters is reduced, a postsynaptic 
hyperpolarization of neurones which reduces the evoked activity in the neuronal 
pathway and disinibition of inhibitory neurones (Dickenson, 1994).
While oxycodone’s analgesic effects are similar to those of morphine, other 
pharmacological characteristics distinguish these two opioids. Oxycodone has oral 
bioavailability of around 62% compared with morphine which is 23.9% (Hoskin et 
al., 1989; Leow et al., 1995) and systemic administration (s.c. or i.p.) of oxycodone 
produced a behavioural antinociceptive effect of about 2-4 times greater than 
morphine (Poyhia and Kalso, 1992). The high oral bioavailability of oxycodone 
maybe a result of its metabolite, oxymorphone, which has analgesic properties while 
morphine undergoes higher first pass metabolism and one of its main metabolites, 
morphine-3-glucuronide (M3G), has been suspected not to elicit any antinociceptive 
effect and/or antagonize the analgesic effect of morphine itself (Smith et al., 1990; 
Gong et al., 1992; Mucci-LoRusso et al., 1998).
In the thesis I will investigate the spinal effect of oxycodone using 
electrophysiological studies and also the antagonism of its action with naloxone and 
1-[(3R, 4 R)-l-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-l,3-dihydro-2 
benzimidazol-2-one known as J-l 13397 (the first non-peptide antagonist of 
nociceptin that binds to human and mouse brain ORLi receptors (Kawamoto et al.,
1999) discussed further in chapter 5).
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3.2 RESULTS
3.2.1 Nociceptin effects on evoked neuronal responses in normal animals
The effect of spinally applied nociceptin (50, 125 and 250 pg) was studied on n=6 
(n= number of animals) dorsal horn neurones and each dose was followed for 60 min. 
The mean depth of neurones in this study was 723 ±31 pm from the surface of the 
spinal cord which corresponds to lamina V-VI of the dorsal horn.
Analysis of all the neurones revealed that nociceptin had no significant effects with 
the first dose (50 pg) see Fig.2 and 3. However with 125 pg of nociceptin the 
following effects were observed: inhibition of C-fibre response of 62.13 ± 11% of 
control (P< 0.01), post-discharge 64.98 ± 24% (P< 0.05), input 69.67 ± 22% (P< 
0.05) and less inhibition of the wind-up 44.03 ± 26% (P<0.05) see Fig.2. Furthermore 
nociceptin (125 pg) had no effect on innocuous responses mediated by Ap-fibres and 
there was less inhibition of AS-fibre responses 41.68 ± 19% (P< 0.01), underlining 
the predominant effect of nociceptin in noxious evoked responses (see Fig.3). The 
inhibition was further increased with the highest dose (250 pg), suggesting a dose 
related response of this peptide see Fig.2-3 and Table2.
In fact, Fig.3 A shows that the level of inhibition increased significantly on all the 
afferent fibres responses except the Ap-fibre where this top dose of nociceptin did 
produce any changes.
These results are similar to several studies done in this laboratory (Stanfa et al., 1996; 
Carpenter et al., 2000), whereby the peptide can modulate nociceptive events by 
reducing wind-up, post-discharge and C-fibres of the neurones.
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Figure 2. Intrathecal nociceptin doses (50, 125 and 250 pg) causes dose-dependent 
inhibition on A) C-fibre, B) Input, C) Wind-up and D) Post-discharge evoked
responses in normal animals (n=6). The effects o f the individual doses were
compared to pre-drug control values and expressed as % inhibition ± S.E.M.
Significance is denoted as **P< 0.01, *P< 0.05 by Tukey and ANOVA tests.
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Figure 3. Intrathecal nociceptin doses (50, 125 and 250 pg) on electrically evoked 
dorsal horn neuronal responses recorded from 6 normal animals, causes A) no 
changes on A-beta fibres evoked responses while B) nociceptin induces dose- 
dependent inhibition on A-delta fibres evoked responses. The effects o f the individual 
doses were compared to pre-drug control values and expressed as % inhibition ± 
S.E.M. Significance is denoted as **P< 0.01 by Tukey and ANOVA tests.
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3.2.2 Effects of intrathecal nociceptin on evoked neuronal responses in
sham operated and neuropathic animals
The role of nociceptin was also investigated in animals which underwent SNL (Spinal 
Nerve Ligated/neuropathic) or sham operation surgery. Both surgical procedures are 
described in the methods section and on the 14th day after the surgery these animals 
were used for the electrophysiology studies. In these experiments I used intrathecal 
injection of the maximum dose of nociceptin (250 pg), and studied n=6 animals in 
each group. Again the recordings were made from the deeper laminae (V-VI) of the 
spinal dorsal hom.
As presented in Table 2, the top dose of nociceptin had no significant effect on A- 
fibre evoked responses. In contrast nociceptin evoked a significant inhibition of C- 
fibre evoked responses and the post-discharge of the cells in both normal and 
neuropathic animals whereas this dose of nociceptin had no significant effect on C- 
fibre evoked responses in sham operated animals compared to baseline. Moreover 
wind-up and input response were significantly inhibited by 250 pg of nociceptin in 
normal animals.
In neuropathic animals these responses were also inhibited but not to the extent as 
that seen in normal animals. However, nociceptin had no effect on the input response 
in sham operated animals and causes a clear facilitation of the wind-up response in 
this group.
Overall it seems that the inhibition observed with 250 pg nociceptin is greater in 
normal animals, followed by the neuropathic animals and neurones in sham operated 
animals are the least effected by nociceptin (Table 2). In fact significant differences 
were found between sham operated rats compared to normal animals while overall no 
significance were found between normal and neuropathic animals (Table 2).
In addition to Tukey and ANOVA tests was employed Mann-Whitney test for the 
comparison of drug effects within the group and the level of significance was taken to 
be P< 0.05.
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Table.2. The effect o f nociceptin on various neuronal responses in normal (n= 6), 
sham operated (n= 6) and neuropathic (n=6) animals. Data are expressed as the % 
inhibition ± S.E.M. Significant effects o f  the individual doses were compared to pre­
drug control values o f  neurones within that group (**P< 0.01, *P< 0.05 by using 
Mann-Whitney test) and differences between groups (SNL or sham) were compared 
with normal animals (¥P< 0.05 using Tukey andANOVA tests).
Afferent
fibres
Normal rats 
with 
250 fig 
Nociceptin
% inhib. ±  s.e.nu
Sham rats 
with 
250 fig 
Nociceptin
% inhib. ±  
s.e.m
SNL rats 
with 
250 fig 
Nociceptin
% inhib. ±  s.e.m
A-beta
A-delta
6.94 ±6.3 19.44 + 5.9 2+ 10.5
46.6 + 16.3 10.89 + 11.3 26 ± 22.9
C-fibre 70.84 + 8.9** -3.75 ±16+ 39.29 + 4*
Post­
discharge 89.42 + 6.1** -15.39 ±10.5+ 65.68 + 10.5*
Wind-up 72.88 + 9.5** -64.37+9.1+ 69.3 + 11.34
Input 87.02 + 10.4** 12.9 ± 22.7+ 40.96 ±22.8+
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3.2.3 Effects of oxycodone on evoked neuronal responses in normal
animals
Oxycodone (1, 10, 50, 100 pg) was applied by intrathecal administration onto the 
spinal cord in normal animals (n=6) and each dose was followed over a time course 
of 60 min. Following the application of the highest dose of oxycodone, the effect of 
oxycodone was reversed by intrathecal administration of 50 pg naloxone on n=3 and 
the other half of the group was treated with 100 pg J-l 13397.
Intrathecal oxycodone produces a smaller inhibitory effect on the Ap-fibre response 
when compared with that of the A5-fibre, C-fibre, post-discharge, input and wind-up 
responses. The lower doses of oxycodone (1 and 10 pg) induced very little inhibition 
of the Ap-fibre response (Fig.4A). Even at the highest doses of oxycodone studied 
(50 and 100 pg) the maximum inhibition of Ap-fibre response did not exceed 32 ± 
4% (Fig.4A). Administration of naloxone revealed a reversal of oxycodone effects 
while J-l 13397 showed no reduction of the inhibition evoked by oxycodone. 
However these changes were not significant.
Oxycodone produces dose-dependent effects on A8-fibre evoked responses (Fig.4C). 
A modest facilitation was observed with the lowest dose (1 pg) followed by increases 
in inhibition as the dose applied is increased. For instance, the maximum percentage 
inhibition achieved was 76 ± 10% with 100 pg oxycodone (P< 0.01).
Similar dose-dependent effects of oxycodone were seen on the C-fibre evoked 
responses (Fig.4B), post-discharge and input of the neurones. Here again a peak 
inhibition of 63 ± 14% and 89 ± 5% was reached with the 100 pg of oxycodone on C- 
fibre (P< 0.01) and input (P< 0.01) evoked responses respectively (Fig 4B and 4D). 
In all cases the inhibition evoked by oxycodone was significantly reversed by 
naloxone, in contrast J-l 13397 failed to show significant changes.
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The effect of oxycodone on the electrically evoked wind-up response was variable 
from one dose to the next. Oxycodone doses of 1, 10 and 50 pg all reveal facilitatory 
actions, with the greatest effect seen at 50 pg (19 ± 32%) However, at the maximum 
dose of 100 pg, a clear inhibition of 69 ± 10% was attained (data not shown). That 
inhibition was significantly reversed by naloxone and slightly reduced by J-l 13397.
105
100
75 -
A) A-BETA
O  5o j
tz m
£ 25 -
i d
T
1 10 50 100
// ■I // ^
100 50
DOSE (ng)
100
75 -
50 -
25 -
B) C-FIBRE
-25 -
-50
T
l A
T
I// //
"i------ i--------- i-------i
1 10 50 100
~T~
100 50
C) A-DELTA
D) INPUT
100 -
T---------1-------- 1-------T
1 10 50 ioo
DOSE Gig)
ioo -
□  Oxycodone ■  J 11339 7  0  Naloxone
Figure 4. The spinal effect o f oxycodone (1, 10, 50 and 100 pg) induces: no change 
on A) A-beta evoked responses while on (B) C-flbre-, C) A-delta- and D) Input- 
evoked responses causes dose-dependent inhibition in normal animals (n= 6). After 
the application o f oxycodone half o f the animals were treated with spinal J -l 13397 
(100 pg) and this did not reverse the inhibition seen with oxycodone, in contrast 
when the remaining animals were treated spinally with naloxone (50 pg), the 
inhibition induced by oxycodone was reversed. Data are expressed as the % 
inhibition ± S.E.M. Significance was found between the groups above indicated, 
**P<0.01 *P<0.05 by Tukey and AN OVA tests.
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3.3 DISCUSSION
3.3.1 Effects of spinal nociceptin on evoked neuronal responses in normal, 
sham operated and neuropathic animals
The current study clearly demonstrates that intrathecal administration of nociceptin 
elicits an antinociceptive effect on spinal dorsal hom neurones in normal animals. 
This inhibitory effect is increased by increasing the doses of nociceptin as shown in 
table2. The dose-dependent inhibitory effect of nociceptin was also observed in other 
studies (Stanfa et al., 1996; Xu et al., 1999).
In particular, from the present study it is evident that nociceptin has no effect on Ap- 
fibre responses and this fact underlines the specificity of this peptide on noxious 
responses of these spinal cord deep neurones. The most marked action of nociceptin 
was found with the maximum dose of 250 pg that caused clear inhibition of C-fibre, 
post-discharge, wind-up and input evoked responses. The greater inhibitory action of 
nociceptin on C-fibre evoked responses when compared to the others afferent fibres 
suggests the predominant effect of the peptide at the pre-synaptic sites, as was also 
seen in patch clamping studies done on SG neurones (Luo et al., 2002). This 
hypothesis seems likely as the receptor is synthesized in the DRG (Wick et al., 1994). 
Actions directly on the deep neurones would be expected to hyperpolarize the 
neurone which would non-selectively reduce all responses. However, nociceptin acts 
also on the post-synaptic site by inhibiting the enhanced neuronal response elicited by 
repeated stimulation known as wind-up response. Also the post-discharge, another 
post-synaptic mechanism which underlies spinal facilitation was inhibited by 
nociceptin.
Both the pre- and post-synaptic effects of nociceptin are supported by the mechanism 
of action of this peptide in the spinal cord which is thought to act through three 
possible mechanisms. The first possible mechanism is the ability of nociceptin to 
inhibit voltage-dependent N-type Ca2+channel currents (Connor et al., 1996) and 
therefore reduce the release of the afferent transmitters. The second is a postsynaptic
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action where nociceptin increases inwardly rectifying K+ conductance (Meunier, 
1997). It is possible that nociceptin causes membrane hyperpolarization by an 
increase in K+ conductance and this membrane hyperpolarization reduces cellular 
excitability and inhibits neurotransmitter release. The third possible mechanism is 
that nociceptin inhibits adenylate cyclase (Meunier, 1997).
The second part of these experiments studied the i.t. injection of a maximum dose of 
nociceptin in a group of neuropathic animals where the spinal nerves L5 and L6 were 
tightly ligated and a group of sham operated animals, whereby the surgical procedure 
was identical to that of the neuropathic group, but spinal nerve ligation was not 
performed.
Similar to the normal animals, this top dose of nociceptin has no effect on Ap-fibre 
response in both sham operated and neuropathic animals.
Similar to the effects observed in normal animals, nociceptin produced a significant 
inhibition of C-fibre and post-discharge responses in neuropathic animals and overall 
the wind-up and input were reduced. Although the inhibitory response observed with 
nociceptin in normal animal was greater compared to neuropathic animals, nociceptin 
has maintained an analgesic role in neuropathic animals. Overall there is no 
significance difference in the effect of nociceptin in normal and neuropathic animals. 
In fact behavioural studies reveal the effectiveness of nociceptin against thermal 
hyperalgesia resulting from either chronic constriction injury of the sciatic nerve 
(Yamamoto et al., 1997) or partial nerve injury in rats (Yamamoto and Nozaki- 
Taguchi, 1997). Abdulla and Smith, (1998) also found that axotomy increases the 
effectiveness of nociceptin on isolated dorsal root ganglion neurones.
However, there is limited information about the basis for the observed 
electrophysiological changes in the nociceptin system in the spinal cord following 
nerve injury and sham operated animals. Recent studies found, using the flexor reflex 
model, that nociceptin induces dose-dependent supression of the reflexes in this 
model in normal, acute inflamed and axotomized animals (Xu et al., 1999). The 
potency of nociceptin to inhibit the flexor reflex was greatest in animals with nerve
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injury followed by normal animals with the inflamed animal group being the least 
effected (Xu et al., 1999). Interestingly the findings of Xu et al., (1999) are somewhat 
similar to what I have seen, namely, that the potency of nociceptin varied according 
to the following order: normal > injury > inflammation. The discrepancy between 
normal and nerve injury may be due to the neuropathic pain model used (Xu 
sectioned the entire sciatic nerve), the experimental measures (neurones vs reflexes).
However, others have reported a similar level of antinociceptive potency of 
nociceptin in normal and inflamed animals, while nociceptin had only a weak effect 
on the tail-flick latency of rats with peripheral nerve neuropathy (Hao et al., 1998). 
Also electrophysiological studies of spinal dorsal horn neurones demonstrate that i.t. 
effectiveness of nociceptin is increased in the presence of acute inflammation 
(Carpenter et al., 2000). In contrast, my experiments show that overall nociceptin has 
no inhibitory effect on sham operated animals, even though these animals persistent 
inflammation or persistent changes induced by an acute inflammation (post-operative 
period) may be suspected. One main difference is that the sham animals were used at 
2 weeks whereas previous studies looked at acute effects of inflammation suggesting 
that the regulation of ORLi receptors may differ with time. Neuropathic animals also 
present sham effect as well as nerve injury while normal animals do not present any 
form of inflammation. Similar changes in sham operated animals were previously 
observed in the effect of another peptide, galanin (Flatters et al., 2002).
It is not clear why some changes are seen in sham animals at 2 weeks but recent 
studies suggested that following peripheral inflammation produced by s.c. injection of 
acute carrageenan there was a marked induction of the levels of nociceptin gene 
transcription in the DRG (Andoh et al., 1997). Nevertheless, this finding does not 
show a change in the density of ORLi receptors, which would be interesting as we are 
already applying high concentration of the peptide directly to the spinal cord. Also 
autoradiographical measures of nociceptin binding in the dorsal horn of the spinal 
cords from animals with chronic inflammation induced by peripheral injection of 
complete CFA showed that nociceptin binding increased in the superficial dorsal horn
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(Jia et al., 1998). Although the densiometric analysis of autoradiograms showed 
nociceptin binding increased in medial and lateral laminae I—II with no change in 
binding occurring in lamina X (Jia et al., 1998), maybe this increase is due to the up- 
regulation of the peptide as also suggested above by Andoh et al., (1997) rather than 
increase of the number of receptors. These studies show once again the complexity of 
this receptor and further underlines the difference between this receptor and the other 
opioid receptors.
Moreover, the mechanisms underlying the reduced effect of nociceptin in neuropathic 
pain and the lack of effectiveness in sham operated animals needs to be further 
explored. However, Briscini et al., (2002) suggested an up-regulation of ORLi 
receptors in the spinal cord or dorsal root ganglia in animals with nerve injury.
Although, most studies predict an increase in nociceptin effects after inflammation 
and nerve injury, it is possible that in the two pathological conditions there is 
plasticity in peripheral and central nervous systems that could further enhance the 
response (or input) of the dorsal horn neurones more than in normal states so that 
inhibition is less as a result of higher levels of excitation. Thus this factor may 
therefore reduce the efficacy of nociceptin in these pain states. It seems from the 
finding of these experiments that peripheral inflammation and nerve injury may 
regulate endogenous nociceptin and its receptor in ways different from or opposite to 
the classical opioid system. Whether development of selective agonists or antagonists 
to the ORLi receptor will clarify the role of nociceptin and its receptor in pain 
transmission will be investigated in the next chapters.
3.3.2 Effects of spinal oxycodone on evoked neuronal responses in normal 
animals
The finding of this experiment indicates that oxycodone induces dose-dependent 
inhibition of spinal dorsal horn neurones. In particular there was clear inhibition of 
noxious induced responses when compared to non-noxious Ap-fibre responses. This
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is in agreement with the ability of opioids to produce a powerful inhibition of small 
afferent fibre input with little effect on large afferent evoked activity and led to 
speculation that opiates may predominantly act pre-synaptically (Yaksh and 
Noueihed, 1985). Alternately, the ability of opioids to suppress non-noxious activity 
in dorsal horn neurones by high doses suggested that the inhibition may be extended 
to postsynaptic neurones (Yaksh and Noueihed, 1985).
The inhibitory effect of oxycodone has been thought to be similar to that of 
morphine’s and to be principally mediated through the mu-opioid receptor (Beaver et 
al., 1978; Yobum et al., 1995). However, Ross and Smith, (1997) have suggested that 
the kappa-opioid receptor is responsible for the antinociceptive effect of oxycodone. 
They have based this hypothesis on the observation that the kappa-opioid receptor 
antagonist, norbinaltorphimine (nor-BNI), was able to attenuate the antinociceptive 
activity of oxycodone whilst sparing the antinociceptive effect of morphine.
The analgesic effect induced by oxycodone in our study was less than the effect of 
morphine obtained in similar studies (Suzuki et al., 1999). Indeed 
electrophysiological studies showed that the analgesic effect seen with i.t. morphine 
was more potent even though the concentration used was 10 times less than 
oxycodone (Suzuki et al., 1999). For example, Suzuki et al (1999) showed that i.t 
morphine (10 pg cumulative dose) produced about 85% of inhibition of C-fibre 
evoked response whereas in my study I found that oxycodone (100 pg cumulative 
dose) produced a 63% inhibition of the same afferent fibre evoked response. This 
reduced spinal effect of oxycodone was also seen when the antinociceptive effect was 
assessed on the tail-flick and hot plate tests after i.t. morphine (Plummer et al., 1990; 
Poyhia and Kalso, 1992), indicating that oxycodone has a poor affinity on spinal 
opioid receptors. This result maybe explained by the fact that the predominant opioid 
receptors in the spinal cord are mu and delta (Dickenson, 2001). On the other hand, 
the effect of oxycodone was almost similar to the inhibition observed with higher 
doses of nociceptin in normal animals. These could be summarized that i.t.
I l l
administration of those opioids agonists on dorsal horn neurones has a potency order 
as follows: morphine > oxycodone > nociceptin.
My present findings have illustrated that after reaching significant antinociceptive 
effect with i.t. oxycodone (cumulative doses 1, 10, 50, 100 pg), the spinal effect of 
oxycodone was reversed with naloxone (50 pg) but not with J-l 13397 (100 pg). This 
is in agreement with the findings of (Poyhia and Kalso, 1992) where the 
antinociceptive effect of oxycodone was antagonized by naloxone. The situation is 
quite opposite with J-l 13397, where there is a total lack of antagonism. The only 
exception was the wind-up response where J-l 13397 seems to reduce the inhibitory 
effect of oxycodone, although all the other evoked responses were not reversed by the 
application of J-l 13397. Overall this result further underlines the selectivity of J- 
113397 (further details of J-l 13397 see chapter 5).
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CHAPTER 4
STUDIES WITH A NOCICEPTIN RECEPTOR AGONIST
4.1 INTRODUCTION
In the previous chapter the antinociceptive effect of nociceptin, the endogenous 
ligand of the opioid-like receptor 1 (ORLi/NOP) was investigated in different pain 
states and raised the possibility that agonists at this receptor may represent a novel 
class of analgesics with therapeutic potential.
In an attempt to further understand the pharmacological characteristics and functional 
role of the ORLi receptor it was important to build on the identification of ORLi 
selective ligands. For instance, one of the first analogs of nociceptin was 
[Try14]OFQ/N, developed to enable the detection of receptor binding and which has 
proven extremely valuable in the characterization of the receptor in both transfected 
cell lines and in the brain (Reinscheid et al., 1995). Another much studied analog of 
nociceptin is the peptide [Arg14, Lys15]NC, which has 3-fold greater binding affinity 
than nociceptin at human ORLi (Okada et al., 2000). Although this peptide has higher 
potency than nociceptin some unwanted effects such as ataxia were more pronounced 
and longer lasting than those elicited by nociceptin (Rizzi et al., 2002). Thus these 
effects may produce limitations in the behavioural assessment of the receptor 
function.
The lack of any nonpeptide agonist of ORLi receptor attracted the interest of several 
pharmaceutical industries in attempts to develop compounds as stable and 
bioavailable analogs of nociceptin.
In this chapter, for the first time, the in vivo electrophysiological effects of compound 
20700857, a novel ORLi receptor ligand obtained from Solvay Pharmaceuticals will 
be investigated.
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4.2 RESULTS
The effect of compound 20700857 was investigated on 36 dorsal horn neurones with 
mean depth 750 ± 50 pm from the surface of the spinal cord and this did not differ 
between groups; inflamed, normal and neuropathic rats. The compound was 
administrated intrathecally (i.t) or subcutaneously (s.c.) at various doses (0.1, 1 and 
10 mg/Kg) and each dose was followed for an hour.
In the carrageenan animals, the inflammation was induced by an injection of 2% 
carrageenan 100 pi in the plantar surface of the hindpaw of the rat (see methods for 
further details). I found that there were no changes in A-beta and C-fibre evoked 
responses in carrageenan and normal rats treated intrathecally or subcutaneously with
0.1, 1 and 10 mg/Kg of compound 20700857 when compared to their respective 
controls (see Fig. 1)
However, post-discharge, input and wind-up of these rats showed some variations 
with respect to their controls (see Fig.2 and 3). In normal animals the lowest dose of
1.t. compound 20700857 did not induce changes in the post-discharge response, while 
higher doses, 1 and 10 mg/Kg, evoked a slight inhibition of 27 ± 21% and 17 ± 34% 
respectively (See Fig.2). In contrast, s.c. injection of this compound caused a 
facilitatory effect on post-discharge response in the normal animals (see Fig.2). 
Greater effects of the drug on the post-discharge response was observed in 
carrageenan animals, where primarily i.t. and s.c. injection caused a facilitatory effect 
(see Fig.3). Moreover, after s.c. injection of 0.1 and 1 mg/Kg in normal animals the 
input response was facilitated by 12 ± 15%, while with the top dose of the compound 
20700857, the input response was facilitated by 32 ± 14% (see Fig.2), while the i.t. 
injection of compound 20700857 in the same animal group produced a tendency to 
inhibition with the lower and the top dose, whereas 1 mg/Kg causes 7 ± 19% 
facilitation (See Fig.2). Again in carrageenan animals s.c. injection of the compound 
induces increased input responses, while the i.t. effect of the compound caused the 
opposite effect (see Fig.3).
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Figure 1. Intrathecal and subcutaneous administration of compound 20700857 has 
no effect on Afi- and C-fibre evoked responses in normal (n=12) and carrageenan 
injected (n=12) animals. Data are expressed as % control ± S.E.M.
123
In carrageenan injected animals the wind-up response was increased with all three 
doses of i.t. compound 20700857, as well as the s.c. injection of the top dose (see 
Fig.3). The remaining doses, namely 0.1 and 1 mg/Kg of compound 20700857 
administered subcutaneously induced a significant inhibition of the wind-up 
responses (53 ± 7% and 70 ± 11% respectively) of deep dorsal horn neurones (see 
Fig.3). Furthermore, subcutaneous injection of 10 mg/Kg of this compound caused 
significant inhibition of 38 ± 5% of the wind-up response in normal animals (Fig.2). 
Overall lower doses of s.c and i.t. injection of the compound induced slight inhibition 
of the wind-up response in normal animals (see Fig.2).
In addition to the electrophysiological study of carrageenan and normal animals, I 
also investigated the effect of i.t. and s.c. injection of compound 20700857 in 
neuropathic animals (see chapter 2 for description of the model), and the results 
observed were as follows:
The A-fibres responses were not altered significantly during i.t. or s.c. injection of the 
compound in study (see Fig.4). Furthermore, similar lack of change in response was 
found for C-fibre, input and post-discharge responses (Fig.5). Although in these 
experiments there was no significant difference between i.t and s.c. injected animals, 
overall i.t. administration of 10 mg/Kg compound 20700857 induces a slight 
inhibitory effect on the electrically evoked responses (Fig.4 and 5). On the other 
hand, mainly a facilitatory effect was seen following s.c administration of the 
compound 20700857 in neuropathic animals (Fig.4 and 5).
In neuropathic animals as previously seen in carrageenan injected animals, low doses 
of compound 20700857 appeared to have an inhibitory effect on the wind-up 
response (Fig.5), and the highest inhibitory action of compound 20700857 on wind­
up response was reached 38 ± 21% after i.t. administration of 1 mg/Kg. However the 
inhibition observed was not significant. In contrast the s.c. injection of 1 and 10 
mg/Kg of the compound in study induced significant increase of 147 ± 6% and 156 ± 
6% on the wind-up response in neuropathic animal (Fig.5).
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Figure 2. Effect o f intrathecally and subcutaneously applied compound 20700857 on 
post-discharge, wind-up and input responses in normal animals (n=12). The effects 
o f the individual doses were compared to pre-drug control values and expressed as % 
control ± S.E.M. Significance is denotedas*P< 0.05 by Tukey and ANOVA tests.
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Figure 3. Effect o f intrathecally and subcutaneously applied compound 20700857 on 
post-discharge, wind-up and input responses in carregeenan injected animals 
(n=12). The effects o f the individual doses were compared to pre-drug control values 
and expressed as % control ± S.E.M. Significance is denoted as*P< 0.05 by Tukey 
andANOVA tests.
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Figure 4. Intrathecal and subcutaneous administration o f compound 20700857 has 
no effect on A-beta and A-delta-fibre evoked responses in neuropathic animals 
(n=12). Data are expressed as % control ± S.E.M.
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4.3 DISCUSSION
The present study shows that in my in vivo electrophysiological study of compound 
20700857, unlike the endogenous peptide, it did not cause a dose-dependent 
inhibition in normal, carrageenan injected and neuropathic animals whatever the route 
of administration.
The compound in study induced complex changes in the responses of the deep dorsal 
horn neurones where the recordings were made. These responses consist of both 
facilitatory and inhibitory effects on the electrical evoked response. On the other 
hand, A-fibres and C-fibre evoked responses were generally unaltered after 
administration of compound 20700857. The absence of a prominent inhibitory effect 
of compound 20700857 could suggest that this compound does not behave as a full 
ORLi agonist or indeed, is not an ORLi agonist. In fact, compound 20700857 when 
compared to the effect of nociceptin, the most studied ORLi agonists, seems to have 
less potency or specificity (see chapter 3). One other possibility is that this 
compound, as a non-peptide, when given systemically, has actions at sites where both 
the pro- and anti-nociceptive effects of the receptor are revealed. However, even 
when direct spinal application was used, it failed to produce the clear and 
reproducible inhibitory effects seen with nociceptin as presented in previous chapters 
and reported by others.
However, the overall results of these experiments shows that compound 20700857 
has an interesting effect on the wind-up response and this varies with the rote of 
administration and the pain states (e.g. normal, carrageenan and neuropathic animals). 
In fact, the wind-up response was significantly increased by s.c. and i.t. 
administration of compound 20700857 in neuropathic and carrageenan injected 
animals respectively. By contrast, s.c. injection of this compound in normal and 
carrageenan animals induces inhibition of the wind-up responses vs their respective 
pre-drug control. This finding may well suggest that compound 20700857 has a role
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in modulation of the mechanisms of wind-up.. Wind-up, as discussed in chapter 1 is a 
measure of the enhanced neuronal response elicited by repeated stimulation and is 
usually evoked by C-fibres stimulation leading to activation of NMDA receptors 
(Mendell and Wall, 1965; Dickenson and Sullivan, 1987). Since the present study 
shows that compound 20700857 did not cause significant changes on either the 
overall C-fibre evoked response or the input response (a measure of afferent 
excitability) both measures that are used for the calculation of the wind-up response, 
the data may suggest that compound 20700857 acts to modulate the NMDA receptor 
in a rather selective manner. However this effect and possible mechanisms needs to 
be further investigated.
In the present study the doses of compound 20700857 used were as advised by the 
company and they covered the range of doses that I have used previously, for instance 
the top dose was twice the concentration of nociceptin used in my electrophysiology 
study (chapter 3).
Overall the result of this study indicates that compound 20700857 is not as potent as 
nociceptin, the endogenous agonist of the ORLi receptor and subsequently the partial 
effect observed with the compound may be due to its ability to modulate other 
receptors that could include the NMDA receptor.
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CHAPTER 5
STUDIES WITH A NOCICEPTIN RECEPTOR 
ANTAGONIST
5.1 INTRODUCTION
One of the most common approaches to investigate the pharmacological activity of a 
certain receptor and to investigate the functional role of the ligand at the receptor is to 
find a selective antagonist of that receptor. In the case of nociceptin, there is general 
agreement that the spinal inhibitory effect of this peptide is not reversed by naloxone 
or requires high doses and even then is incomplete (Faber et al., 1996; Stanfa et al., 
1996; Erb et al., 1997; Liebel et al., 1997; Hao et al., 1998). Thus, it appears that 
nociceptin-induced antinociception is mediated by a novel mechanism independent of 
classical opioid receptors. Subsequently several peptide and non-peptide antagonists 
have been identified to determine whether the effects of nociceptin might be mediated 
by ORLi.
One of the most studied nociceptin antagonists is [Phe1\j/(CH2-NH)Gly2]-nociceptin 
(1-13)-NH2. This peptide acts as a competitive antagonist in guinea big ileum and 
mouse vas deferens (Guerrini et al., 1998). The first study of [PheI\j/(CH2-NH)Gly2]- 
nociceptin (1-1 3)-NH2 using in vivo electrophysiological recordings of dorsal horn 
neurones found that the compound behaves as an agonist after spinal administration 
(Carpenter and Dickenson, 1998). The inhibitory effect of [Phe1\j/(CH2-NH)Gly2]- 
nociceptin (1-1 3)-NH2 was more susceptible to naloxone reversal than that of 
nociceptin (Carpenter and Dickenson, 1998). This may suggest that [Phe1\|/(CH2- 
NH)Gly2]-nociceptin (1-1 3)-NH2 has some activity on other central opioid receptors 
although it has been demonstrated to be selective for peripheral ORLi receptors 
(Guerrini et al., 1998). It was also demonstrated in behavioural studies that i.c.v and
i.t injection of [PheV^HQ-NKlGly2]-nociceptin (1-1 3)-NH2 does not antagonise the 
effect of nociceptin on nociceptive transmission (Candeletti et al., 2000).
It is well known that peptide compounds generally can have the advantages of high 
selectivity and specificity and the disadvantages of metabolic instability and limited 
distribution after administration. Indeed recent researches have been directed to the
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discovery of non-peptide compounds which show low selectivity and specificity but 
better pharmacokinetics (Calo et al., 2002).
The 1- [(3R, 4 R) -l-cyclooctylmethyl-3- hydroxymethyl-4- piperidyl] -3-ethyl-l, 3- 
dihydro-2 benzimidazol-2-one known as J-l 13397, is the first non-peptide antagonist 
of nociceptin and binds to the human and mouse brain ORLi receptor (Kawamoto et 
al., 1999). As a putative non-peptide antagonist, this seemed a potential candidate for 
determining the involvement of the nociceptin system in nociceptive transmission in 
an in vivo preparation.
To elucidate the antagonist effect of J-l 13397, the first in vivo electrophysiological 
study was made to determine the effects of spinally applied J-l 13397 after treatment 
with nociceptin on the electrical evoked responses of spinal dorsal horn neurones. 
Subsequently I investigated the role of the antagonist alone on electrical and naturally 
(mechanically) evoked responses in normal, carrageenan injected, neuropathic and 
sham operated animals. The aim was to ascertain if the antagonist could reveal any 
endogenous activity of nociceptin at the ORLi receptor in these different pain models.
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5.2 RESULTS
5.2.1 Normal animals treated with nociceptin, J-l 13397 and morphine
In this experiment I used normal animals treated with 50, 125 and 250 pg of 
nociceptin as reported in section 3.2.1. Each dose was followed for 60 min and after 
the last dose of nociceptin, 100 pg of J-l 13397 was applied and followed for an hour. 
The effect of nociceptin could last at least 90-120 min (data not shown), and was 
therefore possible to see the effect of an antagonist by applying it 60 min after the 
spinal application of nociceptin. The study was done on n=6 dorsal horn neurones 
with a mean depth of 723 ±31 pm.
The effect of nociceptin on the C-fibre evoked response of spinal neurones was 
reversed from 70.84 ± 9% inhibition to 19.77 ± 7% after 100 pg of J-l 13397 (P< 
0.01), post-discharge from 89.42 ± 6% to 10.25 ± 16% (P< 0.05), wind-up from 72.88 
± 9% to +6.55 ± 19% (P< 0.05) and finally input from 87.02 ± 10% to 27.18 ± 12% 
(P< 0.05), see Fig.lA. Intrathecal J113397 reverses also the analgesic effect of 
nociceptin on A-delta but it could not be tested on A-beta evoked responses, since 
nociceptin had no effect on this response (Fig.2B).
Furthermore, to determine the selectivity of J-l 13397 versus ORLi, I compared its 
action on another opioid receptor, with 1 pg of morphine being applied after J- 
113397 and I then followed the effect of the mu-opioid receptor agonist (n=4 
neurones). This low dose of morphine produced clear inhibition of the C-fibre evoked 
responses, post discharge, input and windup even though J-l 13397 had completely 
reversed the action of nociceptin. For simplicity this effect is illustrated by the wind­
up graph of a single dorsal horn neurones (Fig.2). Morphine produced a profound 
inhibition even in the presence of J-l 13397.
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5.2.2 Normal and carrageenan animals treated with only J-l 13397
The effect of intrathecal injection of 100 pg J-l 13397 was studied on fourteen dorsal 
horn neurones; from normal rats (n=7) and in another group of rats 3 h after induction 
of carrageenan inflammation in the ipsilateral hindpaw (n=7). Their mean depth was 
750 ± 50 pm from the surface of the spinal cord and this did not differ between 
groups. Electrically and naturally (von Frey) evoked neuronal responses were 
recorded from the two groups.
5.2.2.1 Electrically-evoked responses
The application of intrathecal J-l 13397 had no effect on the A-fibres responses of the 
carrageenan rats (Fig.3). J-l 13397, produced a slight facilitatory effect on A8- fibre 
responses in both normal (+18.3 ± 23%) carrageenan-injected (+21 ± 13%) Fig.3. 
Also in the post-discharge responses there was a tendency of J-l 13397 to cause a 
facilitation in the two groups of rats (Fig.3). The situation is quite different on C-fibre 
evoked responses where J-l 13397 had a mild inhibitory effect. This inhibition was 
greater in the carrageenan-injected rats (31 ± 12%) than in normal animals (17 ± 
10%) see Fig.3. In addition wind-up was slightly inhibited in the carrageenan-injected 
rats but there was no effect in the normal rats whereas input responses were inhibited 
to a similar extent in both groups (Fig.4). Significance was not established on these 
electrically evoked responses when compared to their respective controls, thus overall 
100 pg J-l 13397 was observed to have no significant effect on these neuronal 
responses in normal rats or those in the presence of inflammation. Thus, there is no 
evidence for an endogenous tone in the ORLi system under these conditions using 
electrical stimuli.
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Figure 1A. Intrathecal administration o f  nociceptin (50, 125, 250 pg) induces dose- 
dependent inhibition on C-fibre, post-discharge, wind-up and input evoked responses 
in normal animals (n~6). This inhibition was reversed by J - l13397 (100 pg). Data 
are expressed as % inhibition ± S.E.M. Significance was found between the groups 
above indicated, *P<0.05 using Tukey andANOVA tests.
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Figure IB. Intrathecal administration o f  J-l 13397 (100 pig) reverses the analgesic 
effect o f  nociceptin (50, 125, 250 pg) on A-delta evoked response but it could not be 
tested on A-beta evoked response, since nociceptin had no effect on this response 
(n -6  normal rats). Data are expressed as % inhibition ± S.E.M. Significance was 
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Figure 4. Spinally applied J - l13397 (100 pg) has no effect on the wind-up and input 
electrically evoked dorsal horn neuronal responses recorded from normal (n=7) and 
carrageenan (n=7) rats. Data are expressed as % inhibition ± S.E.M.
5.2.2.2 von Frey evoked responses
To further identify the role of J-l 13397 on noxious and innocuous responses, I 
investigated the effect of J-l 13397 on mechanical evoked responses by using von- 
Frey filaments. The use of von Frey forces produced progressive increases in the 
neuronal firing rate proportional to the increase in the von Frey filaments. However, 
there were no changes in von-Frey response in normal animals after J-l 13397 
injection. Similar responses were also observed in animals with carrageenan induced 
inflammation. Interestingly, in these animals with peripheral inflammation, the 
coding of these mechanical stimuli by the spinal neurones was increased compared to 
normal animals for both the low intensity and noxious forces, indicative of 
hypersensitivity in spinal processing.
This study clearly demonstrates that the 100 pg of J-l 13397 compound had no 
significant effect in both normal and inflamed rats. The number of action potentials at 
each von Frey was higher in the carrageenan-injected groups from the control
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situation when compared to the normal animals and this difference remains the same 
also after the injection of J-l 13397. The highest von Frey (75 g) produced a response 
of 697 ± 191 action potentials in carrageenan animals before the injection of J- 
113397 and after the injection the response was 656 ±201 action potentials, while the 
same von Frey produces 356 ± 73 in normal animals without J-l 13397 and 314 ± 68 
action potentials after J-l 13397-injection (Fig.5). This underlines that there is 
difference in baseline responses between animals with inflammation and normal 
animal, yet J-l 13397 has no significant effect on these animals when compared to 
their respective control values.
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Figure 5. Effect o f spinally applied J - l13397 (100 pg) on the naturally evoked dorsal 
horn neuronal responses recorded from normal (n=7) and carrageenan (n-7) rats. 
The control values were obtained before drug administration. The von-Frey filaments 
1-6 correspond to weights 2, 5, 9, 15, 30, 75g respectively. Data were expressed as 
mean number o f action potentials evoked over 10 sec ± S.E.M.
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5.2.3 Neuropathic and sham operated animals treated with only J -l13397
The effect of intrathecal injection of J-l 13397 in cumulative doses (1, 10, 100 jag) 
was studied on twelve dorsal horn neurones; sham-operated (n=6) and neuropathic 
(n=6) rats. Their mean depth was 750 ± 50 pm from the surface of the spinal cord and 
this did not differ between groups. Electrically and naturally (von Frey) evoked 
responses were recorded from spinal dorsal horn neurones in each of the two groups 
and was compared with data of the normal animals obtained from the section 5.2.2.
5.2.3.1 Electrically-evoked responses
In all three animal groups intrathecal injection of J-l 13397 did not cause any change 
in the Ap-fibre induced neuronal activity (Fig.6). This was also observed for the A5- 
and C-fibre activity with the exception of the dose of 100 pg J-l 13397 that produced 
an inhibition of A8-fibre (37 ± 8%) and C-fibre (29 ± 12%) responses in the 
neuropathic group although this was not significant (Fig.6). There was an overall 
increase in the wind-up response after i.t. administration of 1, 10 and 100 pg J- 
113397 in the three animal groups (Fig.7). In particular, this increase of the wind-up 
response was more evident and graded in sham operated animals, where +18 ± 20%, 
+44 ± 32% and +53 ± 15% changes were observed with 1, 10 and 100 pg of J-l 13397 
respectively. However this facilitation was not considered significant when compared 
to the respective control values. In all three animal groups the input and post­
discharge responses showed little change except for the input in the neuropathic rats 
at the highest dose where there was 41 ± 13% inhibition but again significance could 
not be established (Fig.7). Hence overall, 1, 10 and 100 pg J-l 13397 had no 
significant effect on the electrically-evoked neuronal responses of normal, sham or 
neuropathic rats.
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Figure 6. Effect of cumulative spinal administration of J-l 13397 (1, 10, 100 jig) on 
the Ap-, A6- and C-fibres electrically evoked dorsal horn neuronal responses 
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5.2.3.2 von-Frey evoked responses
Neurones in normal and sham animals injected with the lower doses (1,10 pg) of J- 
113397 responded with no overall change compared to their control values (Fig.8 A 
and B). In the presence of neuropathy the neuronal responses were slightly inhibited 
by these lower doses compared to controls but this change was not significant 
(Fig.9A). The neurones were generally more responsive in the neuropathic and sham 
operated rats reflected in the higher number of action potentials produced by the 
mechanical stimuli (Fig. 10).
There was no difference observed in the effects of J-l 13397 100 pg between 
neuropathic and sham groups and for clarity the results from the normal group are not 
displayed on the graph (Fig.9B). The sham and neuropathic rats injected with J- 
113397 100 pg showed less response to the various von Frey stimuli than their 
individual controls although significance could not be established. Overall the 
neuropathic rats injected with J-l 13397 had reduced responses compared to the J- 
113397-injected sham rats but there was no significant difference.
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Figure 8. The figure shows that intrathecal application o f J-l 13397 (1 and 10 pg) did 
not produce changes on the von Frey response in: (A) normal (n=7) and (B) sham 
operated (n=7) animals. The control values were obtained before drug 
administration. The von Frey filaments 1-6 correspond to weights 2, 5, 9, 15, 30 and 
75 g respectively. Data were expressed as mean number o f action potentials evoked 
over 10 sec ± S.E.M.
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Figure 9. The figure shows that: A) spinally applied J-l 13397 (1 and 10 f i g )  has no 
effect on the vor\ Frey response in neuropathic animals (n=6). Also in (B) the spinal 
application o f J-l 13397 (100 f ig )  did not produce a significant difference for the von 
Frey response in sham (n=7) and neuropathic (n=6) animals. The control values 
were obtained before drug administration. The von Frey filaments 1-6 correspond to 
weights 2, 5, 9, 15, 30 and 75 g respectively. Data were expressed as mean number o f 
action potentials evoked over 10 sec ± S.E.M.
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Figure 10: The neuronal response on the mechanically evoked dorsal horn neuronal 
in control situation (obtained before drug administration) in normal (n=7), sham 
operated (n=7) and neuropathic animals (n=7).The figure shows the tendency for 
higher number o f action potentials produced by the von Frey in neuropathic and 
sham operated animals when compared to normal animals. However these 
differences were not significant (Tukey and ANOVA tests) . The von-Frey filaments 1- 
6 correspond to weights 2, 5, 9, 15, 30 and 75g respectively. Data were expressed as 
mean number o f action potentials evoked over 10 sec ± S.E.M.
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5.3 DISCUSSION
5.3.1 Normal animals treated with nociceptin, J - l13397 and morphine
This study demonstrates for the first time using in vivo electrophysiological spinal 
neuronal responses that the inhibitory effect of nociceptin was reversed by J-l 13397. 
In this experiment I used normal animals as they showed the greatest effect of 
nociceptin when treated with cumulative doses of nociceptin (50, 125 and 250 pg).
These doses of nociceptin, in particular, the top dose elicited an antinociceptive effect 
on spinal nociceptive transmission by inhibiting both pre- and post-synaptic 
responses such as A-delta fibre, C-fibre, input, wind-up and post-discharge of the 
recorded neurones. In all studies I used J-l 13397 after obtaining the maximum 
inhibition with nociceptin and clear and almost complete reversals were observed. 
This data is in agreement with the findings on the opposite effect of nociceptin in the 
brain where s.c. injection of J-l 133397 causes a dose-dependent inhibition of the 
hyperalgesia elicited by i.c.v. nociceptin in a tail-flick test with mice (Ozaki et al.,
2000). Furthermore, in vitro studies of mouse brain show that J-l 13397 acts as an 
antagonist at the ORLi receptor when compared to other molecules proposed to be 
ORLi antagonists (Ichikawa et al., 2001). Both studies indicate that J-l 13397 blocks 
the ORLi receptor in a competitive manner and possesses high affinity and selectivity 
for the ORLj receptor over the other opioid receptors. The findings that nociceptin 
does not possess abuse liability as it failed to produce place preference or aversion 
(Devine et al., 1996) could lead to the hypothesis that development of an antagonist 
that is active in this system and might have therapeutic benefit, without the addictive 
effects of opiates.
To provide evidence of the selectivity of J-l 13397, the second part of these 
experiments involved the i.t. administration of 1 pg of morphine after the 
administration of 100 pg of J-l 13397 and here I obtained the marked inhibitory effect
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expected by morphine. This demonstrates that J-l 13397 has no interaction with the 
mu-opioid receptor.
At this point was necessary to investigate the role of the J-l 13397 alone and therefore 
the role of the endogenous nociceptin.
5.3.2 Animals treated with J-l 13397 alone
The idea that endogenous nociceptin has some basal modulatory role in nociceptive 
transmission was suggested after reported evidence that nociceptin immuno-reactive 
like substances can be released from the rat dorsal horn spinal cord (Williams et al., 
1998) and overall, the presence of both the peptide and receptor in the brain and 
spinal cord, for review see (Calo et al., 2000; Mogil and Pasternak, 2001). However 
to elucidate the role of endogenous nociceptin a selective ORLi receptor antagonist 
was required.
The discovery of the selective nociceptin antagonist J11339 by Kawamoto et al., 
(1999) and Ozaki et al., (2000) made possible the further investigation of the 
nociceptin system. In the previous study the interaction between exogenous 
nociceptin and J-l 13397 was investigated and maximal inhibition evoked by 250 pg 
nociceptin was found to be reversed by 100 pg J-l 13397.
It was now possible for the present electrophysiological study investigating the 
effects of J-l 13397 on endogenous nociceptin. In particular I investigated the 
potential role of endogenously released nociceptin in a rat model of inflammation and 
neuropathy using J-l 13397, an antagonist of the ORLi receptor. Overall, J-l 13397 
had no significant effect on the electrically or naturally evoked recordings made from 
deep dorsal hom neurones in normal animals and this did not change after 
inflammation and neuropathy. Overall, this would indicate that endogenous 
nociceptin has no or only a minor role in spinal nociceptive processing and this is not 
altered in chronic pain states.
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If endogenous nociceptin had a major role in inhibiting spinal nociception, then this 
would be blocked by J-l 13397 thus producing facilitation of either ongoing or 
evoked dorsal hom neuronal responses but in this study no significant effect was 
observed. These findings correlate well with studies using a different method of 
studying endogenous nociceptin; studies where mice strains are produced with 
specific disruption of genes encoding the ORLi receptor or nociceptin. No major 
change in basal nociception was detected in these mice (Nishi et al., 1997; Mamiya et 
al., 1998).
5.3.2.1 Endogenous nociceptin in inflammatory pain
The carrageenan model of inflammation was induced in this study to produce a state 
of persistent inflammatory pain. An injection of carrageenan into the plantar surface 
of the hindpaw results in localized inflammation and hyperalgesia. In the present 
study cumulative doses of J-l 13397 (1,10 and 100 pg) did not cause any significant 
change in electrical and mechanical evoked responses in carrageenan treated and 
normal animals when compared to their respective controls. This could indicate that 
there is no clear role of the endogenous nociceptin system in normal animals and that 
it is not modified during acute inflammation. However in carrageenan animals, the 
increased sensitivity to mechanical (von Frey) stimulus was evident from the baseline 
response and this was not changed in the presence of J-l 13397. This enhanced 
excitability of the neurone in the inflammatory state may reflect changes in the 
mediators of inflammation such as prostanoids, peptides, ion and receptor operated 
channels that could increase the observed neuronal responses through peripheral and 
central sensitization (for further discussion see section 1.6.). However, the enhanced 
responses seen after inflammation verify that the expected neuronal changes, 
enhanced responses after carrageenan (itself accompanied by behavioural changes 
such as allodynia and hyperalgesia) are produced with a time course that parallels the 
behaviour (Ren and Dubner, 1999).
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Previous electrophysiological studies by (Carpenter et al., 2000) investigated the 
effects of exogenous i.t. nociceptin in the presence of carrageenan induced 
inflammation. They observed increased inhibitory effects of the peptide agonist on C- 
fibre evoked and input responses in inflammation compared with normal animals and 
suggested that increased nociceptin receptor binding in the superficial laminae of the 
spinal cord after persistent inflammation was a possible explanation (Jia et al., 1998). 
The results from these reports suggest that ORLi receptors are up-regulated following 
persistent inflammation therefore enhancing the inhibitory actions of nociceptin. The 
increased levels of nociceptin due to exogenous administration would presumably 
bind to these ORLi receptors that are increased in number producing increased 
inhibition. It could be suggested that the endogenous nociceptin levels investigated in 
the present study are insufficient to produce a similar increase in inhibition.
However carrageenan inflammation develops relatively rapidly and the increase in 
receptor number described in Jia et al., (1998) study was seen 4 days after 
inflammation as induced by complete Freund’s adjuvant (CFA). The effects observed 
in my study and in Carpenter et al., (2000) were after 3 h. Evidence that the 
prepronociceptin expression can alter rapidly (within 30min) after carrageenan 
inflammation has been reported by Andoh et al., (1997) who described increased 
levels of mRNA message for the nociceptin peptide precursor in the dorsal root 
ganglion. However no evidence for altered physiological consequences of potential 
increased endogenous nociceptin was found in the present study.
In my study the lack of any significant change in electrically and naturally evoked 
responses after J-l 13397 injection in normal and inflamed animals shows that there is 
no significant change in the endogenous nociceptin system in those pain states. A 
lack of specific ORLi receptor until now has hampered studies investigating the 
effects of endogenous nociceptin and so results in this present study cannot be 
compared to many others. However a recent behavioural study investigating 
endogenous nociceptin has been reported, using i.t. J-l 13397 in the rat formalin test, 
a model of acute inflammatory pain, J-l 13397 enhanced the formalin-induced
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agitation behaviour suggesting it was antagonizing the analgesic effect of 
endogenously released nociceptin thus producing an algesic effect (Yamamoto et al.,
2001). In this present study J-l 13397 did not produce facilitation of electrically 
evoked responses indicating an unaltered inhibition of the analgesic effects produced 
by endogenous nociceptin in carrageenan inflammation.
5.3.2.2 Endogenous nociceptin in neuropathic pain.
As in the previous chapter we have seen that nociceptin has an inhibitory effect on 
animals with nerve ligation and therefore it could be assumed that ORLi receptor is in 
some way involved in the control of pain transmission following nerve injury. 
However in the present study I found that both electrical and mechanical induced 
responses were not modified by the application of cumulative doses of J-l 13397. 
Although the highest dose of J-l 13397 induced a tendency to facilitatory effects on 
the wind-up and post-discharge, and on the other hand, A-delta, C-fibre and input 
responses were mildly inhibited by J-l 13397. The lack of significance in these 
experiments underlines the absence of an understandable role of the endogenous 
nociceptin in measures of neuropathic pain. Overall, these experiments suggest that J- 
113397 has no effect on spinal neuronal responses in neuropathic animals. 
Furthermore, in the neuropathic animals, as also seen in sham operated and the 
carrageenan model of inflammation, I could demonstrate a tendency for increased 
sensitivity to von Frey stimuli evident from the control situation. This baseline 
response was higher in the neuropathic and sham rats compared to the normal rats 
indicating enhancement of the neuronal excitability. The presence of a nerve ligation 
would presumably result in a markedly reduced input from peripheral stimulation but 
compensatory mechanisms including transduction changes and structural 
reorganization have been shown to exist after nerve injury (Chapman et al., 1998).
The result of these experiments cannot be compared to others, since there are very 
few studies of endogenous nociceptin and none after nerve injury. Therefore I will
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discuss studies on the effects of exogenous nociceptin (as also discussed in chapter 3) 
as a reference. Briefly, studies with exogenous nociceptin have shown the 
effectiveness of the peptide in neuropathic animals (Yamamoto and Nozaki-Taguchi, 
1997; Yamamoto et al., 1997; Hao et al., 1998). Furthermore, in Xu et al., (1999) 
study the inhibitory effect of nociceptin was found to be increased after nerve injury 
although this study measured only motor-related function rather than sensory 
responses. Although the mechanism of nociceptin in neuropathic animals is unknown, 
Briscini et al., (2002) suggested an up-regulation of ORLi receptors in the spinal cord 
or dorsal root ganglia in these animals. However, this mechanism is not reflected in 
this study, possibly because the endogenous nociceptin levels were not enough to 
bind to these increased receptors and produce increased inhibition, but also as I saw 
that high concentrations of exogenous nociceptin were no more effective in this pain 
state when compared with normal animals (further discussed in chapter 3).
An important point to consider is the differences between nociceptin and the other 
opioid systems. It is well known that peptides such as CCK are upregulated in 
neuropathic pain and they are thought to be one of the main causes of the altered 
opioid actions due to their anti-opioid effect in those pain states. The next chapter will 
investigate the effect of spinal CCK on nociceptin systems.
In conclusion, the findings of these experiments indicate a minimal role for 
endogenous nociceptin in the spinal processing of pain and this action is unaltered in 
the presence of inflammation or neuropathy. Although the former was studied over 3- 
6 hours, the neuropathy studies were done at 2 weeks which would be long enough 
for new protein to be produced (precursor or receptor).
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CHAPTER 6
INTERACTIONS BETWEEN NOCICEPTIN AND 
CHOLEC Y STOKININ
6.1 INTRODUCTION
The predominant form of cholecystokinin (CCK) found in the mammalian central 
nervous system is the carboxy-terminal octapeptide (CCK-8). CCK-8 is the ligand for 
the CCK receptor, there are two types of receptor, CCKa or CCKi (peripheral type) 
and CCKb or CCK2 mainly present in the central nervous system (Moran et al., 1986), 
especially in the rat (Hill and Woodruff, 1990).
The wide distribution of CCK in the central nervous system (Williams et al., 1987; 
Schiffmann and Vanderhaeghen, 1991), in particular, in the superficial laminae of the 
dorsal hom of the spinal cord, suggests an important role of this peptide in the 
modulation of nociceptive transmission. In the first studies defining the physiological 
role for CCK as a functional antagonist of opioid-induced analgesia (i.e. ‘anti- 
opioid’) it was demonstrated that CCK significantly reduces morphine analgesia in 
the rat tail flick test (Faris et al., 1983). In addition, CCK receptor antagonists induce 
enhancement of opioid analgesia (Watkins et al., 1985; Stanfa et al., 1994).
In most experiments CCK does not alter baseline pain thresholds, so it is clear that 
the blockade of morphine analgesia is not due to a direct hyperalgesic effect of CCK 
(Xu and Wiesenfeld-Hallin, 1997). Although the mechanism is not fully understood 
by which CCK antagonises opioid analgesia, there is good evidence that CCK 
counteracts intracellular events subsequent to opioid activation through calcium 
levels (Wang et al., 1992).
CCK may play a role in the physiological determination of opioid actions since in a 
rat model of neuropathic pain, there is an increase in spinal CCK and a reduction in 
the potency of spinal morphine (Xu et al., 1993). This may partly explain cases of 
reduced opioid sensitivity of neuropathic pain in man. In this chapter I will 
investigate whether CCK, known to modulate the other mu, delta and kappa opioid 
systems will also have effect on the actions of nociceptin. This interaction between
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CCK and the ORLi receptor has never been tested at spinal levels. I have therefore 
studied the CCK-ORLi interaction after nerve injury, in sham operated and in normal 
animals.
6.2. RESULTS
The interactions between CCK and nociceptin were studied in normal (n=6), sham- 
operated (n=6) and neuropathic rats (n=6). In addition I also used a group of normal 
(n=6), sham (n=6) and neuropathic rats (n=6) treated only with nociceptin (data from 
chapter 3).
CCK 1 pg was given intrathecally 20 min before the application of 250 pg of 
nociceptin and the neuronal responses were followed until maximum inhibition was 
achieved (normally 1 h). The group treated with only nociceptin 250 pg was also 
followed until maximum effects were achieved. A total of 18 dorsal hom neurones 
were studied in this experiment and their mean depth was 750 ± 50 pm from the 
surface of the spinal cord and this did not differ between groups.
In this study was employed Mann-Whitney test for the comparison of drug effects 
between animal groups and the level of significance was taken to be P< 0.05.
6.2.1 Nociceptin alone
In all three animal groups (normal, sham operated and neuropathic) intrathecal 
injection of nociceptin 250 pg did not cause changes in A(3 induced activity (data not 
shown). In normal and neuropathic rats nociceptin caused a clear inhibition of C-fibre 
evoked responses (normal 70.8 ± 9%, neuropathic 39.3 ± 4%), post-discharge 
(normal 89 ± 6%, neuropathic 65.7 ± 10%), wind-up (normal 72.9 ± 9%, neuropathic 
69 ± 11%) and input (normal 87 ± 10%, neuropathic 41 ± 22%) see Fig. 1-4 (A). 
Although there was a tendency for the effects of nociceptin to be reduced after nerve 
injury this was not significant when compared to normal animals (using Mann- 
Whitney test). Contrarily in sham operated rats, nociceptin did not have any
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inhibitory effect but rather facilitated the wind-up by +64 ± 9% and post-discharges 
increased by +15±10%, both significant (P< 0.05) when compared to the normal 
animals Fig. 1-4 (A).
6.2.2 CCK and nociceptin
The application of 1 pg of CCK did not cause a significant effect in any of the three 
groups although there was a tendency towards a mild facilitation (data not shown). 
After the application of 250 pg of nociceptin in the continued presence of CCK it was 
observed that in normal animals, there were still no effects of nociceptin on A(3- and 
A5-fibre evoked responses. However, in normal animals the marked inhibitory effect 
of nociceptin alone on C-fibre, post-discharge, wind-up and input responses was 
abolished in the presence of CCK (see Fig. 1-4 respectively). Thus, CCK acts as an 
anti-opioid at the ORLi receptor in normal rats as shown by its block of the effect of 
nociceptin.
In sham operated rats where the application of nociceptin alone did not cause any 
inhibition, nociceptin in the presence of CCK caused a significant (P<0.01) 
inhibition of the C-fibre evoked responses from +1.9 ± 7.6% facilitation in normal to 
62 ± 14% inhibition in sham animals with CCK/nociceptin, see Fig. IB. Also wind-up 
was significantly (P<0.01) inhibited to a much greater extent comparing a +27 ± 
35% facilitation in normal animals to 80 ± 7% inhibition in sham rats with CCK plus 
nociceptin, see Fig.3B. There was also significant (P<0.05) inhibition of input 
responses in sham rats after the combination with respect to lack of effect the normal 
animals, see Fig.4 (B).
The inhibitory effect of nociceptin after CCK on the C-fibre, post discharge, wind-up 
and input, response was considerably greater in neuropathic rats and caused an almost 
complete block of activity (86 ± 4%, 97 ± 2%, 88 ± 6% and 96 ± 3% respectively) 
leading to a significant inhibition (P< 0.01 in all cases), see Fig. 1-4 (B).
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Comparison of the effect of 250 pg of nociceptin in sham animals and the 
neuropathic group, both pre-treated with 1 pg of CCK, reveals no difference between 
the groups although they have opposite responses when treated with only nociceptin.
Overall, in the presence of CCK, the inhibitory effect of nociceptin on C-fibre, post­
discharge, wind-up and input, is blocked in normal animals. On the other hand, in the 
presence of CCK the effect of nociceptin is not only restored in sham rats but is 
enhanced in the neuropathic group.
% Inhibition 
lOO-i
50- 
0 -  
-50-
Nociceptin (250pg) CCK (1 pg) + Nociceptin (250pg)
Figure 1. Intrathecal administration of: (A) Nociceptin 250 pg alone causes 
inhibition on C-fibres evoked responses in normal (n=6) and neuropathic (n=6) 
animals but not in sham operated animals (n-6). (B) Nociceptin 250 pg in presence 
o f 1 pg CCK. The inhibitory effect o f nociceptin is blocked in normal animals (n=6) 
but increased in sham operated (n=6) and neuropathic (n=6) animal by CCK. Data 
are expressed as % inhibition ± S.E.M. Significance is made in respect o f the normal 
group (**P<0.01 using Mann-Whitney test).
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POST-DISCHARGE
% Inhibition 
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Nociceptin (250pg) CCK (1 fig) + Nociceptin (250pg)
Figure 2. The figure shows intrathecal administration of: (A) Nociceptin 250 pg 
alone causes inhibition on post-discharge evoked responses in normal (n=6) and 
neuropathic (n=6) animals but not in sham operated animals (n=6). (B) Nociceptin 
250 pg in presence o f 1 pg CCK, the inhibitory effect o f nociceptin is blocked in 
normal animals (n=6) but increased in sham operated (n=6) and neuropathic (n=6) 
animals. Data are expressed as % inhibition ± S.E.M. Significance is made in respect 
o f the normal group (* *P< 0.01, *P< 0.05 using Mann- Whitney test).
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Figure 3. Intrathecal administration of: (A) Nociceptin 250 pg alone causes 
inhibition on wind-up evoked responses in normal (n=6) and neuropathic (n=6) 
animals, while induces facilitation in sham operated animals (n-6). (B) Nociceptin 
250 pg in presence o f 1 pg CCK, the inhibitory effect o f nociceptin is blocked in 
normal animals (n=6) but increased in sham operated (n=6) and neuropathic (n=6) 
animals. Data are expressed as % inhibition ± S.E.M. Significance is made in respect 
o f the normal group (**P<0.01, *P<0.05 using Mann-Whitney test).
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Figure 4. Intrathecal administration of: (A) Nociceptin 250 pg alone causes 
inhibition on input evoked responses in normal (n=6) and neuropathic (n=6) animals 
but not in sham operated animals (n=6). (B) Nociceptin 250 pg in presence o f CCK 1 
pg, the inhibitory effect o f nociceptin is blocked in normal animals (n=6) but 
increased in sham operated (n=6) and neuropathic (n=6) animals. Data are 
expressed as % inhibition ± S.E.M. Significance is made in respect o f the normal 
group (* *P< 0.01, *P< 0.05 using Mann- Whitney test).
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6.3 DISCUSSION
Cholecystokinin has been shown to be a functional anti-opioid peptide at the spinal 
level, an area where both nociceptin and other opioids acting on mu- and delta- 
receptors elicit analgesia. There are a number of important functional differences 
between the ORLi receptor and other opioid receptors and there have been no 
previous studies on the interaction between CCK and the ORLi receptor using 
nociceptin in the dorsal hom of the spinal cord.
The present study shows again, that at the level of the spinal cord, nociceptin behaves 
as an analgesic. Spinal administration of nociceptin inhibits the C-fibre-dependent, 
post discharge, wind-up and input of dorsal hom neurones, whilst sparing the A-fibre 
evoked responses (Stanfa et al., 1996; Carpenter et al., 2000). Other studies have 
supported this with evidence that C-fibre evoked responses are inhibited in preference 
to A-fibre evoked responses (Faber et al., 1996), so that the peptide has selective 
effects on noxious evoked activity and hyperalgesia (Hao et al., 1998). This suggests 
a selective action of nociceptin on noxious evoked responses in agreement with 
previous studies (Faber et al., 1996; Candeletti et al., 2000; Carpenter et al., 2000) 
and my studies in this thesis. Here it was also found that nociceptin had the expected 
spinal analgesic effect in normal and neuropathic rats, although I did not observe any 
analgesic effect in sham operated rats. Clearly there is plasticity in the effects of 
nociceptin and although the sham surgery is an essential control for the neuropathic 
model, we have observed changes in the effect of another peptide, galanin, in this 
condition (Flatters et al., 2002). There are clearly persistent changes that may 
represent post-operative pain conditions, after the sham surgery since it involves 
anaesthesia, exposure of nerve, suturing and recovery is possibly not surprising.
In this study, I found that application of CCK did not cause a significant effect on 
neuronal activity in any of the three groups in agreement with the results of Stanfa 
and Dickenson, (1993) in normal animals and after carrageenan inflammation. In 
normal animals CCK had an expected ‘anti-opioid’ action since it blocked the effects
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of nociceptin in a similar manner to that reported for mu-opioid receptor agonists 
such as morphine (Faris et al., 1983; Baber et al., 1989; Magnuson et al., 1990).
However, I found that CCK enhanced the inhibitory effects of nociceptin in 
neuropathic and in sham rats, comparing to rats treated with only nociceptin. Thus 
CCK does not act as an anti-opioid after either sham surgery or the subsequent nerve 
injury but rather enhances the action of nociceptin.
Thus there are similarities between spinal mu-opioid and ORLi receptor function in 
normal animals and after tissue injury- However, after nerve injury CCK had no ‘anti­
opioid’ action since it failed to block the effects of nociceptin and in fact, tended to 
augment the inhibitory effects of the peptide. This is entirely different from morphine 
since in a rat model of neuropathic pain, there is an increase in spinal CCK and a 
reduction in the potency of spinal morphine (Xu et al., 1993). Other studies have also 
shown reduced effects of systemic but not spinal morphine after nerve injury in this 
electrophysiological model (Suzuki et al., 1999). Since this profile of the CCK- 
nociceptin interaction is very different from that of morphine (Stanfa and Dickenson, 
1993), the results suggests a plasticity in the actions of CCK/nociceptin and further 
emphasises that the ORLi receptor has very different characteristics from the mu- 
opioid receptor at spinal levels. It is interesting to note that these marked changes in 
the inhibitory effect of nociceptin in the presence of CCK in neuropathic and sham 
rats occurs in situations were there is an upregulation of both the CCK receptor and 
ORLi receptor (Xu et al., 1993; Briscini et al., 2002) respectively.
Work from this laboratory has also shown that gabapentin, an anti-convulsant used 
for neuropathic pain patients also has enhanced effects after both sham and nerve 
injury as compared to normal animals (Chapman et al., 1998).
One of the most widely proposed mechanisms of CCK is an involvement in calcium 
signalling. Intracellular calcium is mobilised by CCK, which opposes the suppression 
mediated by opioids of the increase in intracellular calcium. Furthermore, CCK 
reverses the suppression of the K+-induced increase in intracellular calcium produced
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by opioids (Wang et al., 1992). Since gabapentin is thought to modulate calcium 
channel activity and there is an upregulation of the alpha 2 delta subunit of calcium 
channels after nerve injury and enhanced actions of both N (nerve injury) and P 
(tissue damage) after pathological changes (Dickenson et al., 2002), this suggests that 
the CCK/ORLi interaction, as suggested for mu-opioid receptors in normal animals 
may involve intracellular calcium. Another possible mechanism is that CCK, acting 
on CCKb receptors, decreases the availability of the enkephalins, possibly by 
inhibiting the release or increasing the metabolism of the enkephalins (Nichols et al., 
1996).
Whatever the form of the interaction, in normal animals CCK plays a physiological 
role in negatively modulating antinociceptive action of opioid agonists in the spinal 
cord. Since this role is altered after nerve injury and in presence of surgery, the ORLi 
receptor may be a target for the treatment of nerve injury and other pain states but this 
will require production of a non-peptide agonist at this receptor.
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CHAPTER 7
THE SPINAL EFFECTS OF NOCICEPTIN AND DPDPE 
IN SAP AND SP-SAP ANIMALS
7.1 INTRODUCTION
One of the most important goals in the study of pain is in the understanding of 
sensory processing in the spinal cord and subsequently to be able to recognize circuits 
underlying the transmission of information from nociceptive afferents to the brain. 
Progress so far has been limited due to the complex neuronal circuitry within the 
dorsal horn. A key issue would be to understand the function of cells in lamina I of 
the spinal cord which are thought to have a particular important role in nociception 
since this region is one of the main recipient areas for A5- and C-fibre afferent inputs 
(Sorkin and Carlton, 1997). Lamina I neurones are also known to be the main 
projection neurones from the superficial layer, which projects to the brainstem areas 
that are important in the central processing of nociceptive information (Craig and 
Dostrovsky, 1997; Todd et al., 2002).
A sub-population of neurones of lamina I expressing the NK1 receptor are believed to 
play an important role in this process and in recent years several studies have been 
directed towards elucidating the roles of these neurones in nociceptive signaling. 
Although these neurones constitute less than 10% of all lamina I neurones (Brown et 
al., 1995; Mantyh et al., 1997), many of them project to multiple sites within the 
brainstem (Mantyh et al., 1997; Todd et aL, 2000). In particular, the main supraspinal 
target of this projection is the parabrachial (PB) area, in fact the spinoparabrachial 
pathway constitutes a major link between the spinal cord and the brainstem, and has 
neurones implicated in the affective aspect of pain processing (Bernard et al., 1996). 
Also the spinothalamic pathway presents an important pathway involved in sensory 
discrimination aspects of pain (Gauriau and Bernard, 2002), yet in this pathway only 
few lamina I neurones project directly to the thalamus.
Moreover these neurones are activated by substance P (SP) previously described in 
chapter 1. Briefly, SP, an 11-amino-acid peptide contained in small diameter primary 
afferent fibres is released into the dorsal horn upon noxious stimulation (Duggan et 
al., 1988). Substance P by acting on the NK1 receptor activates nociceptive-specific
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dorsal horn neurones and so induces an excitatory effect possibly by synergism with 
the excitatory amino acids (Xu et al., 1992). Moreover, most spinal NK1 expressing 
neurones in lamina I do not contain GABA or glycine receptor and therefore these 
neurones are excitatory neurones within the spinal cord (Littlewood et al., 1995).
In recent years an interesting technique has been developed for the investigation of 
lamina I NK1-expressing neurones in nociceptive signaling. Based on the 
characteristic of internalization of G-protein-coupled-receptors, following noxious 
peripheral stimulation the SP released binds to the spinal dorsal horn neurones 
expressing the NK1 receptor, and subsequently both SP and NK1 receptor are rapidly 
internalized (Bowden et al., 1994; Mantyh et al., 1995). Mantyh and colleagues 
(1997) used this to develop a technique to ablate these lamina I neurones. The authors 
infused into the spinal cord SP conjugated with the ribosome inactivating- protein 
saporin (SAP), so that the SP-SAP complex was internalized only by the 
subpopulation of neurones that express the NK1 receptor. As a consequence of the 
internalization of SAP, the neurones died within 28 days since normal cell function is 
blocked as a result of ribosomal inactivation. Subsequently, they found that animals 
treated with SP-SAP where these lamina I neurones are ablated, exhibit a significant 
attenuation of mechanical and heat hyperalgesia produced by intraplantar injection of 
capsaicin, while in animals treated with saline, SP or SAP alone there are no 
significant changes. The data therefore suggest that these neurones play an important 
role in the behavioral nociceptive responses (Mantyh et al., 1997).
In the light of these findings and by using the same technique I investigated the 
effects of nociceptin and the delta-opioid ligand, DPDPE, using electrophysiological 
evoked responses of deep dorsal horn neurones in these lamina I NK1 depleted 
animals. Taking into account the importance of these lamina I neurones in the control 
of pain, the present experiment was designed to understand the influence if any of the 
ablation of the lamina I NK1 expressing neurones on the function of the nociceptin 
receptor system on spinal processing. Since opioid receptors are found both pre- and 
post-synaptically in spinal circuits, on afferent terminals and spinal neurones within
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the superficial spinal cord, it seemed important to determine if removal of the main 
neuronal population expressing post-synaptic opioid receptors had an effect on spinal 
opioid analgesia.
Nociceptin, the ORLi agonist as previously described in chapter 3, here again was the
•y
central aim of this study. The other compound in the study is DPDPE ([D-Pen ,D- 
Pen^-enkephalin), a highly selective delta-opioid receptor agonist (Stewart and 
Hammond, 1993; Kieffer, 1997). The predominant pre-synaptic effect of this 
compound (Rahman and Dickenson, 1999) made it interesting to investigate whether 
the effect of DPDPE on deep dorsal horn neurones would be effected by the lack of 
lamina I neurones expressing NK1 receptors and post-synaptic opioid receptors.
7.2 RESULTS
Thirty eight dorsal horn neurones with mean depth 770 ± 50 pm were studied in this 
experiment. As already described in the methods section, 28 days before the 
electrophysiological study all animals were given a single dose of intrathecal saline, 
SP-SAP or SAP and named as saline group (n=12), SP-SAP group (n=14) and SAP 
group (n=12) respectively. From day 28, the rats were used for the 
electrophysiological studies where half of the animals were treated with increasing 
doses of intrathecal nociceptin (5, 50, 125 and 250 pg) and in a similar way the 
remaining were treated with 1, 10, 50 and 100 pg of DPDPE.
Electrophysiological studies of the effect of nociceptin (5, 50, 125 and 250 pg) 
showed no inhibition other than tendency of facilitation for the A-beta response in 
three animal groups (see Fig. 1). In contrast the AS- and C-fibre evoked activity show 
combinations of changes in activity after nociceptin which included both facilitatory 
and inhibitory effects. Both afferent fibre evoked responses were facilitated or 
unaltered with lower doses of nociceptin (5 and 50 pg) while higher doses of 
nociceptin induced pronounced inhibition. For example, nociceptin 5 pg produces no 
change (2 ± 8%) on C-fibre evoked response in SAP animals while the top dose 250
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pg induces an inhibition of 40 ± 13% in the same animals (Fig.2). Furthermore lower 
doses of nociceptin caused facilitation of post-discharge, wind-up and input responses 
whereas with the higher dose of nociceptin the inhibition was more prominent in all 
animal groups (Fig.2.) On these responses, the SAP and saline groups show the major 
inhibitory effect when compared to NK1 depleted animals, in fact with nociceptin 
250 pg the wind-up response reached up to 82 ± 11% of inhibition with P< 0.05 and 
77 ± 32% when compared to the respective pre-drug control values.
Overall the data shows that nociceptin induces similar effect in saline and SAP 
animals, suggesting that these two animal groups are similar. However in SP-SAP 
animals there is a tendency for an attenuation in the effect of spinal nociceptin when 
compared to saline and SAP animals. This reduced nociceptin effect in SP-SAP 
animals although was not significant was present on C-fibre and input evoked 
response as well as the wind-up response where the greatest difference (almost 60%) 
between the two animal groups was seen.
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Figure 1. Comparison o f the effect o f spinally applied nociceptin (5, 50, 125 and 250 
pg) on Aft-, Ad- and C-fibre evoked responses from saline (n=6), SAP (n=6) and SP- 
SAP (n-7) animals. Data were expressed as % inhibition ± SEM. No significance 
was found when compared effects o f the individual doses to pre-drug control values 
as well as when compared saline versus SAP and SP-SAP animals (Tukey and 
ANOVA tests).
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Figure 2. Comparison o f the effect o f spinally applied nociceptin (5, 50, 125 and 250 
pg) on Input, Post-discharge and Wind-up responses from saline (n=6), SAP (n=6) 
and SP-SAP (n=7) animals. Data were expressed as % inhibition ± SEM. 
Significance was found in respect o f the corresponding pre-drug control values (*P^ 
0.05 by Tukey andANOVA tests).
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The same electrophysiological study design was used for the remaining animals and 
here the drug used in the study was DPDPE.
Intrathecal injection of 1, 10, 50 and 100 pg DPDPE caused no changes in A(3-fibre 
evoked responses in saline, SAP and SP-SAP animals see Fig.3. However A8- and C- 
fibre evoked responses, post-discharge, input and wind-up were preferentially 
inhibited by DPDPE, suggesting selective action on noxious evoked response.
The effect of DPDPE was in most of the cases a dose related response and with the 
top dose of DPDPE (100 pg) it was possible to reach an almost maximal effect. In 
fact A8-fibre, post-discharge, wind-up and input responses were significantly 
inhibited by the DPDPE 100 pg (see Fig.3 and 4). In particular the inhibitory effect of 
DPDPE reached the highest level of 78 ± 14%, 91 ± 7% and 82 ± 7% on post­
discharges responses in saline, SAP and SP-SAP animals respectively. Although the 
C-fibres evoked responses of saline, SAP and SP-SAP animals was also reduced (49 
± 15%, 47 ±20% and 47 ± 8% respectively) by DPDPE 100 pg, this effect did not 
reach significance level (Fig.3). Moreover the inhibition was also seen with the dose 
of 50 pg of the drug; in particular it was seen that the input response in all animal 
groups was significantly effected (P< 0.05 and P< 0.01) see Fig.4. As can be seen in 
Fig.3, there was also a trend toward inhibition of A8-fibre and post-discharge 
responses while C-fibre and wind-up were not affected by DPDPE 50 pg in all animal 
groups.
Following the maximum inhibition obtained after DPDE (100 pg) in the different 
animal groups, the effects of the drug were reversed by intrathecal injection of 
naloxone (50 pg) and the neuronal response returned to the control values (data not 
shown).
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Figure 3. Effect o f spinal administration o f DPDPE on electrical evoked responses o f 
dorsal horn neurones from saline (n=6), SAP (n= 6) and SP-SAP (n= 7) animals. 
Data were expressed as % inhibition ± SEM. Significance was found in respect o f the 
corresponding per-drug control values (**Pz 0.01, *Pz 0.05 by Tukey and AN OVA
tests).
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In addition to the electrical stimulation used to evoke responses in this experiment I 
also investigated the neuronal response to natural stimuli. In particular I used a range 
of heat stimuli (35, 49, 42, 45, 48 and 50° C) and it was found that in animals with 
ablation of lamina I neurones expressing the NK1 receptor there was overall a 
reduced heat coding response which reached significance level for the noxious 
temperatures between 45-48° C, P< 0.01 (Fig.5). This result was obtained prior to the 
drug study and comparisons were made between SP-SAP versus SAP and saline 
animals, since this last two groups have similar response to the heat stimulus.
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Figure 4. Comparison o f the effect o f spinally applied DPDPE on Wind-up and Input 
evoked responses from saline (n=6), SAP (n=6) and SP-SAP (n=7) animals. Data 
were expressed as % inhibition ± SEM. Significance was found versus the 
corresponding pre-drug control values (***P<; 0.001, **Pz 0.1, *P<r 0.05 by Tukey 
and AN OVA tests).
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Figure 5. Response o f spinal dorsal horn neurones o f saline (h=6), SAP (n=6) and 
SP-SAP (n=7) rats to thermal stimulation o f the peripheral receptive field. Data were 
expressed as mean number o f action potentials evoked over 10 sec ± S.E.M. 
Significance is made SP-SAP versus SAP and saline animals (**P*s 0.01 by Tukey 
andANOVA tests).
This is the first electrophysiological study addressing the effect of nociceptin and 
DPDPE in the spinal processing of sensory information in animals with ablated 
lamina I neurones expressing the NK1 receptor and using saline or SAP animals as a 
control group, since the two groups have similar evoked responses. This technique 
uses site-specific ablation of pharmacologically defined neuronal populations, and so 
is a powerful approach to examining the roles of particular neurones in function 
within integrated systems.
Intrathecal nociceptin depending on the dose used, exerts effects that lead to 
facilitation and inhibition of deep dorsal horn neurones. Low doses of nociceptin
7.3 DISCUSSION
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produce mainly facilitation or maintain unaltered neuronal responses while with 
increasing the dose a shift towards sustained inhibition is seen (C-fibre, input, wind­
up). This effect is detailed in chapter 3 and is in agreement with other studies (Stanfa 
et al., 1996; Xu et al., 1999). Nociceptin did not cause any change in Ap-fibre 
response and this selective action on particular evoked fibre responses strongly 
suggests the predominant role of spinal nociceptin is by acting on pre-synaptic 
neurones as previously seen (chapter 3) and reported by (Luo et al., 2002). 
Furthermore, the inhibitory effect of higher doses of nociceptin on wind-up and post­
discharge, measures of neuronal hyperactivity, may indicate additional post-synaptic 
actions of this peptide.
One of the key points of this study was to elucidate both how the deep dorsal horn 
neuronal responses were altered by the absence of lamina I neurones expressing the 
NK1 receptor and then how this would impact upon the effects of activation of the 
ORL-1 and delta-opioid receptors.
The present study shows that in animals with ablated lamina I neurones expressing 
the NK1 receptor, the neuronal responses to heat were attenuated which agrees well 
with previous studies (Suzuki et al., 2002). In addition, I show that the effect of 
intrathecal nociceptin on deep dorsal horn neurones was attenuated when compared 
with the control group (saline and SAP). The difference was at the highest level 
(about 60%) for the wind-up response in the SP-SAP group after spinal application of 
nociceptin at top dose (250 p.g).
Although it is well known that the lamina I neurones expressing NK1 receptor 
represent only a small proportion of the lamina I neuronal population (Brown et al., 
1995; Marshall et al., 1996; Mantyh et al., 1997) they are important in the ascending 
conduction of nociceptive information (Mantyh et al., 1997) due to their predominant 
projection to a number of supraspinal sites. However, it was found in this study no 
marked change on the effect of nociceptin on deep dorsal horn neurones. The 
response that is mostly influenced was the wind-up response, which is an intrinsic
184
spinal phenomenon relying on lamina I-lamina V circuitry (Dickenson et al., 2004) 
and so would be most subject to modulation by the missing opioid receptors on post- 
synaptic neurones.
To further analyze the importance of the lamina I neurones on the response of deep 
dorsal horn neurones to opioids the second part of these experiments involves the use 
of DPDPE. This was chosen not simply as a comparator acting on another opioid 
receptor system but because it is also peptide in nature and so might have a similar 
pharmacokinetics to nociceptin.
DPDPE induced a dose related inhibition of the electrical evoked response in saline, 
SAP and SP-SAP animals. The highest dose of 100 p,g DPDPE induced the greatest 
inhibition on post-discharge evoke response in those animal groups while A (3-fibre 
respones was the least inhibited. This spared inhibition of DPDPE on Ap-fibre 
responses compared to A8-and C-fibre, suggest a predominant effect of DPDPE on 
pre-synaptic sites, previously reported by Rahman and Dickenson, (1999). Moreover, 
both in Rahman’s and the present study it was shown that DPDPE has an additional 
post-synaptic effect as it was able to inhibit post-synaptic mechanisms such as post­
discharge and wind-up evoked responses. The action of DPDPE on post-synaptic 
sites could be explained by the ability of opioids to extend their inhibitory actions to 
post-synaptic neurones when administrated at higher doses (Yaksh and Noueihed, 
1985) and also by the high distribution (75%) of opioids in the pre-synaptic neurones 
on the central terminals of the primary afferent fibres leaving 25% of receptors on 
spinal neurones (Dickenson, 2001).
The inhibitory effect of DPDPE was mediated by an opioid receptor since this 
inhibition was reversed by naloxone. In particular several studies have shown that the 
spinal effect of DPDPE is through delta-opioid receptor (Dickenson et al., 1987; 
Stewart and Hammond, 1993; Kieffer, 1997). Similar to the other opioids the 
analgesic effect delta-opioid receptor is believed to be mediated via common 
mechanisms with other opioids receptors agonists previously discussed in chapter 3.
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The result of this experiment indicates that although the delta-opioid receptor, like 
other opioid receptors, is primarily distributed on lamina I-II of spinal dorsal horn 
(Besse et al., 1990; Maher et al., 2001) the effects of DPDPE are predominant on the 
pre-synaptic neurones, and the spinal analgesic effect of DPDPE on deep dorsal horn 
neurones was not altered by the depletion of NK1 expressing neurones in the 
superficial lamina. This study is in agreement with Nichols et al., (1999) study, where 
they used spinal infusion of morphine in SP-SAP treated animals and found no 
alteration in the degree of morphine analgesia and suggested that NK1 expressing 
neurones in the dorsal horn are not the major side of action of morphine. This finding 
may well be extended to others opioid receptor agonists such as this delta-opioid 
agonist. Although there is no direct data on the co-localization of opioid receptors and 
NK1 receptors on neurones of the superficial laminae the fact that the spinal analgesic 
effect of nociceptin was slightly attenuated in animals without lamina I NK1 
expressing neurones further underlines the difference between ORLi receptor and 
other opioid receptors.
The results may suggest the co-localisation of NK1 and ORLi receptors and therefore 
by killing those neurones which present 10% of the neuronal population in lamina I 
(Brown et al., 1995; Mantyh et al., 1997) a slight attenuation of the nociceptin 
analgesia in deep dorsal hom neurones is produced. Another explanation could be the 
importance of the depleted neurones on supraspinal modulation of spinal 
transmission, since 80% of lamina I expressing NK1 neurones are projection 
neurones (Todd, 2002) and the lost of these neurones may cause disruption of 
descending excitatory or inhibitory pathways (Urban and Gebhart, 1999) that in turn 
could alter opioid function. Furthermore, it has been hypothesized that the loss of 
lamina I neurones expressing NK1 receptors projecting to the PB areas may turn to 
activate supraspinal site such as PAG and subsequently activation of RVM controls 
the spinal excitability through descending serotonin pathways. This spino-bulbo- 
spino-loop, proposed by Suzuki et al., (2002) may also explain the reduced analgesic 
response seen with SP-SAP animals after intrathecal injection of nociceptin and also 
the reduced heat coding response that was found in SP-SAP animals.
186
REFERENCES
Bernard JF, Bester H and Besson JM. Involvement of the spino-parabrachio - 
amygdaloid and -hypothalamic pathways in the autonomic and affective emotional 
aspects of pain. Prog Brain Res 1996; 107: 243-55.
Besse D, Lombard MC, Zajac JM, Roques BP and Besson JM. Pre- and postsynaptic 
distribution of mu, delta and kappa opioid receptors in the superficial layers of the 
cervical dorsal horn of the rat spinal cord. Brain Res 1990; 521: 15-22.
Bowden JJ, Garland AM, Baluk P, Lefevre P, Grady EF, Vigna SR, Bunnett NW and 
McDonald DM. Direct observation of substance P-induced internalization of 
neurokinin 1 (NK1) receptors at sites of inflammation. Proc Natl Acad Sci U S A 
1994; 91: 8964-8.
Brown JL, Liu H, Maggio JE, Vigna SR, Mantyh PW and Basbaum AL 
Morphological characterization of substance P receptor-immunoreactive neurons in 
the rat spinal cord and trigeminal nucleus caudalis. J Comp Neurol 1995; 356: 327- 
44.
Craig AD and Dostrovsky JO. Processing of nociceptive information at supraspinal 
level. In: Yaksh TL, Lynch III C, Zapol WM, Maze M, Biebuyck JF and Saidman LJ. 
Anesthesia: Biologic Foundations. Vol. Philadelphia: Lippincott-Raven Publishers, 
1997. pp.
Dickenson AH. Opiates. Encyclopedia of life sciences 2001; 1-6.
Dickenson AH, Sullivan AF, Knox R, Zajac JM and Roques BP. Opioid receptor 
subtypes in the rat spinal cord: electrophysiological studies with mu- and delta-opioid 
receptor agonists in the control of nociception. Brain Res 1987; 413: 36-44.
Dickenson AH, Suzuki R, Matthews EA, Raman W, Urch C, Seagrove L and Rygh L. 
Balancing excitations and inhibitions in spinal circuits. In: L. V, AH. D and H. O. 
The pain system in normal and pathological states: A primer for clinicians. Vol. 31. 
Seattle: IASP Press, 2004. pp. 79-105.
Duggan AW, Hendry IA, Morton CR, Hutchison WD and Zhao ZQ. Cutaneous 
stimuli releasing immunoreactive substance P in the dorsal horn of the cat. Brain Res 
1988; 451:261-73.
Gauriau C and Bernard JF. Pain pathways and parabrachial circuits in the rat. Exp 
Physiol 2002; 87: 251-8.
Kieffer BL. Molecular aspect of opioid receptors. In: Dickenson AH and Besson J-M. 
The Pharmacology of pain. Vol. 130. Berlin: Springer, 1997. pp. 281-303.
187
Littlewood NK, Todd AJ, Spike RC, Watt C and Shehab SA. The types of neuron in 
spinal dorsal horn which possess neurokinin-1 receptors. Neuroscience 1995; 66: 
597-608.
Luo C, Kumamoto E, Furue H, Chen J and Yoshimura M. Nociceptin inhibits 
excitatory but not inhibitory transmission to substantia gelatinosa neurones of adult 
rat spinal cord. Neuroscience 2002; 109: 349-58.
Maher CE, Eisenach JC, Pan HL, Xiao R and Childers SR. Chronic intrathecal 
morphine administration produces homologous mu receptor/G-protein desensitization 
specifically in spinal cord. Brain Res 2001; 895: 1-8.
Mantyh PW, DeMaster E, Malhotra A, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, 
Basbaum Al, Vigna SR, Maggio JE and et al. Receptor endocytosis and dendrite 
reshaping in spinal neurons after somatosensory stimulation. Science 1995; 268: 
1629-32.
Mantyh PW, Rogers SD, Honore P, Allen BJ, Ghilardi JR, Li J, Daughters RS, Lappi 
DA, Wiley RG and Simone DA. Inhibition of hyperalgesia by ablation of lamina I 
spinal neurons expressing the substance P receptor. Science 1997; 278: 275-9.
Marshall GE, Shehab SA, Spike RC and Todd AJ. Neurokinin-1 receptors on lumbar 
spinothalamic neurons in the rat. Neuroscience 1996; 72: 255-63.
Nichols ML, Allen BJ, Rogers SD, Ghilardi JR, Honore P, Luger NM, Finke MP, Li 
J, Lappi DA, Simone DA and Mantyh PW. Transmission of chronic nociception by 
spinal neurons expressing the substance P receptor. Science 1999; 286: 1558-61.
Rahman W and Dickenson AH. Electrophysiological studies on the postnatal 
development of the spinal antinociceptive effects of the delta opioid receptor agonist 
DPDPE in the rat. Br J Pharmacol 1999; 126: 1115-22.
Sorkin LS and Carlton SM. Spinal anatomy and pharmacology of afferent processing. 
In: Yaksh TL, Lynch III C, Zapol WM, Maze M, Biebuyck JF and Saidman LJ. 
Anesthesia: Biologic Foundations. Vol. Philadelphia: Lippincott-Raven Publishers, 
1997. pp. 577-609.
Stanfa LC, Chapman V, Kerr N and Dickenson AH. Inhibitory action of nociceptin 
on spinal dorsal horn neurones of the rat, in vivo. Br J Pharmacol 1996; 118: 1875-7.
Stewart PE and Hammond DL. Evidence for delta opioid receptor subtypes in rat 
spinal cord: studies with intrathecal naltriben, cyclic[D-Pen2, D-Pen5] enkephalin 
and [D-Ala2, Glu4]deltorphin. J Pharmacol Exp Ther 1993; 266: 820-8.
188
Suzuki R, Morcuende S, Webber M, Hunt SP and Dickenson AH. Superficial NK1- 
expressing neurons control spinal excitability through activation of descending 
pathways. Nat Neurosci 2002; 5: 1319-26.
Todd AJ. Anatomy of primary afferents and projection neurones in the rat spinal 
dorsal horn with particular emphasis on substance P and the neurokinin 1 receptor. 
Exp Physiol 2002; 87: 245-9.
Todd AJ, McGill MM and Shehab SA. Neurokinin 1 receptor expression by neurons 
in laminae I, III and IV of the rat spinal dorsal horn that project to the brainstem. Eur 
J Neurosci 2000; 12: 689-700.
Todd AJ, Puskar Z, Spike RC, Hughes C, Watt C and Forrest L. Projection neurons in 
lamina I of rat spinal cord with the neurokinin 1 receptor are selectively innervated by 
substance p-containing afferents and respond to noxious stimulation. J Neurosci 
2002; 22:4103-13.
Urban MO and Gebhart GF. Supraspinal contributions to hyperalgesia. Proc Natl 
Acad Sci U S A 1999; 96: 7687-92.
Xu IS, Grass S, Wiesenfeld-Hallin Z and Xu XJ. Effects of intrathecal orphanin FQ 
on a flexor reflex in the rat after inflammation or peripheral nerve section. Eur J 
Pharmacol 1999; 370: 17-22.
Xu XJ, Dalsgaard CJ and Wiesenfeld-Hallin Z. Spinal substance P and N-methyl-D- 
aspartate receptors are coactivated in the induction of central sensitization of the 
nociceptive flexor reflex. Neuroscience 1992; 51: 641-8.
Yaksh TL and Noueihed R. The physiology and pharmacology of spinal opiates. 
Annu Rev Pharmacol Toxicol 1985; 25: 433-62.
189
CHAPTER 8
THE EFFECTS OF OXYTOCIN ON SPINAL 
NOCICEPTIVE PROCESSES
8.1 INTRODUCTION
Chronic pain after nerve or tissue injury as previously discussed in the introduction, 
includes a variety of symptoms and clinical characteristics; spontaneous and 
repetitive pain episodes, allodynia, hyperalgesia, and abnormal temporal summation 
of pain being the most frequent and representative symptoms. Increased knowledge 
about the pathophysiological mechanisms related to pain and analgesia may aid us to 
develop more effective therapies.
One important area is endogenous systems that may control pain. (Magoum, 1940) 
described a descending hypothalamic pathway to the spinal cord that may be involved 
in autonomic function. In fact, the hypothalamic paraventricular nucleus (NPV) 
reaches the spinal cord by a direct pathway (Kuypers and Maisky, 1975; Saper et al., 
1976) and using immunohistochemical procedures it was demonstrated that this 
descending pathway uses amongst others, the peptide oxytocin (OT) (Buijs, 1978). 
Moreover, using in situ hybridization, dynorphin and oxytocin mRNAs are expressed 
in the 40% of PV neurones projecting to the spinal cord, and enkephalin mRNA is 
present in 20% of these neurones (Hallbeck et al., 2001).
It is interesting to note that oxytocin has been studied in different experimental pain 
models in order to obtain evidence for its analgesic effect (Arletti et al., 1993; 
Lundeberg et al., 1994; Ge et al., 2002; Robinson et al., 2002; Condes-Lara et al., 
2003; Yu et al., 2003). Also, in humans lower oxytocin concentrations in spinal fluid 
and plasma were associated with pain states (Alfven et al., 1994; Yang, 1994), and 
oxytocin administration relieved the pain sensation (Madrazo et al., 1987; Yang, 
1994).
On the other hand, several studies reported that systemic oxytocin did not produce 
any analgesic effect (Millan et al., 1984; Xu and Wiesenfeld-Hallin, 1994).
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In an attempt to clarity the role of oxytocin in pain, I performed the present study to 
document the effect of different oxytocin doses on the responses of dorsal hom 
neurones to electrical and mechanical stimulation in normal and neuropathic rats.
8.2 RESULT
Electrophysiological recordings were made from normal (n=36) and neuropathic 
(n=12) rats. The mean depth of the recorded cells was 788 ± 23 pm, and there were 
no differences between normal and neuropathic rats in depths. The recorded cells 
showed evoked responses corresponding to the wide dynamic range category and 
based on their depth, were located in lamina V-VI. The normal rats were divided into 
groups of 6 and each group was used to test one dose, repeated twice, of the 
following oxytocin concentrations: 0.05, 0.1, 2, 5 and 10 International Units (I.U.). 
Each dose was followed for lh and after that the drug was removed and the spinal 
cord was washed with saline and followed for 30 min before reapplying the same 
oxytocin dose. The same procedure was also applied for the neuropathic animals but 
here only doses of land 2 1.U. of oxytocin were used.
8.2.1 Effects of oxytocin on responses evoked by electrical stimulation in 
normal animals
The receptive fields of the recorded cells were found mainly on the toes of the 
ipsilateral hindlimb. Electrical stimulation of the receptive fields produced an 
activation of the recorded cells consisting of A|3-, AS-, C-fibre and Post-discharge 
evoked responses (Fig. 1) as well as input and wind-up. The analysis of these 
responses with respect to different doses of oxytocin did not show a linear dose 
response relationship. Thus, an oxytocin dose of 0.05 I.U. produces a facilitatory 
effect, while doses of 0.1, 1,2, 5, and 10 I.U. produced a progressive decrease in the 
response. None of these responses was significant when compared with the control
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values (these results are not illustrated). Two experiments in normal rats using 2 I. U. 
of oxytocin are shown (Fig.2 and 3), and these figures can be compared to those 
obtained in neuropathic rats (see below).
8.2.2 Effects of oxytocin on responses evoked by mechanical stimulation in 
normal animals
Application of von Frey forces produced progressive increases in the neuronal firing 
rate proportional to the forces applied. As with the electrical stimulation, the peptide 
effects on von Frey responses did not present a linear dose response relationship. In 
general, an oxytocin dose of 0.05 I.U. tended to increase the responses, while 
increasing oxytocin doses progressively decreased the responses. However, neither 
the increases nor the decreases were significantly different from control values.
8.2.3 Effects of oxytocin on responses evoked by electrical stimulation in 
neuropathic animals
An oxytocin dose of 1 I.U. produced a significant reduction in C-fibre (P< 0.05) and 
Post-discharge (P< 0.05) responses to electrical stimulation of the receptive field in 
neuropathic rats. Oxytocin dose of 2 I.U. produced a further pronounced diminution 
in the post-discharge, wind-up, and input values. The reduction of the post-discharge 
in neuropathic rats using 1 and 2 I.U. was the most marked change and was 
significant (P< 0.05) at 10 and 20 min after oxytocin administration (Fig.5 and 4). 
The post-discharge reduction was observed on the first 300-800 ms of the post­
discharge (Fig.4B), but was also observed that the reduction in the post-discharge 
could be observed on the responses spanning the 2 s interval before the next stimulus 
in the train of 16 stimuli (Fig.5). Examples of the effect of 1 and 2 I.U. of oxytocin on 
the post-discharge are shown in Fig.4 and 5. In Fig.5 the post-discharge was analyzed
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during the 300 to 1900 ms period following the stimulation and it shows a significant 
reduction (P< 0.05) after the peptide.
8.2.4 Effects of oxytocin on responses evoked by mechanical stimulation in 
neuropathic rats
As in normal rats, the von Frey stimulation with increasing filament force produced a 
progressive increase in the firing rates. Doses of 1 I.U. of oxytocin produced a 
progressive reduction in the activation of dorsal horn neurones evoked by the von 
Frey filaments in neuropathic animals. It is interesting to note that oxytocin 
significantly reduced (P< 0.01 and P< 0.05) the activation produced by the strongest 
and noxious mechanical stimulation (15, 30, and 75 g von Frey filament) see Fig.6B. 
Furthermore, oxytocin doses of 2 I.U. were also selective, affecting the highest von 
Frey stimulation forces (30 and 75 g).
8.2.5 Comparisons between neuropathic and normal rat responses
The effect of 1 and 2 I.U. of oxytocin was compared in both animal groups, both 
neuropathic and normal rats. The main effect of oxytocin was a significant reduction 
in the post-discharge evoked by electrical stimulation of the receptive field in the 
neuropathic rats, as seen by comparisons between Fig.2 vs. 4 and 3 vs. 5. Also, Fig.5 
presents histograms showing the significant reduction (P< 0.05) at 10 and 20 min 
after application of 2 I.U. of oxytocin and a partial recovery at 30 min in neuropathic 
rats. On the contrary, in normal rats (Fig.3) no reduction in the post-discharge was 
observed. The post-discharge response comparison between normal and neuropathic 
rats using 1 and 2 I.U of oxytocin is displayed in Fig.7. Using 1 I.U of oxytocin, a 
significant (P< 0.05) reduction was observed only when a second dose of oxytocin 
was applied. Using 2 I.U. of oxytocin, the first application produced a significant 
reduction, a partial recovery after wash, and another significant reduction after the
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second oxytocin dose. It is noteworthy that with 2 I.U. of oxytocin I observed an 
increase in the post-discharge in normal rats.
The responses to mechanical stimulation by von Frey filaments were also reduced 
more by oxytocin in neuropathic rats when compared with the control situation. This 
reduction was more pronounced and significant when von Frey filaments with higher 
forces are considered. These results are displayed in Fig.6. where clearly shows that 
the control rate frequencies appear higher but are not significantly different in 
neuropathic rats when they were compared with the normal rats.
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A-beta ' A-delta x C-fibresx Post-discharge
Figure 1. The response o f single dorsal horn neurone on electrical stimulation. Al) 
The 2nd and A 2) The 14th responses to a train o f 16 stimulations are displayed; notice 
the increased response in C-fibre and post discharge evoked responses in A2. B) 
Shows a PSTH, in which can be observed 200 ms prior to the stimulation and the 
different fibres components o f the response: A(T, AS-, C-fibre, and the post 
discharge.
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AFigure 2. The figure shows the response o f single dorsal horn neurone to the 16 
electrical stimulations in: (A) control and (B) during intrathecal administration o f 
oxytocin 2 I. U. in normal animal. In particular the window expands the enhancement 
o f the post-discharge during the 2nd and the 13th stimulation that is not changed by the 
application o f oxytocin (B) when compared to the 2nd and the 13th stimulation o f 
control situation (A) respectively.
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Figure 3. On the left side are plotted 6 recordings o f 16 electrical stimulations in the 
control (1,2 and 3) and during the intrathecal administration o f 2 1.U. o f oxytocin in 
a normal animal. In the upper part o f trace 1, dots indicate the stimulus artifact. 
Notice that the post discharge in traces 4, 5, and 6 remains similar to the control. 
Each record has a 10 min interval. The histogram on the right shows the mean ± 
S.E.M. obtained between 300 to 1900 msec o f the post-discharge. Oxytocin treatment 
caused no significant changes.
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Figure 4. The figure shows the response o f single dorsal horn neurone to the 16 
electrical stimulations in: (A) control and (B) during intrathecal administration o f 
oxytocin 2 1. U. in neuropathic animals. In particular (as shown in the expanded trace 
within the window), the enhancement o f the post-discharge during the 2nd and the 13th 
stimulation shown in control situation (A) and clear reduction in this enhancement 
seen 10 min after the application o f oxytocin (B).
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Figure 5. This figure is similar to Fig.3, but it is during the intrathecal oxytocin 
administration o f 1 1.U. in Chung (neuropathic) animals. In the upper part o f trace 1, 
dots indicate the stimulus artifact. Notice the reduction in the post discharge in traces 
4, 5, and 6. Each record shows a 10 min interval. The histogram at the right shows 
the mean ± S.E.M. obtained between 300 and 1900 msec o f the post-discharge. Notice 
a significant (*P< 0.05, using Tukey and ANOVA tests) reduction at 10 and 20 min 
after 1 1. U. o f intrathecal oxytocin.
2 0 0
1 2 3 4
von Frey
5 6
Control
E23 o t  1 i.u.
d l  Wash
von Frey
Figure 6. Comparison o f the neuronal responses to von Frey mechanical stimulation 
in (A) normal (n=6) and (B) neuropathic (n=6) rats. Normal rats did not show 
significant differences between control, oxytocin 1 I.U., wash, and oxytocin 1 I.U. 
(second dose). In contrast, significant differences (*P< 0.05, * * P <  0.01 using Tukey 
and ANOVA tests) were found in neuropathic animals versus control values when 
used the von Frey filaments 4, 5, and 6. Data were expressed as mean number 
frequency rate (action potentials) evoked over 10 sec ± S.E.M.
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Figure 7. Post-discharge comparison between normal (n=6) and neuropathic (n=6) 
rats with 1 and 2 I.U. o f oxytocin. Notice the significant (*P< 0.05 using Tukey and 
AN OVA tests) increase in normal rats and the reduction in neuropathic animals. 
Also, notice the reduction, recovery, and again reduction during 2 1. U. oxytocin, then 
wash, and again 2 1. U. oxytocin. Data were expressed as % control ± S.E.M.
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8.3 DISCUSSION
The main results of the present study are that a wide range of oxytocin doses, in 
normal animals, does not produce an obvious inhibitory effect on responses of wide 
dynamic range neurones to nociceptive electrical and mechanical stimulation.
On the contrary, in neuropathic animals, oxytocin doses of 1 and 2 I.U. significantly 
reduced the post-discharge evoked by electrical stimulation and the responses to von 
Frey filaments. The activity of Af3-, A8-, C-fibre, and post-discharge in deep 
neurones (lamina V-VI) of the dorsal portion of the spinal cord was also evaluated. I 
also studied the input (the neuronal discharge in response to the first of a series of 16 
electrical stimuli) and the wind-up process. The results showed no significant 
variations in these responses to oxytocin administration in normal rats. This lack of 
acute oxytocin analgesic effects has been previously described on the hot plate 
latency test in normal rats (Xu and Wiesenfeld-Hallin, 1994) using systemic 
administration of low doses. In contrast, a higher dose of oxytocin increased hot plate 
latency, which may be due to non-specific effects of the peptide.
Motor blockade, sedation, vasoconstriction, or decrease in skin temperature may all 
confound any analgesic effect of oxytocin (Xu and Wiesenfeld-Hallin, 1994). 
Furthermore, lesions of the paraventricular hypothalamic nucleus, which is an 
important source of the oxytocin containing neurones projecting to the spinal cord, 
did not change the basal nociception threshold at the spinal level in the rat (Millan et 
al., 1984). Also, experiments done in oxytocin-knockout mice indicate that these 
animals show normal behavioral responses to noxious thermal and mechanical stimuli 
(Robinson et al., 2002). My findings in normal rats do not agree with some previous 
results (Condes-Lara et al., 2003) claiming an inhibitory or analgesic oxytocin effect 
(Arletti et al., 1993; Lundeberg et al., 1994; Yang, 1994; Ge et al., 2002; Yu et al., 
2003).
Other studies suggest that the analgesic oxytocin effects are mediated, at least in part, 
by mu and kappa opioid receptors (Lundeberg et al., 1994; Ge et al., 2002; Lund et
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al., 2002; Yu et al., 2003). Oxytocin analgesic effects are also related to stress- 
induced analgesia, in which oxytocin acts by inhibiting glutamatergic spinal sensory 
transmission (Robinson et al., 2002). This latter oxytocin action on glutamate 
mechanisms has been previously proposed elsewhere (Jo et al., 1998; Condes-Lara et 
al., 2003).
The use of different experimental pain models, routes of administration, and doses 
appear to determine whether this peptide has an analgesic effect. In the present study, 
important differences were obtained in neuropathic rats, never previously studied, 
showing a reduction of the post-discharge produced by electrical stimulation of the 
receptive field and also a significant reduction of the mechanical responses produced 
by von Frey filaments. Both post-discharge and mechanical responses are reduced 
more by 2 I. U. than by 1 I. U. of oxytocin. The different results obtained in normal 
and neuropathic animals revealed an important distinction between these animals, 
illustrating plastic changes occurring as a consequence of nerve injury.
In normal animals one of the proposed mechanisms of oxytocin is that, by acting on 
the oxytocin receptor, a G protein-coupled receptor (Gq), oxytocin mobilizes 
intracellular Ca2+ and opens a non-specific cationic channel or closes a K+ channel 
(Gimpl and Fahrenholz, 2001). In neuropathic animals there is an up regulation of the 
alpha 2 delta subunit of calcium channels after nerve injury and increases of both N 
type (nerve injury) and P type (tissue damage) calcium channels after pathological 
changes (Dickenson et al., 2002), which might explain the inhibition obtained with 
oxytocin in neuropathic animals.
The ability of oxytocin to reduce consequences of N-methyl D- aspartate receptor 
events such as wind-up and post-discharges. Relates to findings that (Condes-Lara et 
al., 2003), oxytocin could block glutamate activation and reduce nociceptive evoked 
responses in spinal cord cells. NMDA receptors are implicated in wind-up 
(Dickenson and Sullivan, 1987; Willis et al., 1996), and intrathecal injection of 
oxytocin produces hyperalgesia (Kitto et al., 1992). In addition NMDA receptor
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antagonists produce a marked, dose-dependent inhibition of C-fibre evoked responses 
(Haley et al., 1992).
Other possible explanation of my findings would include changes in the brainstem 
and midbrain that occur after peripheral nerve damage. Ascending noxious 
information could project to areas such as the hypothalamus paraventricular nucleus, 
which projects to the spinal cord and is an important source of oxytocin. Both 
ascending and descending activity could change after nerve injury and may alter 
oxytocin levels and receptor function at the spinal cord. This could be a possible 
explanation of our findings. Further studies on the oxytocin peptide may reveal 
important links between endocrine peptides functioning as neurotransmitters and 
altered pain states.
Finally, our study suggests that oxytocin has potential therapeutic value as an 
endogenous antinociceptive agent, a target that could lead to drug development.
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CHAPTER 9
FINAL DISCUSSION
The spinal cord is an important part in the functional organization of the central 
nervous system. In particular it has a vital role in the integration, modulation and 
control of sensory information as well as transmitting this information to higher brain 
centres. This has made the spinal dorsal hom a target for many pain studies. The 
studies used in my thesis have been developed for the purpose of analyzing in vivo 
mechanisms of pain. This type of study has the advantage of directly activating the 
primary afferent by electrical stimulation and/or by natural stimuli such as 
mechanical and heat stimuli. This allows the study of the effects of a wide range of 
noxious and innocuous stimuli of different natures. Importantly, the direct measures 
of neuronal activity, involved in the sensory aspects of pain, allows observation of 
supra-threshold measures, not possible in behavioural studies where the endpoint is a 
threshold withdrawal. This allows measures closer to the clinical issues of pain in 
patients where pain levels are above the threshold. Furthermore, the model should not 
be complicated by secondary effects of drugs such as sedation or motor effects that 
could confound behavioural measures. Moreover, direct application of the drug into 
the spinal cord will permit the study of the pharmacological effect of particular 
compounds within a complex neuronal network, which reproduces the physiological 
environment where the drug will be acting. However, it must be said that the model 
only studies efficacy and here drugs may inhibit neuronal responses at doses that 
cause unacceptable side-effects.
In addition the dorsal hom of the spinal cord is subject to a great deal of plasticity 
following pathophysiological changes such as inflammatory and neuropathic related 
pain which presents a clinical problem. Therefore understanding this dynamic circuit 
will enable better management of these painful states.
In this thesis the pharmacological effects of several compounds of interest were 
investigated on deep spinal dorsal hom neurones (V-VI) which are primarily WDR 
neurones, and this was done in different models of pain states.
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One of the major compounds investigated here was nociceptin, the endogenous ligand 
of the fourth opioid receptor, the ORLi receptor. In this study it was confirmed that 
intrathecal application of nociceptin induces analgesic effects on spinal dorsal 
neuronal responses of deep laminae dorsal hom cells in normal rats. This effect was a 
dose-dependent one as has been previously reported by a study done in our laboratory 
(Stanfa et al., 1996) and in others (Xu et al., 1999). The lack of effect of nociceptin 
on the Ap-fibre responses and the greater inhibition seen on the C-fibre evoked 
responses suggests a predominant effect of this compound at pre-synaptic sites 
(action either on afferent terminals or neuronal systems pre-synaptic or upstream to 
the recorded neurone) as direct post-synaptic actions appear less likely due to this 
selective effect of nociceptin on C-fibre responses. However, in accord with Stanfa et 
al., (1996), I found that nociceptin also had a potential action through post-synaptic 
opioid receptors on neurones and hence was able to inhibit post-synaptic mechanisms 
such as wind-up and post-discharge of the recorded neurones. These potential pre-and 
post-synaptic actions of nociceptin are supported by the proposed mechanisms of 
action of nociceptin; for instance nociceptin inhibits N-type calcium channels and it is 
also believed that nociceptin causes membrane hyperpolarization by increasing K+ 
conductance and inhibits adenylate cyclase (Connor et al., 1996; Meunier, 1997). 
Overall these effects attenuate the propagation of action potentials and release of 
neurotransmitters in the afferent sensory nerve fibres in a similar way to that 
proposed by the mechanisms of action of the other opioids (Dickenson, 1994; 
Sawynok, 2003).
Using the top dose of nociceptin in neuropathic animals where the spinal nerves L5 
and L6 were tightly ligated I observed a similar analgesic effect, but this effect was 
less when compared with the normal animals. Although several behavioural and in 
vitro studies suggest the effectiveness of nociceptin in other neuropathic models 
(Yamamoto and Nozaki-Taguchi, 1997; Yamamoto et al., 1997; Abdulla and Smith, 
1998), there is limited information about the basis for the observed 
electrophysiological changes in the nociceptin system in the spinal cord following 
nerve injury and chronic inflammation. I have therefore seen that the potency of
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nociceptin was higher in normal animals followed by animals with nerve injury and 
sham operated animals were the least effected which futher emphasizes the changes 
seen after nerve ligation since these animals received the same preliminary surgery as 
the sham animals. Similar discrepant effects of nociceptin were seen in sham operated 
animals when compared with carrageenan animals in the (Carpenter et al., 2000) 
study. Even though both animals exhibit a degree of peripheral inflammation one 
main difference is that the sham animals were used at 2 weeks whereas previous 
studies looked at acute effects of inflammation suggesting that the regulation of ORLi 
receptors may differ with time.
The mechanisms behind the reduced effect of nociceptin in neuropathic animals and 
the lack of effect in animals with chronic inflammation need further investigation. 
However it is possible that both pain states may present plasticity in peripheral and 
central nervous systems that could further enhance the response of the dorsal hom 
neurones more than in normal states so that inhibition is less as a result of higher 
levels of excitation and subsequently nociceptin may be less effective in those 
animals. Moreover these findings indicate that peripheral inflammation and nerve 
injury may regulate endogenous nociceptin and its receptor in ways different from or 
opposite to the classical opioid system.
To clarify the role of this peptide nociceptin and its receptor much research has been 
directed towards the discovery of non-peptide agonists and antagonists at the ORLi 
receptor. A novel ORLi receptor ligand, named by Solvay Pharmaceuticals as 
compound 20700857 was for the first time investigated here on deep spinal dorsal 
hom neurones. The compound in study did not produce the spinal antinociceptive 
effect seen with nociceptin, suggesting that compound 20700857 may have less 
potency or specificity or may not possible act on ORLi receptor. However the 
complex effect on wind-up evoked response which includes both facilitatory and 
inhibitory effects may indicate a role of this compound on mechanisms behind 
neuronal excitability.
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The discovery of a selective nociceptin antagonist J-l 13397 by Kawamoto et al., 
(1999) and Ozaki et al., (2000) made possible the further investigation of the 
nociceptin system. Using J-l 13397 after obtaining the maximum inhibition with 
cumulative doses of nociceptin, I clearly demonstrated almost a complete reversal by 
this compound of the effects of nociceptin on spinal dorsal hom neurones in normal 
animals. This should prove to be a useful tool for the study of this receptor system. 
This data is in agreement with the studies indicating that J-l 13397 blocks the ORLi 
receptor in a competitive manner and possesses high affinity and selectivity for the 
ORLi receptor (Ozaki et al., 2000; Ichikawa et al., 2001). To further provide evidence 
of the selectivity of J-l 13397 on ORLi over the mu-opioid receptor i.t. administration 
of 1 pg of morphine after the administration of J-l 13397 still induced the marked 
inhibitory effect expected by morphine. J-l 13397 did not produce any antagonistic 
effect on intrathecal oxycodone, another opioid agonist thought to be acting through 
the mu- and/or kappa-opioid receptor (Beaver et al., 1978; Yobum et al., 1995; Ross 
and Smith, 1997). These findings demonstrate that J-l 13397 has no interaction with 
the other opioid receptors. Moreover, through this study I found that the spinal 
analgesic effect of oxycodone was less than the effect of morphine obtained in similar 
studies (Suzuki et al., 1999) and higher than spinal analgesic effect of nociceptin.
Using this selective antagonist of nociceptin actions at the ORLi receptor, it was 
possible to elucidate any potential endogenous activity of nociceptin at the ORLi 
receptor in different pain models. It was found that J-l 13397 had no significant effect 
on the electrically or naturally evoked recordings made from deep dorsal hom 
neurones in normal animals and this was not altered after inflammation and 
neuropathy. Overall, the data indicated that endogenous nociceptin has no or only a 
minor role in spinal nociceptive processing in those pain states. These findings 
correlate well with studies done in nociceptin receptor-knockout mice, where it was 
shown that basal nociceptive thresholds were unchanged in these animals (Nishi et 
al., 1997; Mamiya et al., 1998). The use of this antagonist may help explain the 
functional roles of nociceptin and its receptor in the brain and spinal cord, for review 
see (Calo et al., 2000; Mogil and Pasternak, 2001).
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The effect of opioids in neuropathic pain is a matter of considerable controversy 
(chapter 3). The increases in spinal CCK during neuropathic pain and subsequent 
reduction in the potency of spinal morphine led to suggestions of a role of this 
peptide in this pain state (Xu et al., 1993). Additionally, CCK antagonists were seen 
to potentiate morphine analgesia (Watkins et al., 1985; Stanfa et al., 1994).
Since nociceptin acts at ORLi which is an opioid-like receptor, it was of interest to 
investigate whether CCK has an effect on the nociceptin/ORLi system. Their 
interaction was studied in this thesis for the first time on the spinal cord neuronal 
responses in normal, neuropathic and sham operated rats. In normal animals, 
pretreatment with CCK prevented the inhibitory effect of nociceptin and therefore 
CCK had the expected ‘anti-opioid’ action while in neuropathic and sham operated 
animals, CCK enhanced the analgesic action of nociceptin. The enhanced effect of 
nociceptin obtained after treatment with CCK in sham operated animals could be as a 
result of surgical inflammation. This was also found with morphine (Stanfa and 
Dickenson, 1993) and this enhancement has been attributed to decreases in the 
availability of endogenous CCK (Stanfa and Dickenson, 1993). As a consequence 
there are potential similarities between spinal mu-opioid and ORLi receptor function 
in normal animals and after inflammation. However, in nerve injury, CCK not only 
failed to block the effects of nociceptin but enhanced the inhibitory effects of the 
peptide. This synergism suggests a plasticity in the actions of CCK/nociceptin and 
further emphasises that the ORLi receptor has very different characteristics from the 
mu-opioid receptor at spinal levels.
Since CCK interacts with intracellular mechanism of calcium regulation (Wang et al., 
1992) and in neuropathic pain there is an upregulation of the alpha 2 delta subunit of 
calcium channels and enhanced actions of both N (nerve injury)- and P (tissue 
damage) -type calcium channels after pathological changes (Dickenson et al., 2002), 
suggesting that the CCK/ORLi interaction may involve intracellular calcium. Another 
possible mechanism is that CCK, acting on CCKb receptors, decreases the
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availability of the enkephalins (Nichols et al., 1996). From these findings it appears 
that the ORLi receptor may be a useful target for the treatment of nerve injury and 
other pain states.
The effect of nociceptin was also examined in animals where lamina I NK1 
expressing neurones have been ablated using a saporin-substance P conjugate (SP- 
SAP) and was compared to a control group (saline or SAP). In this study it was 
shown that in NK1 neuronal ablated animals the response of intrathecal nociceptin on 
deep dorsal hom neurones was attenuated when compared with the control group. 
Although the greatest change was seen on the wind-up response, which is an intrinsic 
spinal phenomenon relying on circuit between lamina I-lamina V (Dickenson et al., 
2004), overall the neuronal response was slightly changed due to the lack of lamina I 
NK1 expressing neurones. To further analyze the importance of these neurones on the 
responses of deep dorsal hom to opioids, I also assessed the effect of a delta-opioid 
receptor agonist, DPDPE, in saline, SAP and SP-SAP animals. It was found that the 
spinal analgesic effect of DPDPE on deep dorsal hom neurones was not altered by the 
depletion of NK1 expressing neurones in the superficial lamina. This was in accord 
with (Nichols et al., 1999) study, suggesting that the NK1 expressing neurones in the 
dorsal hom are not the major site of action of morphine which is not surprising given 
the large proportion of pre-synaptic neurones. Thus this finding may well be extended 
to other opioid receptor agonists such as delta-opioid agonist. The attenuation of the 
spinal analgesic actions of nociceptin by this treatment further underlines the 
difference between ORLi receptor and other opioid receptors and this may suggest 
that post-synaptic ORLi receptors have greater contributions to the effect of 
nociceptin when compared to other opioid receptors. Another explanation could be 
that NK1 and ORLi receptors may be co-localised on the same neurones and by 
ablating these neurones which present 10% of the neuronal population in lamina I 
(Brown et al., 1995; Mantyh et al., 1997) may reflect the slight attenuation of the 
nociceptin analgesia in deep dorsal hom neurones.
Moreover, since the majority of lamina I expressing NK1 neurones project to the 
brainstem areas implicated in the affective and discriminative aspect of pain (Mantyh
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et al., 1997; Todd et al., 2000). The disruption of these pathways may activate the 
descending suparspinal mechanisms and as proposed by Suzuki et al., (2002) the 
spino-bulbo-spino-loop descending facilitation may well explain the reduced 
analgesic response seen with SP-SAP animals after intrathecal injection of nociceptin 
and also the reduced heat coding response that was found in SP-SAP animals.
The final pharmacological study presented here is the spinal effect of the 
neurohormone, oxytocin. The spinal effect of oxytocin in normal animals is 
controversial. Here I found that spinal application of oxytocin did not produce any 
significant change in the electrical and mechanical evoked response in normal 
animals, while in neuropathic animals oxytocin produced inhibition of both 
responses. There are several suggestions for these results, for instance since one of 
the proposed mechanism of oxytocin involves intracellular calcium (Gimpl and 
Fahrenholz, 2001) and in neuropathic pain as previously seen with CCK there is 
upregulation of the alpha 2 delta subunit of calcium channels and enhanced actions of 
both N (nerve injury) and P (tissue damage) calcium channels, this may explain the 
inhibition obtained with oxytocin in this pain state. One other possibility could be that 
after nerve injury there might be changes at supraspinal levels that could alter the 
function of oxytocin system at the spinal cord. Indeed, further study of oxytocin at 
supraspinal levels will be required to fully elucidate the role of oxytocin in 
neuropathic animals.
Overall this thesis provides a better understanding of both exogenous and endogenous 
nociceptin on spinal dorsal hom neurones in different pain states. It was successfully 
shown that interaction between nociceptin and CCK enhanced the analgesic affect of 
nociceptin and thus the ORLi receptor may be useful target for the treatment of nerve 
injury and in chronic pain. This study further underlines the difference between the 
ORLi receptor with other opioid receptors and raised the possible involvement of 
population of lamina I neurones in the modulation of nociceptin response on deep 
dorsal hom neurones. In addition, this thesis emphasizes the plasticity of oxytocin 
system in neuropathic animals and its effectiveness in this pain state.
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